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I General Introduction 
I.1 Molecular Patterns in Virus-induced 
Immune Responses 
In order to react to different types of danger with the initiation or enhancement of the 
appropriate responses, the immune system has evolved to distinguish endogenous damage 
from exogenous danger and trigger the activation of the respective downstream signaling 
cascades. Cells can therefore distinguish danger by invading microorganisms from tissue 
damage due to other causes such as heat or cuts.  
Pathogens and microorganisms, which invade a host’s organism, carry pathogen-
associated molecular patterns (PAMPs). PAMPs are a set of conserved small molecular 
motifs that can be recognized by their respective pattern recognition receptors (PRRs) in 
the host. This interaction in turn leads to activation of signaling pathways and the 
initiation of an innate immune response (Schenten and Medzhitov 2011). Damage-
associated molecular patterns (DAMPs) are a pool of structurally diverse endogenous 
molecules that signal tissue damage and alert the immune system of the ongoing 
destruction, in order to enhance immune responses. In the case of necrosis, an 
uncontrolled form of cell death, the dying cell releases all of its endogenous content 
without regulatory mechanisms, leading to the induction of an inflammatory response. 
The intracellular proteins that are released upon necrosis signal cell damage, which led to 
their terminology as “alarmins” (Oppenheim and Yang 2005, Bianchi 2007).  
Both PAMPs and DAMPs bind to their respective PRRs to initiate downstream signaling. 
PRRs can be subdivided into membrane-bound and cytoplasmic PRRs, depending on 
their localization within the cell. Membrane-bound PRRs include Toll-like receptors 
(TLR) and C-type lectin Receptors (CLR). TLRs recognize extracellular cell-wall 
structures from microbes or bacterial and viral nucleic acid components which are 
common to pathogens but not present in host cells and lead to activation of signaling 
cascades (summarized in (Beutler, Jiang et al. 2006)). CLRs are expressed on a variety of 
different cells including immature dendritic cells and are involved in recognition of 
carbohydrates expressed by many pathogens including bacteria, viruses, fungi and 
helminthes and subsequent activation of immune responses (Chen, Lin et al. 2008, Gazi 
and Martinez-Pomares 2009, Drummond and Brown 2011, Paveley, Aynsley et al. 2011, 
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Hardison and Brown 2012). Cytoplasmic PRRs include NOD-like receptors (NLR) and 
RIG-I-like receptors (RLR). NLRs are intracellularly expressed receptors. They can be 
found in lymphocytes, macrophages, dendritic cells and also non-immune cells and they 
recognize sugar chains of bacterial origin. RLRs recognize viral double-stranded and 
single stranded RNA. Two famous members of RLRs that recognize viral patterns are 
RIG-I and MDA5 (Kang, Gopalkrishnan et al. 2002, Yoneyama, Kikuchi et al. 2004). 
RIG-I recognizes 5’-triphosphorylated dsRNA of viral origin (Hornung, Ellegast et al. 
2006). MDA5 also binds to double-stranded RNA from viruses, however the detailed 
features of viral RNA required to activate MDA5 signaling are not fully understood yet 
(Runge, Sparrer et al. 2014).  
Interleukin-33 (IL-33) is a member of the IL-1 family. It is expressed in the nucleus of 
endothelial and epithelial cells and it was found that IL-33 is a dual-function cytokine 
since it acts as a chromatin-associated factor within the nucleus (Carriere, Roussel et al. 
2007, Moussion, Ortega et al. 2008) and as an alarm mediator once released into the 
extracellular space. Upon cellular destruction, cells undergo necrosis and release IL-33 
(Cayrol and Girard 2009, Luthi, Cullen et al. 2009), classifying IL-33 as an alarmin 
(Moussion, Ortega et al. 2008). IL-33 binds to its cell surface receptor consisting of ST2 
in association with the ubiquitous IL-1R accessory protein (IL1RAcP) (Schmitz, Owyang 
et al. 2005, Ali, Huber et al. 2007), which leads to the initiation of signaling pathways 
and downstream activation of nuclear factors NFkB, ERK, p38 and JNK (Palmer and 
Gabay 2011). Interestingly, IL-33 is released into the extracellular space as full-length 
protein. Opposed to what was first proposed and is known for other interleukins like IL-
1β and IL-18, IL-33 is biologically active as a full-length peptide and proteolytic 
cleavage of IL-33 by apoptotic caspases leads to its inactivation (Cayrol and Girard 2009, 
Luthi, Cullen et al. 2009, Talabot-Ayer, Lamacchia et al. 2009). IL-33 was long believed 
to primarily act on Th2 cells and as such was regarded as a cytokine eliciting mainly Th2-
associated immune responses including those leading to asthma and allergic responses 
(summarized in (Liew, Pitman et al. 2010, Garlanda, Dinarello et al. 2013)). However, in 
recent years several lines of evidence suggested that IL-33 also plays a role in Th1-
associated immune responses and as such is not restricted to the Th2 context. IL-33 has 
been shown to enhance production of IFN-γ by iNKT cells, NK cells and CD8+ T cells 
(Smithgall, Comeau et al. 2008, Bourgeois, Van et al. 2009, Yang, Li et al. 2011). 
Importantly in 2012 we have shown that potent anti-viral immune responses require IL-
33 and that signaling via the IL-33/ST2 axis is essential for the clonal expansion of virus-
specific CD8+ T cells and their differentiation into functional effector cells upon antigen-
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encounter during viral infection (see section 1 “The Alarmin Interleukin-33 Drives 
Protective Antiviral CD8+ T Cell Responses”). CD8+ T cells that are in an IL-33 
deficient environment or that are unable to sense IL-33 fail to expand normally show 
reduced cytotoxic potential, do not differentiate into multi-functional effector T cells and 
are finally unable to efficiently control the virus (Bonilla, Frohlich et al. 2012). 
I.2 The Role of Secondary Lymphoid Organ 
Stroma in Adaptive Immune Responses 
Much is known about the role of the hematopoietic compartment in adaptive immune 
responses including B and T cells, on which immunological research has focused for a 
long time. However, evidence has accumulated that non-hematopoietic radio-resistant 
cells in secondary lymphoid organs also play a crucial role in adaptive immune responses, 
a component which has long been underestimated. Primary lymphoid organs (PLOs) like 
thymus and bone marrow and secondary lymphoid organs (SLOs) like spleen and lymph 
nodes are sites of organized lymphoid cell accumulations. B and T cell maturation occurs 
in PLOs, whereas further lymphocyte differentiation and adaptive immune responses take 
place in SLOs, where antigens get efficiently trapped for subsequent exposure to T and B 
lymphocytes (summarized in (Ruddle and Akirav 2009)). The spleen can be divided into 
two areas, the red pulp and the white pulp. The red pulp is the blood-filtering system of 
the spleen, which removes damaged cells and recycles iron (Mebius and Kraal 2005, 
Ruddle and Akirav 2009). The white pulp is organized as lymphoid structure with highly 
vascularized B and T cell compartments (Mebius and Kraal 2005, Ruddle and Akirav 
2009). The radio-resistant (CD45-negative) compartment forms the structure of the 
spleen and consists of three different cell types: CD31+gp38- blood endothelial cells 
(BECs), CD31-GP38+ fibroblastic reticular cells (FRCs) and CD31-GP38- so-called 
double-negative cells (DNs), which are poorly characterized so far. In lymph nodes, an 
additional population of CD31+GP38+ lymphatic endothelial cells (LECs) can be found. 
BECs form the inner lining of blood vessels and are a separation between the inside of the 
vessel and the surrounding tissue. FRCs form the structural backbone in splenic T-cell 
zones. Not much is known about the function of DNs so far (Mebius and Kraal 2005). 
Besides forming three-dimensional networks in the splenic T cell zones, providing a 
scaffold for lymphocyte migration (Link, Vogt et al. 2007, Turley, Fletcher et al. 2010), 
stromal cells have now been shown to be modulators of inflammation and hematopoietic 
cells depend on stromal cells for successful entry, migration and activation in lymphoid 
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organs (Link, Vogt et al. 2007). FRCs are multifunctional cells that produce various 
chemokines, form the scaffold for T cell migration and form a conduit network for the 
transport of small soluble antigens throughout the SLO parenchyma (Nolte, Belien et al. 
2003, Bajenoff, Egen et al. 2006). They furthermore promote survival of naïve T cells by 
production of IL-7 (Link, Vogt et al. 2007) and directly stimulate anti-viral immune 
responses by facilitating interactions between T cells and dendritic cells (DCs) (Bajenoff, 
Egen et al. 2006, Bajenoff, Glaichenhaus et al. 2008). In addition, several reports have 
demonstrated that resident stromal cells can function as antigen-presenting cells in 
secondary lymphoid organs such as lymph nodes and spleen and thus can directly prime 
and activate T cells ((Lee, Epardaud et al. 2007, Nichols, Chen et al. 2007, Cohen, Guidi 
et al. 2010, Fletcher, Lukacs-Kornek et al. 2010), summarized in (Turley, Fletcher et al. 
2010)). In the last years several reports also postulated that FRCs get directly infected by 
LCMV resulting in disruption of the FRC network and loss of immunocompetence, 
which in turn might contribute to immunosuppression and persistence during chronic 
LCMV infection (Mueller, Matloubian et al. 2007, Scandella, Bolinger et al. 2008). 
I.3 Adaptive Immune Responses in Acute 
and Chronic Viral Infection 
Infections with viruses can either be of short- or long-term and are denominated acute and 
chronic, respectively. Whereas acute infections are cleared in a short period of time, 
chronic infections are characterized by prolonged viremia and may never be cleared by 
the host’s immune system such as for human immunodeficiency virus (HIV). In certain 
cases such as human hepatitis B and C virus infections (HBV, HCV) or in murine 
infection with lymphocytic choriomeningitis virus (LCMV), the outcome may either be 
life-long persistence or protracted yet self-limiting infection. The magnitude and 
functionality of adaptive immune responses against acute and chronic viral infections 
show important differences, as exemplified on the basis of the afore-mentioned prototypic 
infection model of LCMV. Its outcome depends on the strain and dose of virus used and 
the MHC class I haplotype of the mouse (Zinkernagel, Pfau et al. 1985). In C57BL/6 (H-
2b) mice, the LCMV strain Armstrong or low doses of the WE strain cause acute 
infections, which are characterized by a rapid onset of disease, if any, and viremia that is 
resolved within one week. High-dose infection with LCMV strain Clone 13 or Docile 
results in protracted or persisting viremia, which is detectable in some tissues for more 
than three months (Ahmed, Salmi et al. 1984, Wherry, Blattman et al. 2003). This 
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difference in outcome is particularly noteworthy, since the clearance of an infection with 
LCMV Armstrong versus infection with LCMV Clone 13 is dependent on only two 
amino acid differences (Bergthaler, Flatz et al. 2010). 
CD8+ T cells play an essential role for the clearance of acute and the control of persistent 
LCMV infection and LCMV has been shown to be an excellent inducer of virus-specific 
CTLs (summarized in (Doherty and Christensen 2000), (Byrne, Ahmed et al. 1984, 
Yewdell and Haeryfar 2005)). Upon acute infection, virus-specific CD8+ T cells get 
activated and clonally expand in response to the antigen stimulation. They up-regulate 
effector markers and differentiate into effector CD8+ T cells expressing inflammatory 
mediators like Interferon-γ and TNF-α and the cytotoxic molecules perforin and 
granzyme B for direct killing of infected cells (Kagi, Ledermann et al. 1994). The 
expansion phase of CTLs is followed by a contraction phase were most (90-95%) of 
effector CTLs undergo apoptosis and the remaining CD8+ T cells differentiate into 
memory T cells. Those memory cells enable a quick re-expansion upon exposure to the 
antigen and consequently a quicker anti-viral response (Wherry and Ahmed 2004). Virus-
specific CTLs also clonally expand in response to chronic LCMV infection. However, in 
the course of chronic LCMV infection many antiviral CTLs get deleted (Moskophidis, 
Lechner et al. 1993) and the remaining ones hierarchically lose effector functions over 
time and develop a functionally impaired state, both of which can be referred to as 
“exhaustion” of virus-specific CTLs (Zajac, Blattman et al. 1998). In consequence the 
remaining cells are impaired in their ability to directly lyse infected cells, proliferate in 
response to antigen-stimuli and produce inflammatory and anti-viral cytokines like IL-2, 
TNF-α and IFN-γ (Zajac, Blattman et al. 1998, Wherry, Blattman et al. 2003). Taken 
together, the continuous exposure to high loads of antigen during chronic infection leads 
to the progressive dysfunction or eventual deletion of virus-specific CTLs, which in turn 
favors long-term persistence of the virus (Ou, Zhou et al. 2001, Fuller and Zajac 2003, 
Wherry, Blattman et al. 2003, Wherry, Ha et al. 2007). 
Acute LCMV infections are controlled virtually exclusively by CD8+ T cell-dependent 
mechanisms, in presence or absence of functional CD4+ T cells (Moskophidis, Cobbold 
et al. 1987, Ahmed, Butler et al. 1988, Rahemtulla, Fung-Leung et al. 1991). In contrast, 
clearance of chronic LCMV infection requires both CD4+ and CD8+ T cells and an only 
temporary unavailability of CD4+ T cells through blockade or depletion drastically 
affects the outcome of infection and prevents eventual resolution of the virus infection 
(Doherty, Allan et al. 1992, Matloubian, Concepcion et al. 1994). Several lines of 
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evidence suggest that chronic LCMV infections are eventually controlled 2-3 months 
after infection via not only CTL- but also B cell-dependent mechanisms, both of which 
are reliant on help from CD4+ T helper cells. Without the help of CD4+ T cells, virus-
specific CTLs get depleted during chronic infection (Battegay, Moskophidis et al. 1994, 
Matloubian, Concepcion et al. 1994). Furthermore it has been shown that LCMV-specific 
antibody responses are essential for the final control and clearance of the virus and that 
the activation of those antibody-producing B cells depends on CD4+ T cell help (Ciurea, 
Hunziker et al. 2001, Bergthaler, Flatz et al. 2009). Similar to CD8+ T cells, also CD4+ T 
cells have been shown to enter a functionally altered state in chronic LCMV infection, 
which is also sometimes referred to as “exhaustion” (Brooks, Teyton et al. 2005). Priming 
and early CD4+ T cell activation have been demonstrated to be comparable in acute and 
chronic infection. This suggests that such “exhaustion” is not a consequence of an early-
programmed event but of continuous antigenic exposure (Brooks, McGavern et al. 2006). 
Nevertheless, CD4+ T cells continue to provide help to CD8+ T cells and B cells during 
chronic infection, which improves control of virus replication. IL-21, which most likely is 
produced by CD4+ T cells, has been shown to shape the functionality of antiviral CD8+ 
T cells and as such to play a vital role for the control of chronic LCMV infection 
(Elsaesser, Sauer et al. 2009, Frohlich, Kisielow et al. 2009, Yi, Du et al. 2009). Taken 
together both CD4+ and CD8+ T cells play an important role in anti-viral immune 
responses against chronic infection and thus for successful clearance of the virus. 
I.4 Arenaviruses in Basic Research and 
Human Disease 
Arenaviruses generally infect rodents but can cause severe illness upon accidental 
transmission to humans. Disease severity and pathology varies amongst members of the 
family and can range from aseptic meningitis caused by LCMV to hemorrhagic fevers 
which can lead to death upon infection with Guanarito, Junin, Machupo or the most 
famous family member Lassa virus (Geisbert and Jahrling 2004). Arenaviruses are 
divided into two groups: the Old World arenaviruses like Lassa virus (LASV) and LCMV 
can be found in Africa. Members of the New World arenaviruses like Junin, Guanarito or 
Machupo virus are widespread in rodent populations of South America (Johnson, Kuns et 
al. 1966, Tesh, Wilson et al. 1993, Mills, Ellis et al. 1994). Junin virus is the only 
arenavirus for which a preventive vaccine is available for clinical use. For all others anti-
viral therapy with the nucleoside analog ribavirin is the only possible treatment so far and 
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affords limited efficacy. Thus there is substantial need for new vaccines and powerful 
treatments for infections with arenaviruses. Development of these tools necessitates a 
more detailed knowledge of the molecular biology of the virus and of the viral factors 
impacting disease outcome and pathogenesis. 
As already alluded to in section I.3, LCMV is a prototypic mouse model virus in research 
on viral infections. As for all arenaviruses, the natural host of LCMV are mice, however, 
several reports revealed that LCMV might also be a neglected human pathogen (Barton 
1996, Wright, Johnson et al. 1997). Since its isolation in the 1930s (Rivers and McNair 
Scott 1935, Traub 1935) studies using this virus have uncovered many key concepts in 
viral immunology and pathogenesis like neonatal tolerance, MHC restriction and T cell 
exhaustion (summarized in (Zinkernagel 2002) and (Oldstone 2002)). LCMV has been 
extensively used to investigate viral molecular biology and immune responses 
particularly in the context of persistent infection.  
I.5 Reverse Genetic Engineering of 
Arenaviruses 
By definition, transfection of purified RNA of negative-strand viruses like LCMV cannot 
initiate an infectious cycle when transfected into permissive cells. This is in large parts 
due to their inability to directly serve as mRNA i.e. they cannot be translated when 
introduced into cells. In order to generate infectious viral particles of negative-stranded 
RNA viruses from cDNA in cultured permissive cells, the viral RNA segments must be 
trans-complemented with the minimal factors required for genome transcription and 
replication. This has complicated the investigation of negative-stranded RNA viruses 
with consequent delays in this research topic. With the help of a minigenome system that 
has been published several years ago, viral cis-acting elements and transacting factors 
involved in transcription, replication and formation of viral particles could finally be 
analyzed (Lee, Novella et al. 2000, Lee, Perez et al. 2002, Perez and de la Torre 2003, 
Pinschewer, Perez et al. 2003, Pinschewer, Perez et al. 2005). Also for other arenaviruses 
like LASV and Tacaribe virus reverse genetic systems have been established (Lopez, 
Jacamo et al. 2001, Hass, Golnitz et al. 2004). In 2006 the recovery of infectious LCMV 
entirely from cDNA was achieved using pol-I/-II or T7/pol-II-driven plasmids, 
respectively (referred to as “viral rescue” (Flatz, Bergthaler et al. 2006, Sanchez and de la 
Torre 2006)). Rescue of LCMV entirely from plasmid enabled the introduction of 
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mutations at will in the viral genome and the investigation of their impact on viral 
phenotypes and cellular and molecular bases of viral pathogenesis. In addition reverse 
genetics based on negative-strand RNA viruses hold great promise and are widely used 
for novel vaccine designs and vector platforms in the fight against viral infections and 
cancer (von Messling and Cattaneo 2004, Vigil, Park et al. 2007). 
I.6 Recombinant Viruses as Vaccine 
Platforms 
Since treatment for patients suffering from viral infections are limited, vaccines are 
considered as one of the most promising and effective tool against infectious diseases. 
Whereas in the past mainly live attenuated viruses were used, the importance of 
recombinant viruses as a novel vaccine platform is steadily increasing since the early 
1980ies (Thummel, Tjian et al. 1981, Mackett, Smith et al. 1982). One of the main 
advantages of recombinant viruses over other technologies is the possibility to modify the 
genetic information of both the vector platform and the antigen at will in a controlled 
fashion. This is in contrast to strategies used for live-attenuated viruses where researchers 
rely on random mutations e.g. acquired during serial passages in order to obtain 
attenuated variants (Olschlager and Flatz 2013). Several recombinant virus platforms 
have been proven protective in animals and also in human trials. The choice of a vector 
platform depends on different factors. It is favorable, if the vector has a similar tropism as 
the target virus. Also the vector has to be able to elicit efficient immune responses against 
the introduced antigen in order to provide efficacy. In the fight against arenaviral 
hemorrhagic fevers, wild-type vesicular stomatitis virus (VSV) was modified to 
recombinant rVSV expressing the glycoprotein of LASV instead of the own GP (Garbutt, 
Liebscher et al. 2004) and vaccinated non-human primates were protected against 
subsequent lethal challenge with LASV (Geisbert, Jones et al. 2005). One of the oldest 
and most successful recombinant chimeric virus as vaccine vector is attenuated yellow 
fever strain 17D (YFV 17D) (Olschlager and Flatz 2013). Genes of Japanese Encephalitis 
Virus or Dengue Virus have been added to the YFV 17D genome, leading to protection of 
vaccinated animals against respective lethal challenge (Chambers, Nestorowicz et al. 
1999, Guirakhoo, Zhang et al. 1999, Guirakhoo, Weltzin et al. 2000, Chambers, Liang et 
al. 2003). Earlier this year the chimeric YF17D/Dengue Virus vaccine has been shown to 
be protective in the world’s first large-scale efficacy study and is expected to be licensed 
in the course of next year (Sanofi-Pasteur 2014a, Sanofi-Pasteur 2014b). A chimeric YFV 
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17D expressing GP of the arenavirus LASV also showed promising results by protection 
of guinea pigs against fatal LASV challenge (Bredenbeek, Molenkamp et al. 2006, Jiang, 
Dalebout et al. 2011).  
Even though the mentioned recombinant viruses have been proven successful for 
vaccination against some infectious diseases, the induction of a multifunctional yet long-
lasting CTL response is still to be achieved. VV-based vectors induce multifunctional 
CTL responses but these are of rather low magnitude (Peters, Jaoko et al. 2007, Harari, 
Bart et al. 2008). In addition, vaccination with rVV-based vectors induces a strong 
vector-specific antibody response, which renders homologous boosts problematic. 
Rescue of replicative LCMV from DNA was an important achievement in order to 
exploit LCMV as a potential vaccine platform (Flatz, Bergthaler et al. 2006, Sanchez and 
de la Torre 2006). It has been demonstrated that replication-deficient LCMV elicits long-
lived T cell responses while the defect in replication ensures stable attenuation and an 
acceptable safety profile (Flatz, Hegazy et al. 2010). The combination of several features 
of LCMV makes it a potential candidate for vaccine delivery. LCMV is known to induce 
a multifunctional and long-lasting T cell response (Homann, Teyton et al. 2001). In 
addition LCMV directly infects DCs, leading to their activation and presentation of the 
vaccine antigen by professional antigen-presenting cells, which in turn is essential for the 
induction of functional CD8+ T cell responses (Probst, Lagnel et al. 2003, Steinman 
2007). LCMV has furthermore been shown to induce only low levels of neutralizing 
antibodies against the glycoprotein of LCMV but high magnitude of protective 
neutralizing antibody responses to foreign antigens, enabling homologous boost strategies 
and underlining its suitability as a potentially novel vaccine vector in clinical use 
(Pinschewer, Perez et al. 2004). An adequate safety profile e.g. by stable attenuation and 
a constant expression of the transgene are two of the most important qualifications a 
potential vaccine vector has to fulfill in order to be evaluated for human applications. A 
recombinant vaccine vector providing these features of an acceptable safety profile 
combined with the induction of a multifunctional protective immune response without the 
generation of neutralizing antibodies thus represents a promising candidate for a vaccine 
platform. 
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II Aims of the Thesis 
The aims of my thesis were threefold.  
Firstly, we wanted to decipher the role of IL-33 in adaptive immunity against acute and 
chronic viral infection.  
Secondly, we aimed at investigating the cellular source of IL-33 and the impact thereof 
on T cell responses to chronic viral infection. 
Thirdly, we intended to develop genetically and phenotypically stable transgene-
expressing replication-competent arenaviruses. 
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1.1 Abstract  
Pathogen-associated molecular patterns decisively influence antiviral immune responses, 
whereas the contribution of endogenous signals of tissue damage, also known as damage-
associated molecular patterns or alarmins, remains ill defined. We show that interleukin-
33 (IL-33), an alarmin released from necrotic cells, is necessary for potent CD8+ T cell 
(CTL) responses to replicating, prototypic RNA and DNA viruses in mice. IL-33 signaled 
through its receptor on activated CTLs, enhanced clonal expansion in a CTL-intrinsic 
fashion, determined plurifunctional effector cell differentiation, and was necessary for 
virus control. Moreover, recombinant IL-33 augmented vaccine-induced CTL responses. 
Radio-resistant cells of the splenic T cell zone produced IL-33, and efficient CTL 
responses required IL-33 from radio-resistant cells but not from hematopoietic cells. 
Thus, alarmin release by radio-resistant cells orchestrates protective antiviral CTL 
responses. 
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1.2 Introduction and Results  
Pathogen-associated molecular patterns (PAMPs) characterize intruding microorganisms 
and are important for adaptive immune responses to viral infection (Schenten and 
Medzhitov 2011). Conversely, endogenous molecular patterns, which indicate tissue 
injury, are referred to as alarmins and form a second class of damage-associated 
molecular patterns (DAMPs) (Oppenheim and Yang 2005). Unlike PAMPs, the potential 
contribution of alarmins to antiviral immune defense remains largely elusive. 
Many viruses are excellent inducers of cytotoxic CD8+ T lymphocytes (CTLs) (Yewdell 
and Haeryfar 2005), the basis of which is incompletely understood. To screen for 
inflammatory signals augmenting antiviral CTL responses, we used lymphocytic 
choriomeningitis virus (LCMV) infection of mice. We performed a genome-wide cDNA 
expression analysis of total spleen tissue from LCMV-infected mice and compared it to 
an analysis of uninfected controls. From a large panel of interleukins and pro-
inflammatory cytokines, interferon-γ (IFN-γ) and IL-33 were most up-regulated (table 
1.S1). The IL-33 receptor ST2, an IL-1 receptor family member also known as T1 and 
IL1RL1, was also up-regulated. 
IL-33 is expressed in the nucleus of nonhematopoietic cells, such as fibroblasts and 
epithelial and endothelial cells of various tissues (Moussion, Ortega et al. 2008), but its 
role in antiviral CTL responses is unknown. Its bioactive pro-inflammatory form is 
released as a result of necrosis but not apoptosis, classifying IL-33 as an alarmin (Cayrol 
and Girard 2009, Haraldsen, Balogh et al. 2009, Zhao and Hu 2010). IL-33 mRNA 
expression peaked at 3 to 5 days after infection and grossly paralleled the kinetics of 
LCMV RNA (Fig. 1.1A). To test whether IL-33 was important for CTL responses to 
LCMV, we performed infection experiments in IL-33–deficient (Il33−/−) mice (Oboki, 
Ohno et al. 2010). Absence of IL-33 reduced the absolute number of CTLs responding to 
the immunodominant LCMV epitope GP33 by >90%. The frequency of epitope-specific 
CTLs was reduced by >75% (Fig. 1.1B). When expressed as a nuclear factor in healthy 
cells, IL-33 is complexed with chromatin and modulates gene expression (Carriere, 
Roussel et al. 2007). Upon release from necrotic cells, however, IL-33 binds and signals 
through ST2 (Schmitz, Owyang et al. 2005, Dinarello 2009). To assess which one of 
these roles of IL-33 accounted for defective CTL responses in Il33−/− mice, we used 
transgenic mice expressing a soluble decoy receptor for IL-33 [Il1rl1-Fc mice (Senn, 
McCoy et al. 2000)]. Il1rl1-Fc mice displayed defective CTL expansion analogously to 
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Il33−/− mice (Fig. 1.S1A). Mice lacking the IL-33 receptor ST2 [Il1rl1−/− (Townsend, 
Fallon et al. 2000)] also mounted similarly reduced responses to all three LCMV epitopes 
tested (Fig. 1.1C and Fig. 1.S1 B and C). This indicated that IL-33 was released to the 
extracellular compartment and signaled through ST2 to amplify antiviral CTL responses. 
Analogous to the responses against LCMV, an RNA virus, Il1rl1−/− mice also exhibited 
significantly reduced CTL responses against murine γ-herpesvirus 68 [MHV-68 
(Ehtisham, Sunil-Chandra et al. 1993)], a DNA virus (Fig. 1.S1D). In further analogy to 
LCMV, MHV-68 induced IL-33 mRNA up-regulation (Fig. 1.S1E). The differences in 
CTL responses to LCMV and MHV-68 were also reflected in reduced antigen-specific 
cytotoxicity (Fig. 1.S1 F and G). However, CTL responses to a nonreplicating 
adenovirus-based vaccine vector were similar in Il1rl1−/− and wild-type (WT) mice (Fig. 
1.S1H). 
Given IL-33 can act as an alarmin, we hypothesized that productive viral replication may 
represent a unifying characteristic of LCMV and MHV-68 infection, differentiating them 
from adenoviral vectors. Indeed, the CTL responses of WT and Il1rl1−/− mice to 
replication-deficient LCMV-based vaccine vector (Flatz, Hegazy et al. 2010) were 
indistinguishable, and the magnitude of these responses was comparable to the magnitude 
of responses observed in WT LCMV-infected Il1rl1−/− mice (Fig. 1.1D). Further, 
Il1rl1−/−mice mounted defective CTL responses against WT vaccinia virus (VV), 
whereas attenuated [thymidine kinase–deficient (Buller, Smith et al. 1985)] VV-based 
vectors induced comparable responses in Il1rl1−/− and WT controls (Fig. 1.S1I). Thus, we 
hypothesized that exogenously administered IL-33 could mimic viral replication to 
enhance vaccine-induced CTL responses. Indeed, recombinant IL-33 significantly 
augmented CTL responses to VV-based vectors and viruslike particles (VLPs) (Fig. 1.1 E 
and F. 
CTLs play a pivotal role in the resolution of primary viral infection (Buller, Smith et al. 
1985, Fung-Leung, Kundig et al. 1991, Ehtisham, Sunil-Chandra et al. 1993, Flatz, 
Hegazy et al. 2010). Il1rl1−/− mice controlled low-dose LCMV infection (Fig. 1.S1J) but 
displayed elevated viremia after high-dose LCMV infection and often progressed to viral 
persistence, whereas WT control mice eliminated the virus (Fig. 1.1G and Fig. 1.S1K). 
ST2-deficient mice also displayed a log increase in splenic MHV-68 titers and three logs 
increase in pulmonary VV titers (Fig. 1.1 H and I). LCMV-neutralizing antibody 
responses were comparable in Il1rl1−/− mice and WT controls (Fig. 1.S1L), suggesting 
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that defective CTL responses of Il1rl1−/− mice were at the root of impaired LCMV 
control. 
LCMV can cause lethal CTL-mediated immunopathologic disease of the central nervous 
system when administered intracranially (Fung-Leung, Kundig et al. 1991). Five out of 
six WT mice developed terminal disease within 10 days, whereas all Il1rl1−/− mice 
survived without clinical signs of immunopathology (Fig. 1.1J). 
The IL-33 receptor ST2 has predominantly been detected on mast cells and CD4+ T 
helper type 2 cells (Lohning, Stroehmann et al. 1998, Xu, Chan et al. 1998, Liew, Pitman 
et al. 2010), reportedly exerting pleiotropic effects on helminth-specific immunity, 
allergy, anaphylaxis, autoimmune, and cardiovascular disease (Liew, Pitman et al. 2010, 
Palmer and Gabay 2011). Conversely, ST2 expression on human and mouse CTLs has 
only recently been found under select in vitro culture and differentiation conditions (Yang, 
Li et al. 2011). Hence, we investigated which cells were sensing IL-33 for augmenting 
antiviral CTL responses. To this end, we reconstituted lethally irradiated mice with an 
approximately 1:1 mixture of WT (CD45.1+) and ST2-deficient bone marrow (CD45.1–) 
(Fig. 1.2A and Fig. 1.S2A). Compared with uninfected mice, WT cells were 10-fold 
overrepresented in the population of antigen-specific CTLs responding to LCMV 
infection (Fig. 1.2A). In contrast, the repartition of WT and Il1rl1−/− B cells remained 
unaltered (Fig. 1.S2A). These observations suggested that virus-reactive CTLs respond to 
IL-33 directly. Independent evidence was obtained when T cell receptor–transgenic 
GP33-specific CTLs (Pircher, Burki et al. 1989) (P14 cells) were adoptively transferred, 
followed by LCMV challenge (Fig. 1.2B). Impaired expansion of ST2-deficient P14 cells 
in WT recipients corroborated CTL-intrinsic ST2 signaling. As expected, no such 
differences were seen between control and ST2-deficient P14 cells in the IL-33–depleted 
environment of Il1rl1-Fc mice (Fig. 1.2B). Primary CTL responses to LCMV are CD4 T 
cell independent (Rahemtulla, Fung-Leung et al. 1991), and the differences in CTL 
responses between WT and Il1rl1−/− mice persisted when CD4+ T cells were depleted 
(Fig. 1.S2B). Altogether, these findings established a CTL-intrinsic role of ST2 signaling 
in the expansion of antiviral CTLs. 
On day 6 after LCMV infection, we observed ST2 expression on up to 20% of virus-
specific CTLs, representing the peak of expression as monitored on activated (CD62Llow) 
CTLs (Fig. 1.2 C and D, and Fig. 1.S2 C and D). In P14 cells, we detected a simultaneous 
peak of ST2 mRNA (Fig. 1.2E). IL-33 signaling through ST2 involves the adaptor 
protein MyD88 and downstream phosphorylation of p38 mitogen-activated protein kinase 
The Alarmin Interleukin-33 Drives Protective Antiviral CD8+ T Cell Responses 
 26 
(Schmitz, Owyang et al. 2005). Exposure of day 6 LCMV-infected splenocytes to IL-33 
ex vivo increased phospho-p38 levels in control P14 cells but not in ST2-deficient ones 
(Fig. 1.2F). In concordance with induction of ST2 expression upon activation, IL-33 
failed to trigger detectable phospho-p38 signals in naïve P14 cells but did so on day 6 and 
8 after infection (Fig. 1.2G). MyD88 serves important CTL-intrinsic functions, but the 
upstream receptor(s) accounting for these effects had remained elusive (Rahman, Cui et 
al. 2008). In agreement with previous reports, Myd88−/− P14 cells expanded significantly 
less than control P14 cells when adoptively transferred into WT recipients and challenged 
with LCMV (Fig. 1.2H). In the IL-33–depleted environment of Il1rl1-Fc recipients, 
however, control and Myd88−/− P14 cells responded equivalently, suggesting that 
defective expansion of Myd88−/− P14 cells was largely attributable to a lack of ST2 
downstream signaling. 
CTL functionality represents an important correlate of protective capacity (Appay, van 
Lier et al. 2008). A substantial proportion of control P14 effector cells were 
plurifunctional, co-expressing IFN-γ, tumor necrosis factor (TNF)-α, IL-2, and the 
degranulation marker CD107a in various combinations (Fig. 1.3A). Conversely, about 
95% of ST2-deficient P14 cells were monofunctional or lacked effector function (Fig. 
1.3A). Reduced plurifunctionality was also observed in polyclonal antiviral CTL 
populations of ST2-deficient compared with WT mice (Fig. 1.S3A). Coexpression of 
granzyme B and CD107a indicates efficient cytotoxicity and was nearly undetectable in 
ST2-deficient P14 cells (Fig. 1.3B). Control P14 cells also contained significantly higher 
levels of the anti-apoptotic protein Bcl-2 than ST2-deficient cells (Fig. 1.3C). 
We performed genome-wide cDNA expression profiling of control and ST2-deficient 
effector P14 cells, yielding 63 differentially expressed candidate genes (Fig. 1.S3B and 
table 1.S2). We validated differential expression of Klrb1c (NK1.1) and Clec2i, which 
influence effector cell differentiation and proliferation (Ljutic, Carlyle et al. 2005, Tian, 
Nunez et al. 2005); Ifitm1 and Ifitm3, which mediate the antiproliferative effects of IFN-γ 
and pro-apoptotic signals (Dobrzanski, Reome et al. 2004); and Tspan5, which affects 
cell proliferation, migration, and adhesion (Koopman, Kopcow et al. 2003); thus 
corroborating the broad and profound effects of ST2 signals on the CD8+ effector T cell 
transcriptome (Fig. 1.3D). The gene that encodes KLRG-1, which is a marker of effector 
CTLs (Joshi, Cui et al. 2007), was also among the gene array candidates. Indeed, ST2-
deficient P14 cells and virus-specific CTLs of Il1rl1−/− mice exhibited a significant 
reduction in KLRG-1highCD127low effector CTLs, failed to express NK1.1, and expressed 
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somewhat higher levels of the inhibitory receptor PD-1 (Fig. 1.3 E and F, and Fig. 1.S3 C 
to E). With transition to the memory phase, however, the size of the LCMV-specific CTL 
pool and the cells’ KLRG-1 expression became similar in WT and Il1rl1−/− mice, and 
vaccinated Il1rl1−/− mice controlled LCMV challenge infection as efficiently as WT 
controls (Fig. 1.S3 F and G). This supported the concept that inflammatory signals are 
more important for primary effector CTL responses than for memory formation (Rahman, 
Cui et al. 2008, Rahman, Zhang et al. 2011). 
To characterize the cellular source of IL-33 bolstering antiviral CTL responses, we 
generated reciprocal bone marrow chimeras by using WT or Il33−/− mice (Fig. 1.4A). WT 
recipient mice generated significantly more LCMV-specific CTLs than Il33−/− recipients, 
irrespective of the IL-33 competence of the bone marrow. These data suggested that 
radio-resistant, and thus nonhematopoietic, cells are the main source of IL-33. IL-33+ 
cells were only detected in the spleen of chimeras generated from WT recipients, 
irrespective of the bone marrow received (WT or Il33−/−, Fig. 1.4B). IL-33+ cells 
colocalized predominantly with CD3+ cells but only sparsely with B cells (Fig. 1.4C and 
Fig. 1.S4). This was compatible with IL-33 expression by fibroblastic reticular cells 
(Moussion, Ortega et al. 2008), a stromal cell population of the T cell zone and known 
target of LCMV infection (Mueller, Matloubian et al. 2007). 
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1.3 Discussion  
In light of the evidence for IL-33 to act as an alarmin (Haraldsen, Balogh et al. 2009, 
Zhao and Hu 2010), our findings offer a previously unknown molecular link to 
understand how viral replication, commonly thought of as “danger” (Gallucci and 
Matzinger 2001), can enhance CTL responses to infection. The nonredundancy with 
PAMPs is noteworthy, particularly in the context of viral replication, which provides 
abundant PAMP signals (Schenten and Medzhitov 2011). The observed LCMV dose 
dependency suggests that the IL-33–ST2 axis is most relevant under conditions of high 
viral burden. We identified nonhematopoietic cells in the splenic T cell zone expressing 
IL-33. Depending on the site of initiation and expansion of T cell responses, other cell 
types expressing IL-33 may also supply this cytokine to CTLs (Le Goffic, Arshad et al. 
2011), and potential regulation by the soluble form of ST2 remains to be investigated 
(Becerra, Warke et al. 2008). 
PAMPs act primarily on professional antigen-presenting cells and thereby are decisive for 
efficient priming of CTLs (Joffre, Nolte et al. 2009). IL-33 and possibly also other 
alarmins have complementary and nonredundant functions and, in the case of IL-33, act 
on antiviral CTLs directly. Taken together, this study establishes a paradigm for the role 
of nonhematopoietic cells providing alarmins to augment and differentiate protective 
CTL responses to viral infection. 
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1.4 Methods 
1.4.1 Mice and animal experimentation  
IL-33-/- mice (Oboki, Ohno et al. 2010) were obtained through the RIKEN Center for 
Developmental Biology (Acc. No. CDB0631K; http://www.cdb.riken.jp/arg/ 
mutant%20mice%20list.html). Il1rl1-/-, Il1rl1-Fc, P14 and P14 Myd88-/ mice have been 
described (Pircher, Burki et al. 1989, Senn, McCoy et al. 2000, Townsend, Fallon et al. 
2000, Rahman, Cui et al. 2008). Animal experiments were performed at the Universities 
of Geneva and Zurich and at the Charité and German Rheumatism Research Center 
Berlin in accordance with the Swiss and German laws for animal protection, respectively, 
and with permission from the local veterinary offices. 
1.4.2 Gene expression analysis  
Affymetrix GeneChip Mouse Gene 1.0 ST and Applied Biosystems TaqMan RT-PCR 
assays were utilized for assessing gene expression. TaqMan results were normalized to 
GAPDH. RNA from FACS-sorted T cells was pre-amplified using the Sigma Aldrich 
Transplex WTA kit.  
1.4.3 Viruses, vaccine vectors and cytokine treatment  
LCMV-WE was administered at a dose of 200 PFU intravenously (low dose) unless 
specified. For intracerebral infection, 105 PFU of LCMV Armstrong were given. 2x106 
PFU of recombinant (thymidine kinase-deficient) vaccinia virus vector expressing 
LCMV-GP (Flatz, Hegazy et al. 2010) and 4x105 PFU wild type vaccinia virus strain WR 
were given intravenously. 105 PFU of MHV-68 were given intraperitoneally, 3x105 PFU 
of rLCMV vectors (Flatz, Hegazy et al. 2010) were administered intravenously, and 
vaccination with 200 µg of VLPs carrying GP33 (Storni, Lechner et al. 2002) was 
performed subcutaneously. Infectious LCMV, vaccinia virus and MHV-68 titers, and 
LCMV RNA were quantified as described (Adler, Messerle et al. 2000, Flatz, Hegazy et 
al. 2010). Recombinant IL-33 (eBioscience, 4 µg per dose) was administered daily 
intraperitoneally, starting on day 1 after vaccination. 
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1.4.4 T cell assays, antibody measurements and phospho-p38 
MAPK detection  
Epitope-specific T cells were enumerated using MHC class I tetramers (Beckman 
Coulter) and dextramers (Immudex), and by intracellular cytokine assays (Flatz, Hegazy 
et al. 2010). CTL activity was measured in primary ex vivo Cr51 release assays. EL-4 
cells serving as targets in primary ex vivo CTL assays were loaded with the LCMV-
epitope GP33 (KAVYNFATC) or with a mixture of MHV-68 peptides p79 (TSINFVKI) 
and p56 (AGPHNDMEI). LCMV-neutralizing antibodies were determined in plaque 
reduction assays (Pinschewer, Perez et al. 2004). For FACS detection of phospho-p38 
MAPK, cells were serum starved for 5 hours prior to adding recombinant mouse IL-33 
(R&D Systems) or mock for 30 min., then were fixed, permeabilized and stained using 
Phosflow Lyse/Fix buffer, Phosflow perm buffer III and PE anti-phospho-p38 (all from 
BD Pharmingen). For flow cytometric detection of cell surface ST2, splenocytes were 
pre-incubated with anti-mouse Fcγ-receptor antibody (clone 2.4G2) followed by staining 
with digoxigenin-coupled anti-mouse ST2 antibody (clone DJ8, mdbisoscience). For 
detection, a PE-coupled anti-digoxigenin Fab antibody (Roche) was used. To augment the 
PE signal we performed two rounds of amplification using the PE FASER Kit (Miltenyi 
Biotec). As a specificity control for surface ST2 detection by the above procedure (Fig. 
1.S2C, D), Fc block was washed away, and surface ST2 was blocked by incubation of the 
splenocytes with uncoupled ST2 antibody (10 µg/ml). Subsequently, unbound antibody 
was washed away and the cells were stained as described above. For detection of surface 
ST2 on MHC class I tetramer-binding CD8+ T cells, ST2 surface staining and 
amplification were performed first, followed by extensive washing with PBS/2% BSA. 
Only subsequently the splenocytes were incubated with the respective MHC class I 
tetramer. Further antibodies for flow cytometry were from BD Pharmingen, Biolegend, 
eBiosciences. 
1.4.5 Immunohistochemistry  
PFA-fixed tissues were subject to antigen retrieval (microwave), perioxidase inactivation 
(PBS/3% H2O2) and blocked (PBS/10% FCS). Goat anti–mouse IL-33 (R&D Systems), 
rat anti–human/mouse CD3 (Serotec) and rat anti-mouse/human B220/CD45R 
(eBioscience) served as primary antibodies and were visualized by an avidin-biotin 
technique with 3,3′-diaminobenzidine (nuclear haemalaun counterstaining) for light 
microscopy or with species-specific Alexa555- or Alexa488-conjugated secondary 
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antibodies (Invitrogen) together with DAPI (Sigma-Aldrich) in fluorescence/confocal 
microscopy.  
1.4.6 Bone marrow chimeras and adoptive cell transfer  
Recipients of bone marrow (5x106 cells) were lethally irradiated (11 Gy) the day before 
transfer, and residual T cells were depleted (100 µg T24 anti-Thy1 antibody 
intraperitoneally). We purified P14 CD8+ T cells for transfusion (104 cells per recipient) 
by magnetic cell sorting (Miltenyi Biotec). 
1.4.7 Statistical analysis  
One-way ANOVA with Bonferroni’s or Dunnett's post-test were used for multiple 
comparisons as indicated, unpaired two-tailed student's t test to compare two groups, and 
logrank tests for survival curves (Graphpad Prism software vs. 4.0b). p<0.05 was 
considered statistically significant (*), p<0.01 as highly significant (**). 
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1.5 Figures 
 
Figure 1.1: The IL-33–ST2 pathway drives protective CTL responses to replicating 
viral infection.  
(A) Kinetic analysis of IL-33 and LCMV RNA expression in the spleen after LCMV infection. 
Symbols represent the mean ± SEM of four mice. N = 1 (N refers to the number of times an 
experiment was performed). (B and C) The number of GP33-specific CTLs in the spleen, as 
detected by peptide–major histocompatibility complex (MHC) tetramer staining, on day 8 
after LCMV infection. Bars represent mean ± SEM of five mice. N = 1 (B) or 3 (C). (D) 
Epitope-specific CTLs of WT and Il1rl1−/− mice responding to replicating WT LCMV infection 
or to replication-deficient rLCMV vectors. Bars represent the mean ± SEM of five mice. N = 2. 
P < 0.0001 by one-way analysis of variance (ANOVA). Results of Bonferroni’s posttest are 
indicated. n.s., not significant; *P < 0.05; **P < 0.01. (E and F) WT mice were vaccinated 
with recombinant VV vector expressing LCMV-GP (E) or with GP33-carrying VLPs (F) on 
day 0 and were treated with IL-33 or diluent [phosphate-buffered saline (PBS)] daily from 
day 1 to 7, and CTL responses were determined on day 8. Bars represent the mean ± SEM 
of four to five mice. N = 2 (E) or 1 (F). (G) Viremia after infection with 2 × 106 plaque-forming 
units (PFU) of LCMV-WE. Symbols represent the mean ± SEM of five mice. N = 2. (H) 
Splenic MHV-68 titers on day 10 after infection. Bars represent the mean ± SEM of five mice. 
N = 1. (I) Pulmonary VV titers on day 8 after infection. Bars represent the mean ± SEM of 
four to five mice. N = 1. (J) Incidence of choriomeningitis after intracerebral LCMV infection. 
Terminally diseased animals were killed in accordance with Swiss law. Survival was 
compared by using the log rank test. Groups of six mice were used. One of two similar 
experiments is shown. Unpaired two-tailed student’s t test was used for statistical analysis in 
(B), (C), (E), (F), (H), and (I). 
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Figure 1.2: CD8+ T cell–intrinsic signaling through ST2 and MyD88 augments antiviral 
CTL responses.  
(A) Irradiated recipients were reconstituted with WT (CD45.1+) and Il1rl1−/− (CD45.1–) bone 
marrow. Flow cytometric analysis of WT and Il1rl1−/− total CD8+ T cells before infection (left) 
and virus-specific CD8+ T cells 8 days after LCMV challenge (right). Values represent mean 
frequency ± SEM of three mice. N = 2. (B) Control (CD45.1+CD45.2–) and Il1rl1−/− 
(CD45.1+CD45.2+) P14 CD8+ T cells (104) were cotransferred into WT and Il1rl1-Fc recipient 
mice (CD45.1–CD45.2+) and were enumerated on day 8 after LCMV. Bars represent the 
mean ± SEM of four mice per group. P < 0.0001 by one-way ANOVA. Results of 
Bonferroni’s posttest are indicated. One representative of three similar experiments is shown. 
(C) Control and Il1rl1−/− P14 cells (104) were individually transferred into WT recipients (left). 
Peptide-MHC tetramer–binding cells in WT and Il1rl1−/− mice were studied (right). On day 6 
after LCMV infection, the indicated cell populations in spleen were analyzed for ST2 
expression by flow cytometry. Values represent the mean ± SD of three mice. N = 2. (D) 
Flow cytometric analysis of splenic CD62LlowCD8+ T cells over time after LCMV infection. 
Symbols represent the mean ± SEM of three mice (WT days 2 to 8; Il1rl1−/− day 6) or the 
mean of two mice (other symbols). N = 2. (E) Quantitative reverse-transcription polymerase 
chain reaction (qRT-PCR) analysis of ST2 mRNA levels in P14 CD8+ T cells. Day 6 and 8 
values represent the mean ± SEM of three mice. RNA samples from three donor mice were 
pooled for combined analysis on days 0 and 4. N = 1. (F and G) Flow cytometric analysis of 
intracellular phospho-p38 expression in control and Il1rl1−/− P14 cells isolated on day 6 (F) or 
over time after LCMV infection and treated ex vivo with recombinant IL-33. Symbols in (G) 
represent the mean ± SEM of three mice. Unpaired two-tailed student’s t test was used for 
statistical analysis. One representative of two similar experiments is shown. (H) Control 
(CD45.1+CD45.2–) and Myd88−/− (CD45.1+CD45.2+) P14 cells 
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Figure 1.3: Broad and profound influence of ST2 signaling on effector CTL 
differentiation and functionality.  
(A to C) CD45.1+ control and ST2-deficient P14 CD8+ T cells (104) were adoptively 
transferred into WT recipient mice, which were then challenged with LCMV. Cytokine profile 
(A), cytolytic phenotype (B), and Bcl-2 expression (C) were assessed on day 8 after LCMV 
infection. Bars represent mean ± SEM of three mice. Values in (C) represent geometric 
mean indices (mean ± SD of three mice per group). N = 1 [(A) and (B)] or 2 (C). (D) Gene 
expression profile of P14 cells from recipients as in (A) to (C). The full set of differentially 
expressed genes is displayed in fig. 1.S3B (also listed in table S2). We validated select 
genes by qRT-PCR. Symbols show individual mice. N = 1. (E and F) Phenotypic analysis of 
splenic Il1rl1−/− and control P14 CD8+ T cells from day 8 LCMV-infected WT recipients as 
in (A) to (C). Values indicate mean ± SD of three mice. Naïve control P14 T cells are shown 
as reference in (F) (gray shaded). N = 1. Unpaired two-tailed student’s t test was used for 
statistical analysis. 
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Figure 1.4: Radio-resistant cells of the T cell zone produce IL-33 for efficient CTL 
induction.  
(A) Bone marrow chimeras were generated by using Il33−/− and WT recipients as indicated. 
Two months later, the CTL response to LCMV infection was determined (day 8 after 
infection). Bars represent the mean ± SEM of five mice. P = 0.0038 by one-way ANOVA. 
Results of Bonferroni’s posttest are indicated. N = 2. (B) Spleens from chimeras as in (A) 
were analyzed for IL-33–expressing cells by immunohistochemistry. The scale bar indicates 
50 μm. The image was acquired at 100-fold magnification. Representative pictures from one 
out of four animals are shown. (C) IL-33+ cells (green) are predominantly found in the T cell 
zone (characterized by CD3+ T cell clusters, red). DAPI (4′,6′-diamidino-2-phenylindole) was 
used to stain nuclei (blue). The central white rectangle is displayed at higher magnification in 
the top left corner of the large image. The small images at right show close vicinity of IL-33+ 
cells and CD3+ T cells. Scale bars indicate 200 μm (large image) or 50 μm (small images 
and inset). Images were acquired at 200-fold magnification by using a slide scanner (large 
image and inset) and at 400-fold magnification by confocal microscopy (small images). 
Representative pictures from one out of four mice are shown. 
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1.6 Supplementary Tables and Figures  
Supplementary Table 1.S1. Interleukin and inflammatory cytokine expression 
in LCMV infection 
Gene1 
Gene 
abbrevia
tion 
Genbank 
reference 
sequence 
Fold change 
(infected vs. 
uninfected) 
p-value stepup (p-value) 
            
Interleukins and inflammatory cytokines           
interferon gamma Ifng NM_008337 12.47 0.00 0.02 
interleukin 33 IL33 NM_001164724  4.60 0.00 0.05 
secreted phosphoprotein 1  Spp1 NM_009263 3.65 0.00 0.06 
tumor necrosis factor (ligand) Tnfsf9 NM_009404 3.25 0.02 0.10 
interleukin 6 IL6 NM_031168 2.76 0.01 0.08 
interleukin 10 IL10 NM_010548  2.54 0.01 0.10 
tumor necrosis factor (ligand) Tnfsf10 NM_009425  2.54 0.00 0.04 
interleukin 1 family, member 9 Il1f9 NM_153511  2.15 0.12 0.30 
Fas ligand (TNF superfamily, member 6) Fasl NM_010177  2.03 0.00 0.03 
interleukin 1 alpha Il1a NM_010554 1.92 0.00 0.04 
growth differentiation factor 15 Gdf15 NM_011819  1.92 0.00 0.05 
tumor necrosis factor Tnf NM_013693 1.87 0.00 0.04 
macrophage migration inhibitory factor  Mif NM_010798  1.86 0.01 0.08 
inhibin beta-A Inhba NM_008380 1.86 0.01 0.10 
interleukin 1 beta Il1b NM_008361 1.85 0.12 0.30 
interleukin 21 Il21 NM_021782 1.82 0.01 0.08 
interleukin 15 Il15 NM_008357  1.71 0.00 0.04 
kit ligand  Kitl NM_013598  1.36 0.01 0.08 
platelet factor 4 Pf4 NM_019932 1.34 0.02 0.12 
colony stimulating factor 1 (macrophage) Csf1 NM_007778 1.32 0.01 0.08 
colony stimulating factor 2 (granulocyte-macrophage) Csf2 NM_009969 1.32 0.02 0.13 
tumor necrosis factor (ligand) superfamily, member 14 Tnfsf14 NM_019418  1.29 0.06 0.20 
aminoacyl tRNA synthetase complex-interacting 
multifunctional protein 1 Aimp1 NM_007926 1.25 0.05 0.18 
leukemia inhibitory factor  Lif NM_008501  1.25 0.14 0.33 
interleukin 27 Il27 NM_145636  1.18 0.16 0.35 
tumor necrosis factor (ligand) superfamily, member 4 Tnfsf4 NM_009452 1.17 0.06 0.20 
CD70 antigen Cd70 NM_011617  1.15 0.15 0.35 
tumor necrosis factor (ligand) superfamily, member 8 Tnfsf8 NM_009403 1.12 0.33 0.54 
complement component 3  C3 NM_009778 1.12 0.07 0.23 
bone morphogenetic protein 5  Bmp5 NM_007555 1.09 0.20 0.40 
interferon alpha 2 Ifna2 NM_010503 1.08 0.31 0.52 
interleukin 12b Il12b NM_008352 1.07 0.59 0.76 
tumor necrosis factor (ligand) superfamily, member 11 Tnfsf11 NM_011613 1.07 0.21 0.42 
interleukin 23, alpha subunit p19 Il23a NM_031252 1.04 0.48 0.67 
interleukin 17A Il17a NM_010552 1.03 0.59 0.76 
interleukin 28B Il28b NM_177396 1.03 0.70 0.83 
interleukin 11 Il11 NM_008350  1.02 0.86 0.93 
interleukin 3 Il3 NM_010556  1.02 0.61 0.77 
interleukin 24 Il24 NM_053095  1.02 0.79 0.89 
bone morphogenetic protein 1 Bmp1 NR_033241 1.01 0.90 0.95 
interferon beta 1 Infb1 NM_010510  1.01 0.95 0.98 
interleukin 20 Il20 NM_021380 1.00 0.98 0.99 
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bone morphogenetic protein 8b Bmp8b NM_007559  -1.00 1.00 1.00 
interleukin 17C Il17c NM_145834 -1.01 0.93 0.96 
Tnfsf12-tnfsf13 readthrough transcript 
Tnfsf12-
Tnfsf13 NM_001034097 -1.01 0.92 0.96 
interleukin 1 family, member 6 Il1f6 NM_019450  -1.01 0.84 0.92 
interleukin 19 Il19 NM_001009940 -1.01 0.89 0.94 
growth differentiation factor 3 Gdf3 NM_008108  -1.01 0.87 0.93 
interleukin 4 Il4 NM_021283  -1.01 0.72 0.85 
interleukin 1 family, member 8 Il1f8 NM_027163  -1.02 0.93 0.96 
myostatin Mstn NM_010834  -1.02 0.83 0.91 
interferon alpha 4 Ifna4 NM_010504  -1.02 0.72 0.85 
interferon alpha 4 Lefty1 NM_010094  -1.03 0.75 0.86 
interleukin 34 Il34 NM_029646  -1.03 0.55 0.73 
secretoglobin, family 3A, member 1 
Scgb3a
1 NM_170727 -1.03 0.72 0.85 
interleukin 17D Il17d NM_145837  -1.03 0.37 0.58 
interleukin 5 Il5 NM_010558  -1.03 0.74 0.86 
fibroblast growth factor 10 Fgf10 NM_008002  -1.04 0.68 0.82 
growth differentiation factor 2 Gdf2 NM_019506  -1.04 0.53 0.72 
interleukin 25 Il25 NM_080729  -1.04 0.76 0.87 
interleukin 9 Il9 NM_008373  -1.05 0.46 0.66 
interleukin 22 Il22 NM_016971 -1.05 0.70 0.83 
bone morphogenetic protein 10 Bmp10 NM_009756  -1.06 0.64 0.79 
interleukin 17F Il17f NM_145856 -1.06 0.65 0.80 
tumor necrosis factor (ligand) superfamily, member 18 Tnfsf18 NM_183391 -1.06 0.50 0.69 
interferon alpha 1 Ifna1 NM_010502  -1.07 0.14 0.33 
interleukin 1 family, member 10 Il1f10 NM_153077 -1.07 0.41 0.61 
interleukin 31 Il31 NM_029594  -1.07 0.45 0.65 
TNFAIP3 interacting protein 2 Tnip2 NM_139064 -1.07 0.33 0.54 
bone morphogenetic protein 7 Bmp7 NM_007557 -1.07 0.23 0.44 
interleukin 22 Il22 NM_016971  -1.07 0.61 0.78 
interleukin 18 Il18 NM_008360  -1.07 0.63 0.79 
interleukin 17B Il17b NM_019508 -1.08 0.22 0.43 
interleukin 2 Il2 NM_008366  -1.09 0.21 0.42 
interleukin 1 family, member 5 (delta) Il1f5 NM_001146087 -1.09 0.28 0.50 
C-reactive protein, pentraxin-related Crp NM_007768 -1.09 0.39 0.59 
colony stimulating factor 3 (granulocyte) Csf3 NM_009971 -1.10 0.12 0.30 
cardiotrophin 2 Ctf2 NM_198858  -1.10 0.08 0.24 
transforming growth factor, beta 1 Tgfb1 NM_011577  -1.10 0.31 0.52 
interleukin 13 Il13 NM_008355  -1.12 0.27 0.48 
growth differentiation factor 9 Gdf9 NM_008110  -1.13 0.21 0.42 
tumor necrosis factor (ligand) superfamily, member 
13b 
Tnfsf13
b NM_033622 -1.13 0.33 0.54 
growth differentiation factor 1 Gdf1 NM_001163282 -1.14 0.20 0.40 
bone morphogenetic protein 3 Bmp3 NM_173404  -1.15 0.20 0.41 
interleukin 28A Il28a NM_001024673 -1.16 0.42 0.63 
cardiotrophin 1 Ctf1 NM_007795  -1.17 0.14 0.33 
interleukin 12a Il12a NM_001159424 -1.19 0.08 0.24 
growth differentiation factor 5 Gdf5 NM_008109  -1.22 0.05 0.18 
inhibin alpha Inha NM_010564 -1.24 0.10 0.27 
fibrosin Fbrs NM_010183  -1.30 0.01 0.08 
interleukin 16 Il16 NM_010551  -1.33 0.00 0.04 
bone morphogenetic protein 4 Bmp4 NM_007554 -1.42 0.08 0.24 
bone morphogenetic protein 6 Bmp6 NM_007556 -1.46 0.00 0.06 
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1 Wt mice were infected with LCMV or were left uninfected (n=3 each), and five days later 
total spleen RNA was processed for genome-wide cDNA expression analysis. The table 
displays known interleukins and soluble inflammatory mediators (compiled from the 
SABiosciences Mouse Inflammatory Cytokines & Receptors PCR Array, SABiosciences 
Mouse Common Cytokines PCR Array and Lonza Mouse Cytokines and Receptors 96 
StellARray qPCR Array) and selectively the IL-33 receptor ST2. 
bone morphogenetic protein 2 Bmp2 NM_007553  -1.47 0.02 0.10 
growth differentiation factor 11 Gdf11 NM_010272  -1.50 0.01 0.09 
lymphotoxin A Lta NM_010735 -1.55 0.02 0.10 
growth differentiation factor 10 Gdf10 NM_145741 -1.62 0.00 0.06 
CD40 ligand Cd40lg NM_011616  -1.63 0.01 0.08 
FMS-like tyrosine kinase 3 ligand Flt3l NM_013520  -1.74 0.00 0.04 
interleukin 7 Il7 NM_008371 -1.74 0.00 0.06 
lymphotoxin B Ltb NM_008518 -1.86 0.01 0.09 
            
Interleukin 33 receptor           
ST2 Il1rl1 NM_001025602 3.07 0.00 0.04 
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Supplementary Table 1.S2. Differentially expressed genes in wt and Il1rl1-/- 
effector CTLs 
Gene1 Gene abbreviation 
Genbank 
reference 
sequence 
Fold 
difference 
(ST2-/- vs. 
wt) 
p-
value 
stepup 
(p-value) 
RIKEN cDNA I830127L07 gene I830127L07Rik XM_0014771
02 
0.06 0.00 0.00 
killer cell lectin-like receptor subfamily B member 
1C 
Klrb1c NM_008527 0.11 0.00 0.00 
small nucleolar RNA, C/D box 34 Snord34 NR_002455 0.16 0.00 0.00 
small nucleolar RNA, C/D box 32A Snord32a NR_000002 0.18 0.00 0.00 
thymine DNA glycosylase Tdg NM_011561 0.23 0.00 0.02 
small nucleolar RNA, C/D box 61 Snord61 NR_002903 0.24 0.00 0.01 
small nucleolar RNA, C/D box 35A Snord35a NR_000003 0.27 0.00 0.00 
MRT4, mRNA turnover 4, homolog (S. cerevisiae) Mrto4 NM_023536 0.31 0.00 0.03 
small nucleolar RNA, C/D box 82 Snord82 NR_002851 0.34 0.00 0.00 
predicted gene, ENSMUSG00000053178 ENSMUSG00000053
178 
NM_0010426
70 
0.38 0.00 0.01 
tetraspanin 5 Tspan5 NM_019571 0.40 0.00 0.00 
killer cell lectin-like receptor subfamily G, member 1 Klrg1 NM_016970 0.40 0.00 0.02 
C-type lectin domain family 2, member i Clec2i NM_020257 0.41 0.00 0.00 
RIKEN cDNA I830127L07 gene I830127L07Rik XM_0014771
02 
0.06 0.00 0.00 
killer cell lectin-like receptor subfamily B member 
1C 
Klrb1c NM_008527 0.11 0.00 0.00 
small nucleolar RNA, C/D box 34 Snord34 NR_002455 0.16 0.00 0.00 
small nucleolar RNA, C/D box 32A Snord32a NR_000002 0.18 0.00 0.00 
thymine DNA glycosylase Tdg NM_011561 0.23 0.00 0.02 
small nucleolar RNA, C/D box 61 Snord61 NR_002903 0.24 0.00 0.01 
small nucleolar RNA, C/D box 35A Snord35a NR_000003 0.27 0.00 0.00 
MRT4, mRNA turnover 4, homolog (S. cerevisiae) Mrto4 NM_023536 0.31 0.00 0.03 
small nucleolar RNA, C/D box 82 Snord82 NR_002851 0.34 0.00 0.00 
predicted gene, ENSMUSG00000053178 ENSMUSG00000053
178 
NM_0010426
70 
0.38 0.00 0.01 
tetraspanin 5 Tspan5 NM_019571 0.40 0.00 0.00 
killer cell lectin-like receptor subfamily G, member 1 Klrg1 NM_016970 0.40 0.00 0.02 
C-type lectin domain family 2, member i Clec2i NM_020257 0.41 0.00 0.00 
RIKEN cDNA I830127L07 gene I830127L07Rik XM_0014771
02 
0.06 0.00 0.00 
killer cell lectin-like receptor subfamily B member 
1C 
Klrb1c NM_008527 0.11 0.00 0.00 
small nucleolar RNA, C/D box 34 Snord34 NR_002455 0.16 0.00 0.00 
small nucleolar RNA, C/D box 32A Snord32a NR_000002 0.18 0.00 0.00 
thymine DNA glycosylase Tdg NM_011561 0.23 0.00 0.02 
small nucleolar RNA, C/D box 61 Snord61 NR_002903 0.24 0.00 0.01 
small nucleolar RNA, C/D box 35A Snord35a NR_000003 0.27 0.00 0.00 
MRT4, mRNA turnover 4, homolog (S. cerevisiae) Mrto4 NM_023536 0.31 0.00 0.03 
small nucleolar RNA, C/D box 82 Snord82 NR_002851 0.34 0.00 0.00 
predicted gene, ENSMUSG00000053178 ENSMUSG00000053
178 
NM_0010426
70 
0.38 0.00 0.01 
tetraspanin 5 Tspan5 NM_019571 0.40 0.00 0.00 
killer cell lectin-like receptor subfamily G, member 1 Klrg1 NM_016970 0.40 0.00 0.02 
C-type lectin domain family 2, member i Clec2i NM_020257 0.41 0.00 0.00 
RIKEN cDNA I830127L07 gene I830127L07Rik XM_0014771
02 
0.06 0.00 0.00 
killer cell lectin-like receptor subfamily B member 
1C 
Klrb1c NM_008527 0.11 0.00 0.00 
small nucleolar RNA, C/D box 34 Snord34 NR_002455 0.16 0.00 0.00 
small nucleolar RNA, C/D box 32A Snord32a NR_000002 0.18 0.00 0.00 
thymine DNA glycosylase Tdg NM_011561 0.23 0.00 0.02 
small nucleolar RNA, C/D box 61 Snord61 NR_002903 0.24 0.00 0.01 
small nucleolar RNA, C/D box 35A Snord35a NR_000003 0.27 0.00 0.00 
MRT4, mRNA turnover 4, homolog (S. cerevisiae) Mrto4 NM_023536 0.31 0.00 0.03 
small nucleolar RNA, C/D box 82 Snord82 NR_002851 0.34 0.00 0.00 
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predicted gene, ENSMUSG00000053178 ENSMUSG00000053
178 
NM_0010426
70 
0.38 0.00 0.01 
tetraspanin 5 Tspan5 NM_019571 0.40 0.00 0.00 
killer cell lectin-like receptor subfamily G, member 1 Klrg1 NM_016970 0.40 0.00 0.02 
C-type lectin domain family 2, member i Clec2i NM_020257 0.41 0.00 0.00 
RIKEN cDNA I830127L07 gene I830127L07Rik XM_0014771
02 
0.06 0.00 0.00 
killer cell lectin-like receptor subfamily B member 
1C 
Klrb1c NM_008527 0.11 0.00 0.00 
small nucleolar RNA, C/D box 34 Snord34 NR_002455 0.16 0.00 0.00 
small nucleolar RNA, C/D box 32A Snord32a NR_000002 0.18 0.00 0.00 
thymine DNA glycosylase Tdg NM_011561 0.23 0.00 0.02 
small nucleolar RNA, C/D box 61 Snord61 NR_002903 0.24 0.00 0.01 
small nucleolar RNA, C/D box 35A Snord35a NR_000003 0.27 0.00 0.00 
MRT4, mRNA turnover 4, homolog (S. cerevisiae) Mrto4 NM_023536 0.31 0.00 0.03 
small nucleolar RNA, C/D box 82 Snord82 NR_002851 0.34 0.00 0.00 
predicted gene, ENSMUSG00000053178 ENSMUSG00000053
178 
NM_0010426
70 
0.38 0.00 0.01 
tetraspanin 5 Tspan5 NM_019571 0.40 0.00 0.00 
killer cell lectin-like receptor subfamily G, member 1 Klrg1 NM_016970 0.40 0.00 0.02 
 
1 CD45.1+ control and Il1rl1-/- P14 indicator CD8 T cells (104) were transferred to separate 
groups of wt recipient mice and were challenged with LCMV. Eight days later, LCMV-
specific CD45.1+ CD8+ indicator CTLs were sorted by flow cytometry and were processed 
for genome-wide cDNA expression analysis (n=3 for each group). Genes are displayed, 
which were ≥2-fold differentially expressed, with a step-up p-value of <0.05. 
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Figure 1.S1: IL-33 drives protective CTL responses to replicating viral infection, is 
induced by MHV-68, and is necessary for control of high dose but not low dose LCMV 
infection. 
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Figure 1.S1: IL-33 drives protective CTL responses to replicating viral infection, is 
induced by MHV-68, and is necessary for control of high dose but not low dose LCMV 
infection. 
A-D: Splenic LCMV-specific CTLs on day 8 (A-C) and MHV-68-specific CTLs (D) on day 10 
after infection. Bars represent the mean±SEM of five (A-C) or four (D) mice. One out of two 
similar experiments is shown in A and B. N=1 for C-D. E: Kinetic analysis of IL-33 mRNA 
expression in the spleen after MHV-68 infection. Symbols represent the mean±SEM of four 
mice. P<0.0001 by 1-way ANOVA. Results of Dunnett’s post-test comparing against day 0 
values are indicated. n.s.: not significant ; *: p<0.05 ; **: p<0.01. N=1. F-G: Splenocytes as in 
A-D were tested in primary ex vivo Cr51 release assays. N=2 (F) or 1 (G). H-I: CTL response 
to replication-defective adenoviral vector expressing GP33 (H) and wt vaccinia virus or 
recombinant vaccinia virus vector expressing LCMV-GP (I). Bars represent the mean±SEM 
of three to five mice. One representative of two similar experiments is shown. J: LCMV titers 
in spleen after infection with 200 PFU (standard low dose) of LCMV-WE. Symbols represent 
the mean of two to six mice per time point. Data are combined from three experiments. K: 
Viremia after infection with 2x106 PFU of LCMV Clone 13. Symbols represent the 
mean±SEM of four to six mice per group. N=1. L: LCMV-neutralizing antibody in serum after 
infection with 2x106 PFU of LCMV-WE (high dose, same experiment as in Fig. 1.1G) as 
determined in plaque reduction assays (Pinschewer, Perez et al. 2004). Bars and symbols 
represent the mean±SEM of four to five mice. One representative of two similar experiments 
is shown. The p-values displayed in the figures were obtained using unpaired two-tailed 
student’s t test. 
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Figure 1.S2: Unaltered repartition of ST2-competent and -deficient B cell 
compartments after LCMV infection, impaired CTL induction in Il1rl1-/- mice 
irrespective of CD4+ T cells, and ST2 expression on antiviral CD8+ T cells.  
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Figure 1.S2: Unaltered repartition of ST2-competent and -deficient B cell 
compartments after LCMV infection, impaired CTL induction in Il1rl1-/- mice 
irrespective of CD4+ T cells, and ST2 expression on antiviral CD8+ T cells.  
A: Irradiated recipients were reconstituted with wt (CD45.1+) and Il1rl1-/- (CD45.1-) bone 
marrow. Flow cytometric analysis of wt and Il1rl1-/- B220+ B cells before (left) and after 
LCMV challenge (right). Values represent mean frequency±SEM of three mice. N=2. B: Wt 
and Il1rl1-/- mice were depleted of CD4+ T cells as described (Pinschewer, Perez et al. 2004) 
or were left untreated. CTL responses were measured on day 8 after LCMV infection. Bars 
show the mean±SEM of four mice. One representative of two similar experiments is shown. 
C: ST2 expression of splenic CD8+ T cells on the indicated days after LCMV infection (same 
experiment as displayed in Fig. 1.2D). As a specificity control, ST2-antibody block was 
performed as described in Methods. One representative mouse out of two to three per group 
and time point is shown. N=2. D: Control and Il1rl1-/- P14 cells (104) were individually 
transferred into wt recipients (left panels on day 6 and 8, respectively). Peptide-MHC 
tetramer-binding cells of wt and Il1rl1-/- mice were analyzed on day 6 and 8, and are 
displayed in the center and right panel, respectively. P14 donor cells (left panels) and 
endogenous peptide-MHC-binding CTL populations in spleen were analyzed for ST2 
expression by flow cytometry. The top row provides comparative histogram charts of 
representative mice shown in the bottom rows. Representative samples from two to three 
mice per group and time point are shown. N=1. 
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Figure 1.S3: Reduced plurifunctionality, differential gene expression profile and 
surface marker expression, and defective expansion of Il1rl1-/- CTLs in the effector 
phase.  
A: Wt and Il1rl1-/- mice were infected with LCMV, and the plurifunctionality of GP33-specific 
CD8+ T cells was assessed on day 8 after infection by intracellular cytokine stain. Bars 
display the mean±SEM of four mice. The p-values displayed in the figure were obtained by 
unpaired two-tailed student’s t test. N=1. B: Gene expression profile of control and Il1rl1-/- 
P14 cells from recipients as in Fig. 1.3A-C. Differentially expressed genes (≥2-fold different, 
step-up p-value <0.05) are displayed for individual mice (same as in Table S2). N=1. C-E: 
Control and Il1rl1-/- P14 cells (104) were individually transferred into wt recipients (top row). 
The Alarmin Interleukin-33 Drives Protective Antiviral CD8+ T Cell Responses 
 46 
Peptide-MHC tetramer-binding cells of wt and Il1rl1-/- mice are displayed in the center and 
bottom rows. On day 8 after LCMV infection the indicated cell populations in spleen (P14, 
GP33-Tet+ or NP396-Tet+) were phenotypically characterized by flow cytometry. Naïve 
control P14 T cells (top row) and naïve wt CD8+ T cells (center and bottom row) are shown 
as reference (gray shaded). Plots are representative for three (P14) or two to three mice 
(Tet+) per group in one experiment. N=1 (P14) or 3 (Tet+ cells). F: Wt and Il1rl1-/- mice were 
infected with 200 PFU of LCMV Armstrong i.v. Virus-specific peptide-MHC tetramer-binding 
CTLs were monitored in blood over time and enumerated in spleen on day 30, and their 
KLRG-1 expression was analyzed. Symbols and bars represent the mean±SEM of four mice. 
One representative of two similar experiments is shown. G: Wt and Il1rl1-/- mice were 
immunized with replication-deficient rLCMV vector (Flatz, Hegazy et al. 2010). On day 206 
after immunization these animals and an unvaccinated group of wt mice were challenged 
with 2x106 PFU LCMV Clone 13 i.v. Viral titers were determined in spleen three days later. 
Bars show the mean±SEM of five mice. P<0.0001 by 1-way ANOVA. Results of Bonferroni’s 
post-test are indicated. n.s.: not significant ; **: p<0.01. One representative of two similar 
experiments is shown. 
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Figure 1.S4: Paucity of IL-33+ cells in the splenic B cell zone.  
IL-33+ cells (green) are rarely found in the B cell zone (characterized by dense clusters of 
B220+ T cells, red). Nuclei are counterstained with DAPI (blue). The scale bar indicates 
200 µm. The image was acquired at 200-fold magnification using a slide scanner. 
Representative pictures from one of four sections are shown. 
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2 Interleukin-33 and Stromal Cells 
in Chronic Viral Infection 
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2.1 Summary  
In response to viral infection endogenous molecules, called alarmins, are released from 
necrotic cells serving as a signal of tissue damage. Besides various effects of the alarmin 
Interleukin-33 (IL-33) on Th2-biased immune responses, we have previously 
demonstrated its importance for the initiation of a potent CD8+ T cell (CTL) response to 
acute infection with several prototypic replicating RNA- and DNA-viruses (Bonilla, 
Frohlich et al. 2012). Whereas CD8+ T cells manage to clear acute LCMV infection 
independently and even in the absence of CD4+ T cells (Moskophidis, Cobbold et al. 
1987, Ahmed, Butler et al. 1988, Rahemtulla, Fung-Leung et al. 1991), an only temporary 
blockade of CD4+ T cell help abrogates control of chronic LCMV infections and mice 
become lifelong carriers. LCMV-specific CD8+ T cell responses were completely lost in 
persistently infected animals upon deletion of CD4+ T cells, underlining the critical role 
of CD4+ T cell help for maintaining potent antiviral CTL responses during chronic viral 
infection (Matloubian, Concepcion et al. 1994). Furthermore LCMV-specific antibody 
responses produced by B cells are essential for control and clearance of persistent LCMV 
infection, the activation of which also depends on CD4+ T cell help (Bergthaler, Flatz et 
al. 2009). Thus both CD4+ and CD8+ T cell populations are critical for the outcome of 
chronic infection (Doherty, Allan et al. 1992, Matloubian, Concepcion et al. 1994).  
In this study we investigated whether signaling via the IL-33/ST2 axis is important for 
CD4 and CD8 T cell responses to chronic LCMV infection. We found that IL-33 plays a 
crucial role for the expansion and maintenance of both CD8+ and CD4+ T cells as well as 
for the differentiation of virus-specific CD4+ T cells in chronic viral infection. Using a 
novel IL-33 reporter mouse we identified fibroblastic reticular cells (FRCs) as the main 
IL-33 expressing cells in secondary lymphoid organs. By means of GFP-tagged reporter 
viruses and immunohistochemistry we demonstrate that blood endothelial cells but not 
FRCs are a main early stromal cell target of systemic LCMV infection. We furthermore 
present data suggesting that virus-specific CD8+ T cells require a constant ST2-mediated 
survival signal in order to be maintained in the chronic infection context and that lack of 
ST2 signaling affects the tissue distribution and differentiation of virus-specific CD4+ T 
cells towards a T follicular helper cell phenotype. 
The present data extends our knowledge on the role of IL-33 as an alarmin in Th1-biased 
immune responses to the context of chronic viral infections. More detailed knowledge on 
the factors that influence and shape immune responses to persistent viral infections are 
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essential to refine immunotherapeutic approaches to chronic viral infections like HIV and 
HCV, which represent major global health challenges. In the absence of a preventive 
vaccine, a detailed understanding of the mechanisms underlying chronicity and imperfect 
immune control should allow for the development of innovative therapies against these 
diseases. 
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2.2 Introduction 
The immune system has developed mechanisms to sense endogenous damage signals or 
exogenous danger and trigger activation of signaling cascades to finally initiate or 
enhance the appropriate immune responses. Upon necrosis, intracellular proteins are 
released from the dying cell in an uncontrolled fashion. Some of these endogenous 
molecules, called “alarmins”, can indicate cell damage and warn the immune system of 
the necrotic event (Oppenheim and Yang 2005, Bianchi 2007). Interleukin-33 (IL-33) is a 
member of the IL-1 family, which can be released by necrotic cells upon tissue injury 
(Cayrol and Girard 2009, Luthi, Cullen et al. 2009), classifying it as an alarmin 
(Moussion, Ortega et al. 2008). Once in the extracellular space, it binds to its cell surface 
receptor consisting of ST2 in association with the ubiquitous IL-1R accessory protein 
(IL1RAcP) (Schmitz, Owyang et al. 2005, Ali, Huber et al. 2007) and leads to activation 
of downstream signaling cascades (Palmer Gabay). 
IL-33 has primarily been shown to play a role in the context of Th2-associated immune 
responses like asthma and allergic responses and in responses against parasitic infections 
(summarized in (Liew, Pitman et al. 2010, Garlanda, Dinarello et al. 2013)). However, 
IL-33 has also been shown to be an enhancer of IFN-γ production by iNKT cells, NK 
cells and CD8+ T cells (Smithgall, Comeau et al. 2008, Bourgeois, Van et al. 2009, Yang, 
Li et al. 2011). Thus the role of IL-33 is not exclusive to Th2 responses. Indeed, in 
section 1 we have shown that IL-33 is essential for the establishment of a potent anti-viral 
immune response and that IL-33 signaling is necessary for the clonal expansion and 
functionality of cytotoxic CD8+ T cells during viral infection. In case of a lack of IL- 33 
signaling on responding CD8+ T cells, they showed impaired cytotoxicity, reduced 
secretion of cytokines and impaired virus control (Bonilla, Frohlich et al. 2012).  
While CD8+ T cells manage to resolve acute viral infections independently of the 
presence of CD4+ T cells (Moskophidis, Cobbold et al. 1987, Ahmed, Butler et al. 1988, 
Rahemtulla, Fung-Leung et al. 1991), even a transient depletion or blockade of CD4+ T 
cells in the course of chronic infection has drastic effects on the immune response and 
prevents clearance of the virus (Doherty, Allan et al. 1992, Matloubian, Concepcion et al. 
1994). As a consequence both CD4+ and CD8+ T cells play an important role in anti-
viral immune responses in the chronic infection context and thus for successful clearance 
of the virus. In the course of chronic infection antiviral CTLs can be deleted or 
functionally inactivated (Moskophidis, Lechner et al. 1993, Zajac, Blattman et al. 1998), 
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commonly referred to as “exhaustion” of virus-specific CTLs. The knowledge of factors 
that are regulating maintenance of T cells in chronic infection is, however, very limited. 
IL-21 is the only cytokine known to be required for the physical maintenance and 
functionality of virus-specific CD8+ T cells in chronic viral infections (Elsaesser, Sauer 
et al. 2009, Frohlich, Kisielow et al. 2009, Yi, Du et al. 2009).  
We have demonstrated IL-33 to be vital for expansion of virus-specific cells in acute viral 
infection and we have shown that radio-resistant cells are the source of IL-33, the release 
of which finally drives efficient T cell responses (Bonilla, Frohlich et al. 2012), 
suggesting a prominent role of stromal cells for the outcome of viral infections. Also 
other reports have investigated the cellular source of IL-33 and found cells in mouse 
epithelial barrier tissues, lymphoid organs, brain, embryos and inflamed tissues, but not in 
endothelial vessels to express IL-33 (Pichery, Mirey et al. 2012). Notably the absence of 
IL-33 in endothelial vessels represents an important species-specific difference between 
humans and mice (Baekkevold, Roussigne et al. 2003, Carriere, Roussel et al. 2007). 
Based on immunofluorescence and flow cytometry and the expression of VCAM-1 
fibroblastic reticular cells (FRCs) were suggested to be the cellular source of IL-33 
(Moussion, Ortega et al. 2008, Pichery, Mirey et al. 2012, Hardman, Panova et al. 2013). 
FRCs are stromal cells and as such are a part of the non-hematopoietic compartment in 
secondary lymphoid organs. The non-hematopoietic (CD45-negative) connective tissue 
compartment of the spleen forms the structural backbone and is made up of three cell 
types: blood endothelial cells (CD31-positive, gp38-negative), fibroblastic reticular cells 
(CD31-negative, gp38-positive) and yet poorly characterized so-called double-negative 
cells. Blood endothelial cells line the interior surface of blood vessels and serve as a 
barrier between vessel lumen and tissue. Fibroblastic reticular cells form the three-
dimensional architecture in splenic T-cell zones. The functions of double-negative cells 
remain to be investigated (Mebius and Kraal 2005). 
We demonstrate that IL-33 released by FRCs is crucial for the expansion, maintenance 
and differentiation of virus-specific T cells in chronic viral infection, most likely by a 
continuous low-level signaling via the IL-33/ST2 axis rather than a one time imprinting 
event. This highlights the importance of IL-33 and the non-hematopoietic cell 
compartment in immune responses in the chronic infection context. 
Interleukin-33 and Stromal Cells in Chronic Viral Infection 
 54 
2.3 Material and Methods 
2.3.1 Cells 
BHK-21 cells were cultured in high-glucose Dulbecco’s Eagle medium (DMEM; Sigma) 
supplemented with 10 % heat-inactivated fetal calf serum (FCS; Biochrom), 10 mM 
HEPES (Gibco), 1 mM sodium pyruvate (Gibco) and 1x tryptose phosphate broth 
(Sigma). MC57 cells were maintained in Minimum Essential Medium (MEM; Sigma) 
complemented with 5 % heat-inactivated FCS, 2 mM L-glutamine (Gibco) and penicillin-
streptomycin (100’000 U/ml penicillin and 50 mg/l streptomycin; Gibco). Both cell lines 
were cultured at 37 °C in a humidified 5 % CO2 incubator. 
2.3.2 Plasmids 
The pol-I L, pC-NP and pC-L plasmids have previously been described (Flatz, Bergthaler 
et al. 2006). For the generation of the pol-I S plasmid encoding for GFP as a reporter 
gene and either NP or GP, we used a pol-I Bbs/Bsm cloning plasmid as a basis (pol-I 5’-
BsmBI_IGR_BbsI_3’), which enables the insertion of genes at the 5’ or 3’ UTR with 
site-specific restriction/ligation using BsmBI or BbsI, respectively. GP was inserted by 
BbsI digest at the 3’ position into the pol-I Bbs/Bsm plasmid and GFP with BsmBI 
restriction/ligation at the 5’ position. pol-I S encoding for GFP and NP (pol-I 5’-
GFP_IGR_NP-3’) were cloned by inserting NP by BbsI digestion and ligation into the 
pol-I Bbs/Bsm cloning plasmid and GFP by BsmBI cloning.  
2.3.3 DNA transfection of cells and rescue of reporter 
viruses 
BHK-21 cells were seeded into 6-well plates at a density of 4x105 cells/well and 
transfected 24 hours later with different amounts of DNA using lipofectamine (3 µl/µg 
DNA; Invitrogen) according to the manufacturer’s instructions. For rescue of tri-
segmented viruses entirely from plasmid DNA, the two minimal viral trans-acting factors 
NP and L were delivered from pol-II driven plasmids (0.8 µg pC-NP, 1 µg pC-L) and 
were co-transfected with 1.4 µg of pol-I L and 0.8 µg of both pol-I driven S segments. 72 
hours after transfection the supernatant was harvested and passaged on BHK-21 cells for 
further amplification of the virus. Viral titers in the supernatant were determined by focus 
forming assay. 
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2.3.4 Viruses 
Wild-type LCMV strain Clone 13 (Cl13; (Ahmed, Salmi et al. 1984)), originally derived 
from wild-type LCMV Armstrong, and strain WE (Scott and Rivers 1936) have 
previously been described. Stocks of wild-type and recombinant viruses were produced 
by infecting BHK-21 cells at a multiplicity of infection (moi) of 0.01 and supernatant was 
harvested 48 hours after infection. Viral titers were analyzed by focus forming assay. 
Mice were infected intravenously with 200, 5x105 or 2x106 plaque forming units (PFU). 
2.3.5 Focus forming assay 
Titers of LCMV are determined by focus forming assay as previously described 
(Battegay, Cooper et al. 1991). LCMV is a non-cytolytic virus that does not lyse its host 
cells and as such does not create plaques. Nevertheless units in this work will be 
expressed in the more commonly used term plaque forming units (PFU) instead of the 
correct term focus forming units (FFU). MC57 cells were used for focus forming assay if 
not stated otherwise. Cells were seeded at a density of 1.6x105 cells per well in a 24-well 
plate and mixed with 200 µl of 10-fold serial dilutions of virus prepared in MEM/ 2 % 
FCS. After 2-4 hours of incubation at 37 °C, 200 µl of a viscous medium (2 % 
Methylcellulose in 2x supplemented DMEM) were added per well to ensure spreading of 
viral particles only to neighboring cells. After 48 hours at 37 °C the supernatant was 
flicked off and cells were fixed by adding 200 µl of 4 % paraformaldehyde (PFA; 
applichem) in PBS for 30 minutes at room temperature (all following steps are performed 
at room temperature). Cells were permeabilised with 200 µl per well of BSS/ 1 % Triton 
X-100 (Merck Millipore) for 20 minutes and subsequently blocked for 60 minutes with 
PBS/ 5 % FCS. For staining of NP-positive foci a rat anti-LCMV-NP monoclonal 
antibody was used as a primary staining antibody at a dilution of 1:30 in PBS/ 2.5 % FCS 
for 60 minutes. Plates were washed three times with tap water and the secondary HRP-
goat-anti-rat-IgG was added at a dilution of 1:100 in PBS/ 2.5 % FCS and incubated for 1 
hour. The plate was again washed three times with tap water. The color reaction (0.5 g/l 
DAB (Sigma D-5637), 0.5 g/l Ammonium Nickel sulfate in PBS/ 0.015 % H2O2) was 
added and the reaction was stopped after 10 minutes with tap water. Stained foci were 
counted manually and the final titer calculated according to the dilution. 
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2.3.6 Mice 
IL-33-/- (Oboki, Ohno et al. 2010), ST2-/- (Senn, McCoy et al. 2000), ZP3-Cre 
(Lewandoski, Wassarman et al. 1997), Smarta1 (SM1) (Oxenius, Bachmann et al. 1998) 
and P14 (Pircher, Burki et al. 1989) mice have previously been described. ST2-/-SM1 
mice and ST2-/-P14 mice were obtained by intercrossing SM1 or P14 mice with ST2-/- 
mice, respectively. IFNAR-/-P14 mice have previously been reported (Crouse, 
Bedenikovic et al. 2014) and were kindly provided by Prof. A. Oxenius. C57BL/6J 
(“B6”) mice were either purchased from Charles River or bred in-house. All mice were 
bred and housed under specific pathogen-free (SPF) conditions. They were bred at the 
Institut für Labortierkunde of the University of Zurich, Switzerland. All animal 
experiments were performed at the Universities of Geneva and Basel in accordance with 
the Swiss law for animal protection and the permission of the respective responsible 
cantonal authorities of Geneva and Basel. Infection of the mice was done via the 
intravenous route. Natural killer (NK) cells were depleted by injecting doses of 300 µg 
anti-NK1.1 antibody (clone PK-136; BioXCell) intraperitonally on day -2, 0, 3 and 6 with 
day 0 being the day of LCMV injection. 
2.3.7 Adoptive cell transfer 
LCMV-specific CD8+ P14 cells were purified from the spleen of respective transgenic 
mice by magnetic cell sorting using the “Naïve CD8a+ T Cell Isolation Kit, mouse” 
(Miltenyi Biotec) according to the manufacturer’s protocol. For purification of LCMV-
specific CD4+ SM1 cells from spleens of respective transgenic donors we used the 
“CD4+ T Cell Isolation Kit II” (Miltenyi Biotec) followed by magnetic cell sorting 
according to the company’s instructions. Purity of the cell suspension was verified by 
flow cytometry and 500 or 5000 transgenic cells per recipient were transferred 
intravenously in Balanced Salt Solution (BSS; 0.01 g/l Phenol Red, 0.14 g/l CaCl2·2 H2O, 
8 g/l NaCl, 0.4 g/l KCl, 0.2 g/l MgSO4·7 H2O, 0.2 g/l MgCl·6 H2O, 60 mg/l KH2PO4, 
0.24 g/l Na2HPO4·2 H2O, 1 g/l D-Glucose; KH2PO4: Sigma, everything else: Fluka).  
2.3.8 Flow cytometry 
Blood and single cell suspensions obtained from lymph nodes, spleen and liver were 
stained with antibodies against CD4 (RM4-5 or GK1.5), CD8 (53-6.7), CD45R/B220 
(RA3-6B2), CD45.1 (A20), CD45.2 (104), CD90.1 (OX-7), Ter-119 (TER-119), CD31 
(390), gp38 (Podoplanin; 8.1.1), CXCR5 (2G8). Dead cells were excluded with either 7-
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AAD or Zombie UV Fixable Viability Kit (Biolegend). CD8+ T cells specific for 
LCMV-epitopes GP33 or GP276 were analyzed using MHC class I tetramer staining (TC 
Metrix) as previously described (Gallimore, Glithero et al. 1998). Expression of ST2 on 
the cell surface was analyzed by staining blood or splenocytes with a digoxigenin-
coupled anti-mouse ST2 antibody (DJ8; mdbiosciences) and detecting the signal with a 
secondary PE-conjugated anti-digoxigenin Fab antibody (Roche). The PE-singal was 
further amplified with two rounds of amplification using the PE FASER Kit (Miltenyi 
Biotec) according to the manufacturer’s instructions. All stainings were performed in 
FACS buffer (PBS/ 2 % FCS/ 5 mM EDTA/ 0.05 % sodium azide) if not stated 
differently.  
The cytokine profile of splenocytes was determined by intracellular cytokine staining. For 
this purpose, spleen cells were restimulated with 1 µg/ml of GP64-80 peptide for 5 hours 
at 37°C in a humidified 5% CO2 incubator in presence of 5 µg/ml brefeldin A (added 
after 1h). Cells were fixed in 2 % paraformaldehyde (PFA; Applichem) and intracellular 
cytokine staining was performed in FACS buffer containing 0.05 % saponin (Sigma) with 
antibodies against IFN-γ (XMG1.2), TNF-α (MP6-XT22) and IL-2 (JES6-5H4). 
The expression of surface and intracellular molecules as well as GFP expression was 
analyzed on a Beckman Coulter Gallios or a BD LSR Fortessa flow cytometer using 
Kaluza (Beckman Coulter) or FlowJo software (Tree Star, Ashland, OR). 
2.3.9 Immunofluorescence 
Immunofluorescence stainings were performed by collaborators in the groups of Prof. 
Doron Merkler at University of Geneva and Prof. Sanjiv Luther at University of 
Lausanne. Briefly, organs from PFA-perfused mice were isolated and fixed in 4% PFA 
for 1 hour. The tissue was saturated in 30% sucrose and embedded on 100% OCT Tissue-
Tek freezing medium. Sections were cut and stained with antibodies specific for CD31, 
LCMV-NP, Podoplanin (gp38) or IL-33 and with DAPI to stain DNA. 
2.3.10 Isolation of cells 
Single-cell suspensions for the analysis of lymphocytes from spleen, liver or lymph nodes 
were obtained by mashing the organs with a piston through a 70 µm cell strainer (BD 
Biosciences). 
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Stromal cells from spleens and lymph nodes (inguinal, axillary and brachial) were 
isolated by cutting the respective organs into small pieces and incubating the tissue in 
RPMI containing 1 mg/ml Collagenase IV (Worthington), 40 µg/ml DNAseI (Roche) and 
2 % (vol/vol) FCS for 30 minutes at 37°C stirring at a speed of 300 rpm. The cell 
suspension was homogenized by pipetting and incubated for another 30 minutes until no 
visible pieces were present anymore. The cell suspension was passed through a 70 µm 
cell strainer and the enzymatic digestion was stopped by addition of FACS buffer (recipe 
in the flow cytometry section). The proportion of stromal cells was enriched by lysing 
erythrocytes with ACK Lysis Buffer (0.15 M NH4Cl, 10 mM KHCO3, 0.1 mM EDTA) 
for 45 seconds at room temperature and by depleting hematopoietic CD45+ cells by 
magnetic cell sorting using anti-CD45 beads (Miltenyi Biotec). 
Hepatic stromal cells were isolated by chopping the liver into small pieces and incubating 
the tissue with RPMI containing 2.4 mg/ml collagenase type I (Gibco), 0.2 mg/ml 
DNAseI (Roche) and 10 % FCS stirring at 300 rpm at 37°C. After 30 minutes the tissue 
was homogenized with a 18G needle and incubated for another 30 minutes at 37°C. 
Remaining chunks were homogenized with a 21G needle and the resulting cell 
suspension filtered through a 70 µm cell strainer. The enzymatic digestion was stopped 
by adding FACS buffer and the suspension was enriched for stromal cells by lysing 
erythrocytes and depleting hematopoietic CD45+ cells as described in the previous 
paragraph. 
2.3.11 Statistical Analysis 
Statistical significance was determined by 1-way ANOVA followed by Bonferroni’s 
post-test for multiple comparisons using Graphpad Prism software (version 6.0d). 
p values of p > 0.5 were considered not statistically significant (ns), whereas p values of 
p < 0.5 were considered significant (*) with gradations of p < 0.1 (**) and p < 0.01 (***) 
being highly significant. 
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2.4 Results  
Generation of a mouse line reporting IL-33 expression by means of GFP. 
We have previously reported that the alarmin Interleukin-33 is necessary for eliciting 
potent CD8+ T cell responses against prototypic RNA- and DNA-viruses, amongst them 
LCMV (Bonilla, Frohlich et al. 2012). Experiments with bone-marrow chimeric mice, 
where lethally irradiated wild-type or IL-33 deficient mice were reconstituted with IL-33 
competent or IL-33 deficient bone marrow, demonstrated that IL-33 produced by non-
hematopoietic stromal cells was essential to drive efficient anti-viral CD8+ T cell 
responses. Immunofluorescence analysis had confirmed IL-33 expression by radio-
resistant cells in the T cell zone of spleens. Following these observations we wanted to 
further analyze which stromal cell type expresses IL-33. We also aimed at a tool to 
analyze IL-33 expression by flow cytometry, which thus far has not been possible with 
antibody-based methods. For a quantitative readout of IL-33 levels on a per cell basis, we 
aimed at generating a mouse line reporting expression of IL-33 by means of GFP. We 
took advantage of an IL-33 deficient mouse line that carries a GFP gene and a 
downstream neomycin resistance gene (neoR) that is flanked by loxP sites (“MT allele”; 
Fig. 2.1A) (Oboki, Ohno et al. 2010). The entire cassette is inserted in the second exon of 
the IL-33 open reading frame (ORF), thus its expression is controlled by the IL-33 
promoter. However, the knock-in as such did not provide any detectable reporter activity 
(data not shown). We hypothesized that expression of the neomycin resistance gene, 
which is controlled by a strong promoter, interferes with and suppresses upstream 
expression of GFP to undetectable levels. By intercrossing these mice with ZP3-Cre mice 
that express the loxP site-specific DNA recombinase Cre in oocytes (Lewandoski, 
Wassarman et al. 1997), the loxP-flanked neoR downstream of GFP was excised (à “IL-
33 reporting allele”; Fig. 2.1A). Indeed, upon excision of neoR, IL-33 promoter-driven 
GFP expression was not suppressed anymore and could readily be detected by flow 
cytometry. 
Fibroblastic reticular and lymphatic endothelial cells are the main producers of 
interleukin-33 in secondary lymphoid organs. 
In order to test whether our breeding strategy led to detectable GFP expression in IL-33 
producing cells, we isolated stromal cells from the spleens of uninfected IL-33 reporter 
mice. The regulatory mechanisms of IL-33 expression are not well understood yet and it 
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has not been conclusively analyzed so far whether positive or negative feedback loops 
play a role for regulation of IL-33 expression. Taking this into consideration, we used our 
IL-33 reporter mice in a hemizygous background, so that they were IL-33 competent. 
This enabled us to reduce the risk for artifacts due to the lack of IL-33 in the system. We 
established an optimized protocol for the isolation of splenic stroma by collagenase 
digestion of the tissue followed by depletion of hematopoietic CD45+ cells. When 
analyzing the resulting single-cell suspension by flow cytometry (Fig. 2.1B-D), we 
excluded erythrocytes and all remaining CD45+ hematopoietic cells. The expression 
pattern of the endothelial cell marker CD31 and the fibroblast marker gp38 (Podoplanin) 
allowed us to distinguish fibroblastic reticular cells (FRC; gp38+CD31-) from blood 
endothelial cells (BEC; gp38-CD31+) and double-negative stromal cells (DN; gp38-
CD31-) (Fig. 2.1B). Each of the three stromal cell populations was further analyzed for 
their GFP expression and the percentage of GFP+ cells within the respective 
compartment was quantified (Fig. 2.1C-D). Whereas DNs and BECs only had a very 
small population of GFP+ cells (DN: 0.13 %; BEC: 0.15 %), 45 % of FRCs showed a 
pronounced population of GFP+ and thus IL-33 producing cells (Fig. 2.1D; one 
respresentative histogram of the GFP profile of FRCs is shown in Fig. 2.1C). The same 
held true when analyzing the total amount of GFP+ cells per spleen, in that we also found 
most of the GFP+ cells to be FRCs (Fig 2.1D). In parallel we isolated the stroma of 
lymph nodes from uninfected IL-33 reporter mice by collagenase digestion and analyzed 
it by flow cytometry. The stroma compartment in lymph nodes consists of four 
populations, which also can be distinguished by expression of CD31 and gp38. 
Expression patterns of FRC, BEC and DN were the same as in spleen but unlike in spleen, 
a fourth stromal cell population, the lymphatic endothelial cells (LEC) can be identified 
by expression of both markers CD31 and gp38 (Fig. 2.1E). Analysis of the percentage of 
GFP+ cells confirmed FRCs as the main GFP+ expressing cell type but also more than 
10 % of LECs were found positive for GFP under naïve conditions (Fig. 2.1F), whereas 
BECs and DNs only showed a very low percentage of GFP+ cells (0.06 % and 0.38 %, 
respectively). However, since LECs are comparatively rare in lymph nodes, FRCs 
quantitatively made up for the majority of GFP+ cells in that organ. Importantly, we also 
analyzed the hematopoietic compartment of the organs of IL-33 reporter mice. However, 
GFP+ cells were virtually absent within this compartment (< 0.01 % of the analyzed 
population; data not shown).  
We tested whether the IL-33 reporting mouse line was a faithful reflection of IL-33 
expression patterns. Spleens and lymph nodes of hemizygous IL-33 reporter mice were 
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co-stained with anti-IL33 specific antibodies and analyzed by immunofluorescence (Fig. 
2.2A+C; done by H-Y. Huang and S. Favre in the Luther lab at UNIL). We found that 
virtually all cells that were stained by the anti-IL-33 antibody were also positive for GFP. 
In addition we found GFP single-positive cells, which probably can be explained by the 
higher sensitivity of the GFP signal as compared to immunofluorescence staining with an 
IL-33 specific antibody. We also validated our homozygous IL-33 deficient mice, which 
did not show any immunofluorescence staining with the IL-33 specific antibody, neither 
in spleen nor in lymph nodes (Fig. 2.2B+D; done by H-Y. Huang and S. Favre in the 
Luther lab at UNIL). Consequently we can conclude that our IL-33 reporting mice 
reliably detect IL-33 promoter activity and that fibroblastic reticular cells and lymphatic 
endothelial cells are the main producers of IL-33 in resting secondary lymphoid organs. 
By validating our IL-33 reporter mouse line we also confirmed our earlier findings that 
the IL-33 signal originates from the non-hematopoietic compartment of SLOs (Bonilla, 
Frohlich et al. 2012). 
Blood endothelial cells rather than IL-33 producing fibroblastic reticular cells are the 
primary stromal cell target of LCMV in spleen. 
We have shown that IL-33 is important for an anti-viral immune response against LCMV. 
The mechanism, however, that triggers release of IL-33, remains to be elucidated. In 
order to investigate whether release of IL-33 could be a consequence of infection of the 
IL-33 expressing cells we generated recombinant reporter viruses, which allow us to track 
infected cells by expression of GFP. It has been shown that it is possible to introduce 
foreign genes of interest into the genome of normally bi-segmented wild-type LCMV. 
Following a published strategy (Emonet, Garidou et al. 2009) we introduced two copies 
of the green-fluorescent protein (GFP) into the genome of wild-type LCMV. This 
resulted in recombinant viral particles with three RNA segments (1L + 2S) instead of one 
L and one S segment in wild-type LCMV (Fig. 2.3A+B). We rescued the tri-segmented 
reporter virus (r3LCMV-GFP) in cell culture by reverse genetic systems (Flatz, 
Bergthaler et al. 2006, Flatz, Hegazy et al. 2010). r3LCMV-GFP-infected cells express 
GFP allowing their identification by flow cytometry. We infected C57BL/6 mice with 
5x105 PFU of either r3LCMV-GFP or wild-type LCMV and isolated splenic stromal cells 
three days after infection. Stromal cell subpopulations were identified by their expression 
of gp38 and CD31 (Fig. 2.3C) and analyzed for GFP expression (Fig. 2.3D-E). The 
percentage and absolute number of GFP+ i.e. r3LCMV-GFP-infected cells within each 
stromal cell population was quantified (Figure 2.3F). As expected, wild-type LCMV-
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infected animals showed only background levels of GFP (Fig. 2.3D and “ctrl” in Fig. 
2.3F). In r3LCMV-GFP infected animals, GFP+ cells were undetectable in the double-
negative population and only 1.13 % of FRCs showed detectable GFP signal. We found 
comparably more (7.4 %) reporter virus-infected BECs. Also when expressed as absolute 
numbers of GFP+ cells per spleen, infected BECs were at least 50 times more abundant 
than infected FRCs or DNs (Fig. 2.3F). This finding was further corroborated by 
immunofluorescence analysis on tissue sections. We infected mice i.v. with wild-type 
LCMV and stained spleen sections for the endothelial cell marker CD31 and LCMV 
nucleoprotein (NP) to identify infected BECs. Indeed we found a considerable number of 
cells costained for both CD31 and NP in all our spleen sections (Fig. 2.3G; stains 
performed by I. Wagner in the Merkler lab at UNIGE). This validated our findings 
obtained by flow cytometry and at the same time demonstrated that recombinant 
r3LCMV shows the same tropism as wild-type LCMV. An analogous pattern of 
r3LCMV-GFP distribution was found in hepatic stromal cells on day three after infection  
(Figure 2.3H). CD31+ gp38-negative BECs can be distinguished from other populations 
of CD31-negative stromal cells. Again, wild-type LCMV infected animals served as 
negative controls (ctrl). Whereas no infected cells could be detected in the CD31- liver 
stromal cells, 4 % of the BECs were found to be GFP+. Thus we concluded that BECs 
rather than FRCs are the predominant stromal target cell population in early LCMV 
infection. 
Lack of ST2 leads to depletion of virus-specific CD8+ T cells during chronic LCMV 
infection. 
To test whether signaling via IL-33/ST2 is necessary for the maintenance of virus-
specific CTLs during chronic viral infection, we infected either ST2-deficient or wild-
type C57BL/6 mice with a high-dose of LCMV Clone 13 to establish chronic infection. 
We tracked frequencies of LCMV-specific CD8+ T cells over time by flow cytometry 
(Fig. 2.4A-B). GP276-specific CD8+ T cells, which are the dominant population of anti-
viral CD8+ T cells in chronic infection, were depleted within 44 days after infection in 
ST2-deficient mice, whereas GP276-specific CTLs in wild-type mice were stably 
maintained (Fig. 2.4C). GP33-specific CD8+ T cells showed the same trend even though 
a lot less pronounced (Fig. 2.4C). Consequently, this suggests that signaling via the IL-
33/ST2 pathway is important for the maintenance of virus-specific CTL responses during 
chronic infection. 
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T cell-intrinsic signaling via IL-33/ST2 is essential for stable maintenance of virus-
specific CTLs during chronic infection. 
We have shown that the induction of a potent virus-specific CD8+ T cell response and 
more precisely the clonal expansion of these CTLs is reliant on CTL-intrinsic IL-33/ST2 
signaling in acute infection (Bonilla, Frohlich et al. 2012). In the previous figure we 
demonstrated that lack of the ST2 receptor leads to the disappearance of virus-specific 
CTLs during chronic infection. We now aimed to investigate whether this observation is, 
analogously to our data published for acute viral infections, also mediated by T cell-
intrinsic signaling. We adoptively transferred (adTf) a physiological number of transgenic 
LCMV-specific CD8+ T cells (P14) into C57BL/6 recipient mice. P14 cells were specific 
for the LCMV epitope GP33-41 (GP33) but were either ST2-competent (wt P14) or ST2-
deficient (ST2ko P14). One day after adTf we infected the recipients with high-dose 
Clone 13 or low-dose LCMV strain WE. Infection with a high dose (2x106 PFU) of Clone 
13 leads to the establishment of a chronic infection, whereas low dose of LCMV WE 
results in an acute infection. Blood was taken on different time points after infection and 
the expansion and maintenance of the adoptively transferred virus-specific indicator 
CD8+ T cells was analyzed by flow cytometry (Fig. 2.5A-B). Expansion and survival of 
the transferred P14 cell population was analyzed in the context of chronic (Fig. 2.5C) or 
acute infection (Fig. 2.5D) and results were graphed as percentage of transferred P14 
cells of the total CD8+ T cell pool in blood (upper panels). Additionally we calculated the 
“maintenance” of these cell populations by expressing these values as percentage of the 
peak of population expansion on day 9 after infection (lower panels). Thereby we 
normalized for the defective expansion in the early phase after infection. Whereas ST2-
competent virus-specific CD8+ T cells showed stable frequencies over time both under 
chronic and acute infection conditions, a marked difference was noted when comparing 
the maintenance of ST2-deficient P14 cells in acute and chronic infection. In acute 
infection ST2ko P14 cells showed defective expansion, reflected by the lower numbers 
on day 9 after infection, but thereafter were stably maintained, parallel to wild-type P14 
cells (Fig. 2.5D). This contrasted sharply with the outcome in chronic infection. ST2ko 
P14 cells were not maintained, showed continuously decreasing frequencies in blood, and 
in most animals reached technical detection limits around 44 days after infection (Fig. 
2.5C). Therefore signaling via the IL-33/ST2 pathway seemed to be critical both for the 
expansion and the maintenance of virus-specific CD8+ T cells by CTL-intrinsic signaling 
in chronic viral infection. Besides the frequency of the transferred cells in the blood, we 
also investigated the distribution of the transferred cells in lymphoid organs by analyzing 
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spleen and lymph nodes 24 days after chronic (Fig. 2.5E) or acute infection (Fig. 2.5F). In 
all tissues analyzed and in both infection settings we consistently found less ST2ko P14 
cells than wild-type cells, due to the defective expansion of ST2-deficient cells. However, 
there were no marked differences in the overall distribution of the respective cell-types in 
the organs analyzed. Thus the tissue distribution of virus-specific CD8+ T cells does not 
seem to be affected by the presence or absence of ST2/IL-33 signaling. Since expansion 
of ST2-deficient P14 cells is impaired in the early phase after both acute and chronic 
infection, a concern could have been that this uneven starting point might have affected 
our conclusion regarding the maintenance of these cells in a chronic setting. To even-up 
for the defective expansion, we transferred the usual number of wt P14 cells and in 
parallel into a separate group of recipients a 10-fold higher number of ST2ko cells, 
followed by infection of the recipients one day later. We tracked the frequency of the 
transferred cells in the blood throughout the course of acute or chronic infection (Fig. 
2.5G-H). The higher input of ST2ko P14 cells was reflected in comparably higher 
frequencies in blood on day 6, both in chronic and acute infection settings. This was 
expected since CD8+ T cell expansion had not yet reached its peak and the influence of 
the IL-33/ST2 axis plays mostly at later time points (Bonilla, Frohlich et al. 2012). In 
acute infection, comparably stronger expansion of the wild-type P14 cells between day 6 
and day 9 eliminated the 10-fold differences to ST2ko P14 cells, such that equal levels 
were reached. Thereafter both populations were stably maintained until at least day 27 
(Fig. 2.5H). Also in chronic infection the differences in transferred cell numbers were 
detectable until day 6 after infection. Between day 6 and 15, wt P14 cells expanded 
further and were stably maintained thereafter. Conversely, ST2ko P14 cells did not 
expand further after day 6 but exhibited continuously declining frequencies (Fig. 2.5G). 
In summary this figure showed that virus-specific CD8+ T cells that cannot sense IL-33 
are defective both in expansion and maintenance in chronic viral infection, confirming 
that the depletion of ST2-deficient CTLs during chronic viral infection is due to T cell-
intrinsic signaling. 
A subset of virus-specific CTLs in chronic infection continuously expresses surface 
ST2. 
Our previous experiments had shown that virus-specific CD8+ T cells depended on IL-
33/ST2 signals to expand and be maintained in chronic viral infection. However, it 
remained unclear whether they retained the ability to sense IL-33-mediated expansion 
and survival signals throughout chronic infection or whether their differential behavior 
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reflected a phenotypic “imprinting” mechanism due to a one-time signal early during 
infection. Expression levels of the cellular receptor ST2 can be detected by ST2-specific 
antibody staining and flow cytometry. We reasoned that continuous or transient receptor 
expression on virus-specific CTLs would give important hints on the possibilities for 
continuous ST2 signaling. We adoptively transferred wild-type or ST2ko P14 cells into 
wild-type hosts and infected them one day later with LCMV to establish either acute or 
chronic infection. We measured ST2 expression on the surface of transferred P14 cells 
throughout infection (Fig. 2.6A-B). We quantified labeling intensity in flow cytometry to 
assess expression levels (Fig. 2.6C) and determined the percentage of ST2+ cells within 
the transferred population over time (Fig. 2.6D). In order to control for potential inter-
experimental variability of staining intensity at different time points, we normalized both 
readouts on every time point to the background values represented by the ST2ko P14 
cells. Both, fluorescence intensity and the percentage of ST2+ cells showed that ST2 
expression is highest on day 6 after infection with decreasing levels thereafter. Similar 
kinetics were detected for both infection settings. Even though the levels of ST2-
expression and the percentage of ST2+ cells were declining over time, ST2 was 
detectable on a subset of cells for at least 27 days after infection (representative 
histograms of day 23 shown in Figure 2.6E). Consequently, ST2 expression seemed 
higher in the early phase of infection but a subset of virus-specific cells apparently 
retained the receptor throughout the chronic phase. 
Up-regulation of ST2 on activated LCMV-specific CD8+ T cells is independent of 
IFNAR signaling. 
It is well established that signaling through the type I interferon receptor (IFNAR) is 
essential for clonal expansion of adoptively transferred LCMV-specific CD8+ T cell 
populations (Kolumam, Thomas et al. 2005). Even in the absence of NK cells, which 
were found to be largely accountable for this phenotype, a more modest but still clearly 
defective expansion of IFNAR-deficient P14 cells was suggestive for T cell-intrinsic 
proliferative defects in the context of IFNAR deficiency (Crouse, Bedenikovic et al. 
2014). In order to elucidate whether IFNAR signaling was necessary for up-regulation of 
ST2 on the surface of LCMV-specific CTLs, we adoptively transferred wild-type or 
IFNAR-deficient P14 cells into NK cell-depleted C57BL/6 recipients, infected them one 
day later with LCMV and analyzed the frequency of transferred cells on different time 
points by flow cytometry (Fig. 2.7A). As expected and in agreement with the mentioned 
publication, IFNAR-deficient cells were considerably impaired in clonal expansion upon 
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LCMV infection (Fig. 2.7C). However, levels of ST2 on the surface of transferred cells 
were indistinguishable on wild-type and IFNAR-deficient cells, no matter whether ST2 
expression was analyzed at the level of protein (fluorescence intensity) or as percentage 
receptor-bearing cells (Fig 2.7D). Therefore signaling via IFNAR did not seem to account 
for the induction of ST2 and the deficient clonal expansion of ST2-deficient virus-
specific CD8+ T cells. 
Early up-regulation and subsequent reduction in IL-33-expressing cell numbers and 
IL-33 protein levels in the LCMV-infected spleen. 
In our previous report we have shown by quantitative PCR that IL-33 mRNA levels are 
up-regulated after acute infection, with kinetics paralleling viral genome copy numbers in 
the spleen. Additionally, we observed an increase in IL-33 expression when analyzing IL-
33 levels of FRCs in secondary lymphoid organs of acutely LCMV-infected GFP reporter 
mice (data not shown). Here we wanted to investigate whether chronic LCMV infection 
led to an increase in cellular IL-33 levels or in the number of IL-33-expressing cells. We 
established chronic LCMV infection in hemizygous IL-33 reporter mice and analyzed 
splenic stroma on different time points after infection (Fig. 2.8A). The non-hematopoietic 
compartment of the spleen was analyzed by flow cytometry (Fig. 2.8B) and analogously 
to uninfected mice (Fig. 2.1 and 2.2), FRCs were found to be the dominant cell type 
producing IL-33 under infection conditions. We analyzed IL-33 reporter levels as 
reflected in GFP mean fluorescence intensity of GFP+ FRCs and detected a rise in IL-33 
expression on a per cell level. We also counted the total number of GFP+ FRCs per 
spleen (Fig. 2.8C) and found it to increase. By both readouts the initial slight increase of 
IL-33 levels and IL-33-expressing cells up until day 8 after infection was followed by a 
decline in the subsequent chronic phase of infection. However, even though this tendency 
was detected both on a per-cell level as well as in the percentage of IL-33 expressing 
FRCs, we acknowledge the effect to be more modest than suggested by earlier reports on 
FRC kinetics in acute LCMV infection (Scandella, Bolinger et al. 2008).  
The functionality of LCMV-specific CD4+ T cells does not depend on ST2/IL-33 
signaling.  
We have shown that ST2-deficient virus-specific CD8+ T cells have a defect in 
expansion and maintenance during chronic infection. Furthermore, we have demonstrated 
in our previous publication that ST2 signaling has a profound impact on ex vivo 
Interleukin-33 and Stromal Cells in Chronic Viral Infection 
 67 
functionality of anti-viral CTLs in acute infection, which is widely thought to correlate 
with the protective capacity of CD8+ T cells (Appay, van Lier et al. 2008). Whereas 
CD4+ T cells are not necessary for the resolution of an acute LCMV infection, it has been 
shown that CD4+ T cells play a critical role for the outcome of chronic infections 
(Matloubian, Concepcion et al. 1994). In order to investigate whether ST2-signaling also 
has an impact on anti-viral CD4+ T cell effector function in chronic LCMV infection, we 
adoptively transferred 500 wild-type or ST2-deficient LCMV-specific CD4+ T cells (wt 
SM1 or ST2ko SM1) into C57BL/6 mice and infected the recipients one day later with 
LCMV to establish acute or chronic infection. Fourteen days later we analyzed the 
capacity of transferred SM1 cells to produce the prototypic inflammatory Th1 cytokines 
IFN-γ, TNF-α and IL-2 after peptide stimulation (Fig. 2.9A). We quantified the single, 
double- or triple-producers of these cytokines for both, SM1 cells originating from 
chronically (Fig. 2.9B) or acutely infected mice (Fig. 2.9C). In both cases ST2-deficient 
SM1 cells were at least as functional as wild-type SM1 cells. During chronic infection 
there even seemed to be somewhat higher numbers of IFN-γ/TNF-α double-producers 
and IFN-γ/TNF-α/IL-2 multifunctional CD4+ T cells. In the light of these findings, 
ST2ko CD4+ T cells seemed to form fully functional Th1 cells in chronic viral infection. 
Lack of ST2-signaling impacts the tissue distribution of CD4+ T cells in chronic 
infection. 
The experiments in Figure 2.9 have demonstrated that signaling via IL-33/ST2 is not 
essential for the Th1 cytokine profile of antiviral CD4+ T cells. However, since we had 
previously shown that IL-33 signaling is critical for expansion and maintenance of virus-
specific CD8+ T cells, we performed analogous adoptive transfer experiments with virus-
specific CD4+ T cells in order to investigate whether ST2-deficient SM1 cells showed 
defective population expansion analogously to ST2ko P14 cells. We transferred 500 wild-
type or ST2ko SM1 cells into C57BL/6 recipients and infected the mice one day later 
with LCMV to establish acute or chronic infection. The frequency of the transferred cells 
was analyzed on several time points after infection (Fig. 2.10A-B). In acute infection we 
detected an impaired expansion of ST2ko SM1 cells as compared to wild-type SM1 cells. 
But cells that had expanded until day 9 after infection were thereafter maintained 
similarly to wild-type cells (Fig. 2.10D). In chronic infection, virus-specific wt SM1 cells 
expanded as expected and after a peak around day 6-9 exhibited detectable albeit modest 
population contraction when progressing towards the chronic phase (Fig. 2.10C). In 
contrast, we could barely detect any transferred ST2ko SM1 cells in the blood and 
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populations were too small to calculate reliable “maintenance” values (n.d. in Figure 
2.10C). Thus we investigated whether the transferred CD4+ T cells were differentially 
distributed in different organs. Wild-type SM1 cells showed an equal distribution in 
blood, spleen and lymph nodes of chronically LCMV-infected recipients. Conversely, the 
distribution of ST2ko CD4+ T cells was severely distorted (Fig. 2.10E). In striking 
contrast to their virtual absence from blood, adoptively transferred ST2ko SM1 were 
found both in spleen and lymph nodes in numbers quite similar to wild-type cells. This 
suggested that the tissue distribution of ST2ko SM1 cells was affected by the lack of ST2 
signaling and that these cells were retained in lymphoid organs and did not efficiently 
recirculate through the bloodstream. This phenotype was not detected in acute infection, 
and ST2ko cells were found at comparable frequencies in all three tissues analyzed (Fig. 
2.10F).  
Absence of ST2 favors the differentiation of virus-specific CD4+ T cells into a T 
follicular helper cell phenotype. 
Given that ST2-deficient CD4+ T cells are retained in lymphoid organs and don’t 
efficiently recirculate in the bloodstream, we hypothesized that the lack of ST2-signaling 
might influence the differentiation program of these cells which in turn might be at the 
root of an altered tissue distribution. T follicular helper cells (Tfh) are specialized 
providers of B cell help in germinal centers and as such are located mostly in lymphoid 
organs. Homing chemokine receptors such as CXCR5 represent a hallmark of the Tfh 
phenotype and we hypothesized that such a differentiation might retain them in secondary 
lymphoid organs and provide help to B cells. We transferred 500 wild-type or ST2ko 
SM1 cells into C57BL/6 recipients and infected the mice one day later with LCMV Clone 
13 to establish chronic infection. Fifteen days later we analyzed the transferred SM1 cells 
in the spleen for CXCR5 expression (Fig. 2.11A-B). We found that CXCR5+ cells were 
significantly overrepresented within the ST2ko SM1 population as compared to wt SM1 
cells (Fig. 2.11C). Thus ST2-deficiency promoted the differentiation of virus-specific 
CD4+ T cells towards a T follicular helper phenotype. 
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2.5 Discussion 
We present data that extends our knowledge on the essential role of IL-33/ST2 signaling 
in efficient T cell responses during acute viral infection to the context of chronic 
infections. Viral replication is commonly referred to as “danger” for the host’s immune 
system (Gallucci and Matzinger 2001) and our previous report has provided evidence that 
also damage due to viral replication can directly enhance antiviral CTL responses via the 
alarmin IL-33 (Bonilla, Frohlich et al. 2012). As shown here, virus-specific CTLs that 
cannot sense the Interleukin-33 during chronic infection fail to be maintained over time 
and are continuously depleted. This implies a constant necessity for damage signals like 
IL-33 in the extracellular space in persistent viral infections like LCMV in mice or HIV 
and HBV in humans in order to enhance effector functions and ensure maintenance of 
potent CTL responses.  
Our flow cytometry and immunofluorescence-based findings of IL-33 expression by 
FRCs is in line with the expression pattern of this cytokine found in other recently 
published reporter systems (Moussion, Ortega et al. 2008, Pichery, Mirey et al. 2012, 
Hardman, Panova et al. 2013). This validates our IL-33 reporter mouse as a faithful tool 
to further investigate IL-33 expression in various conditions and in an at least semi-
quantitative fashion without the need for prior processing of cells or tissues. Our 
approach and the citrine reporter mouse (Hardman, Panova et al. 2013) are the first live 
cell reporters that enable investigation of IL-33 expression in mice directly in vivo and 
under various inflammatory or pathological conditions, whereas previous studies were 
limited to quantification of mRNA levels in tissues or immunohistochemical analyses of 
a lacZ-based reporter offering little quantitative insights. We have detected only a slight 
trend towards up-regulation of IL-33 protein in the early phase of chronic infection, both 
in terms of fluorescence intensity and total numbers of GFP+ FRCs per spleen. This was 
somewhat unexpected, since we had previously reported an increase in IL-33 mRNA 
detected by qPCR (Bonilla, Frohlich et al. 2012), and GFP fluorescence intensity in our 
IL-33 reporter mice after acute LCMV infection also was found to be augmented (data 
not shown). Conversely, we found a significant decrease of IL-33 expressing FRCs in 
later phases of the infection (day 15-23). It is known that chronic LCMV infection results 
in reduced cellularity and altered splenic architecture (Odermatt, Eppler et al. 1991), 
especially a loss of FRCs during Clone 13 infection has previously been reported 
(Mueller, Matloubian et al. 2007). In our hands total numbers of FRCs remained normal 
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upon Clone 13 infection, whereas a slight but significant reduction in total number of IL-
33 expressing FRCs was apparent in later phases of the infection. This discrepancy could 
be explained by the differential methodology applied (immunohistochemistry with tracer 
localization by Mueller et al. vs. flow cytometry by us). The decrease in IL-33 expressing 
FRCs in chronic infection might be a result of the disruption of the splenic architecture, 
which would be in line with the mentioned publications. Alternatively and 
mechanistically more attractive, a selective loss as a result of cell death of IL-33 
expressing FRCs could represent a sophisticated albeit unknown biological mechanism to 
release IL-33 into the extra-cellular space leading to activation of and rendering it 
bioavailable for signaling to immune cells. This in turn requires the FRCs in SLOs to 
have a massive turn over rate in order to provide constant supply of the danger signal but 
at the same time to replace dying cells and ensure an intact lymphoid organ structure in 
persistent infection.  
It has been postulated that FRCs were a main target of LCMV Clone 13 and that high 
numbers of FRCs both in spleen and lymph nodes were directly infected by LCMV 
(Mueller, Matloubian et al. 2007). This contrasts with results obtained in our study. Our 
flow cytometric analyses of mice infected with reporter viruses could not confirm such a 
tropism of LCMV. We found a pronounced population of infected BECs of murine 
spleen and liver, but total numbers of infected FRCs per spleen were negligible in our 
hands, which may be due, at least in parts, to their comparatively rare occurrence in 
lymphoid organs. This discrepancy could be explained by different technical readouts. 
We used flow cytometry with the endothelial cell marker CD31 and the fibroblast marker 
gp38 (Podoplanin) to differentiate stromal cell subsets, whereas Mueller et al. based their 
findings on the immunohistochemical analysis of ER-TR7 stained spleen and lymph node 
sections. Doubts have cast over the specificity of the ER-TR7 antibody and its utility for 
the identification of FRCs in tissues, owing to the antibody’s propensity for staining 
extracellular matrix. Another technical difference between our study and the one by 
Mueller consists in our use of tri-segmented reporter viruses. However, all available 
evidence suggests that these reporter viruses faithfully recreate the natural virus’ tropism 
(Emonet, Garidou et al. 2009). Additionally, we have confirmed our findings by 
immunohistochemistry using wild-type virus. Conversely, our finding of LCMV tropism 
for BECs is in agreement with data published by Frebel et al. in 2012 (Frebel, Nindl et al. 
2012). They used a flow cytometric approach to analyze liver and lung tissue upon 
LCMV infection by staining for LCMV nucleoprotein NP and the endothelial cell marker 
CD31 and identified endothelial cells as a major viral target. 
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There are two potential explanations for differential maintenance of wild-type and ST2-
deficient CD8+ T cells. A continuous survival and/or differentiation signal via the IL-
33/ST2 pathway might be required for the maintenance of virus-specific T cells or a one-
time “imprint” type of signal via the IL-33/ST2 pathway could program cells for survival. 
We favor the explanation of a continuous survival and/or differentiation signal over the 
imprinting signal, which would have to be obtained during the early phase of the response. 
This hypothesis is supported by our finding that a considerable level of ST2 remains on at 
least a subset of LCMV-specific CD8+ T cells throughout chronic infection and late after 
acute infection. The mechanisms and signaling cascades leading to ST2 up-regulation and 
maintenance remain unclear. We can exclude, however, that up-regulation of ST2 on the 
surface of virus-specific CD8+ T cells depends on IFNAR. 
Our data on the altered recirculation behavior of ST2-deficient CD4+ T cells and the 
ST2-inhibited Th1 differentiation of SM1 cells seem surprising at first glance because 
ST2 on CD4+ T cells is commonly thought of as a marker of Th2 differentiation 
(Lohning, Stroehmann et al. 1998) and would not be expected to influence Th1-biased 
responses at all. However, a recent study showing impaired IFN-γ production of ST2ko 
CD4+ T cells in Salmonella infection and LPS stimulation is in line with our findings 
(O'Donnell, Pham et al. 2014). Our analyses of CD4+ T cells in the LCMV context were, 
however, restricted to the first 9-14 days after infection, and we cannot rule out at present 
that the observed phenotypic differences vanish later on. It is known that levels of antigen 
and the cytokine milieu can drive CD4+ T cells into a variety of different T helper 
phenotypes. This enables a certain degree of flexibility and plasticity of the immune 
responses. However, whereas Brooks et al. have shown that exhaustion of CD4+ T cells 
is the result of continuous exposure to viral antigens, the mechanisms that govern CD4+ 
T cell differentiation in persistent viral infection are only incompletely understood 
(Brooks, McGavern et al. 2006). Interleukin-21 has been characterized as one of the main 
players for potent CD4+ T cell help in chronic viral infection and it was also found 
essential for maintaining not only the help to CD8+ T cells (Elsaesser, Sauer et al. 2009, 
Frohlich, Kisielow et al. 2009, Yi, Du et al. 2009) but also for stimulation of germinal 
center B cells and antibody production in the late phase of infection (Ozaki, Spolski et al. 
2002, Linterman, Beaton et al. 2010, Zotos, Coquet et al. 2010). Fahey et al. have 
furthermore shown that viral persistence directly influences differentiation of CD4+ T 
cells to preferentially develop into Tfh cells rather than Th1 helper cells (Fahey, Wilson 
et al. 2011). A very recent publication suggests that de novo Th1 generation is suppressed 
during viral persistence by a type-I IFN-mediated mechanism, which in turn favors 
Interleukin-33 and Stromal Cells in Chronic Viral Infection 
 72 
almost exclusive differentiation of CD4+ T cells into Tfh cells instead of Th1 cells 
(Osokine, Snell et al. 2014). Indeed, ST2 seems to have an impact on CD4+ T cell 
differentiation since ST2-deficient mice expressed significantly more CXCR5 on their 
surface, a receptor required for localization of T cells into the B cell follicles where they 
drive germinal center formation and provide B cell help through direct cell-cell 
interactions and secretion of cytokines like IL-21 (reviewed in (Crotty 2011)). This might 
be indicative for a preferential differentiation of ST2-deficient cells into Tfh cells.  
In summary, we present evidence that damage signals represent an important molecular 
signature for the hosts’ continuous efforts at clearing chronic viral infections. Gaining a 
more detailed knowledge of the events that shape immune responses in the chronic 
infection context is important to improve existing or develop new therapeutic 
interventions against infectious diseases and cancer. 
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2.6 Figures 
 
Figure 2.1: Fibroblastic reticular cells and lymphatic endothelial cells are the main IL-
33 producing cell populations in uninfected lymphatic organs. 
(A) A mouse strain that reports expression of IL-33 by means of GFP was generated by 
removing a loxP-flanked neomycin resistance gene (neoR) downstream of the GFP open 
reading frame of an IL-33 deficient line (Oboki, Ohno et al. 2010). IL-33 deficient mice 
carrying the mutant allele (“MT allele”; obtained from S. Nakae) were intercrossed with ZP3-
Cre mice encoding the loxP site-specific DNA recombinase Cre in oocytes resulting in the 
excision of the neor cassette (à “IL33 reporting allele”) and expression of the reporter gene 
GFP under the control of the IL-33 reporter. (B-D) Single-cell suspensions of spleens from 
uninfected IL-33 reporter mice were prepared by collagenase digestion, stained with CD45.2, 
Ter-119, gp38 and CD31-specific antibodies and analyzed by flow cytometry. (B) Gating 
Interleukin-33 and Stromal Cells in Chronic Viral Infection 
 74 
strategy and identification of three splenic stromal cell populations by expression of gp38 
and CD31 (gated on single Ter119-CD45.2- cells): fibroblastic reticular cells (FRCs; 
gp38+CD31-), blood endothelial cells (BECs; gp38-CD31+) and double negative stromal 
cells (DN; gp38-CD31-). (C) Representative histogram of the GFP profile of gp38+CD31- 
FRCs (gated on CD45.2-, Ter119-, CD31-, gp38+). (D) Quantification of the GFP+ 
populations within the three stromal cell types FRC, BEC and DN as percentage (left panel) 
or total cell numbers per spleen (right panel). Symbols and bars represent the mean±SEM of 
three mice per group. Representative data from one out of at least three independent 
experiments are shown. ns, not statistically significant (p ≥ 0.05); ***: p < 0.001 (1-way 
ANOVA followed by Bonferroni’s post-test for multiple comparisons). (E) Lymph nodes of 
uninfected IL-33 reporter mice were digested with collagenase. The resulting single cell 
suspension was stained with CD45.2, Ter119, gp38 and CD31-specific antibodies and 
analyzed by flow cytometry. (E) Identification of the four stromal cell populations in lymph 
nodes by expression of gp38 and CD31 (gated on single Ter119- CD45.2- cells): FRCs 
(gp38+CD31-), BECs (gp38-CD31+), lymphatic endothelial cells (LECs; gp38+CD31+) and 
double negative stromal cells (DN; gp38-CD31-). (F) Percentage (left panel) and total 
amount (right panel) of GFP+ cells of the four stromal cell populations in lymph nodes: FRCs, 
DNs, BECs and LECs. Bars represent the mean±SEM of three mice per group. 
Representative data from one out of at least three independent experiments are shown. ns, 
not statistically significant (p ≥ 0.05); *: p < 0.05; **: p < 0.01; ***: p < 0.001 (1-way ANOVA 
followed by Bonferroni’s post-test for multiple comparisons). 
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Figure 2.2: Validation of the IL-33 reporter mouse line by immunofluorescence.  
Spleens of hemi- (A) or homozygous (B) IL-33 reporter mice were cut and stained for 
Podoplanin (gp38) and IL-33 and co-staining of the IL-33 specific stain with the IL-33 
reporting GFP signal of the reporter mice was analyzed by immunohistochemistry. 
Analogously sections of lymph nodes of hemi- (C) and homozygous (D) IL-33 reporter mice 
were stained with DAPI and an IL-33 specific antibody and analyzed by 
immunofluorescence. The sections shown are representative of at least three animals.  
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Figure 2.3: Blood endothelial cells are the primary stromal cell type infected by LCMV. 
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(A-B) Schematic representation of the genomic organization of wild-type LCMV (wt LCMV; 
A) and tri-segmented GFP-encoding LCMV (r3LCMV-GFP; B). The bi-segmented genome of 
wild-type LCMV consists of one S segment encoding for the glycoprotein GP and 
nucleoprotein NP and one L segment encoding for the matrix protein Z and the viral 
polymerase L (A). The genome of tri-segmented LCMV (r3LCMV) consists of one L and two 
S segments with two copies of GFP inserted into each one of the S segments (B). (C-F) We 
infected C57BL/6 mice i.v. with 5x105 PFU of wild-type LCMV (D) or r3LCMV-GFP (E), 
isolated splenic stromal cells by collagenase digestion three days after infection and 
analyzed them by flow cytometry. The gating strategy for the identification of the three 
splenic stromal cell subsets (FRC: gp38+CD31-; BEC: gp38-CD31+; DN: gp38-CD31-) is 
depicted in (C). (D-E) Representative FACS plots of the GFP expression profile of each 
stromal cell population for one wild-type LCMV infected mouse (D) and one r3LCMV-GFP 
infected mouse (E). (F) Quantification of the percentage (left panel) and the total amount of 
GFP+ cells per spleen (right panel) within each stromal cell type in the spleen of r3LCMV-
GFP-infected mice (wt LCMV infected mice as ctrl). (G) Spleens of mice infected with 5x105 
PFU of wild-type LCMV were stained for CD31 (green) and the LCMV nucleoprotein (NP; 
red) and sections were analyzed by immunofluorescence. Representative sections are 
shown in (G). Uninfected organs were used as negative control (data not shown). (H) Liver 
stromal cells were obtained by collagenase digestion of the organ and the resulting single 
cell suspension was analyzed by flow cytometry. Stromal cells were classified as 
CD31+gp38- BECs or CD31- stromal cells and the percentage of GFP+ cells was quantified. 
Mice infected with wild-type LCMV served as negative controls. Bars represent the 
mean±SEM of four mice per group. Representative data from one out of at least two 
independent experiments are shown. ns, not statistically significant (p ≥ 0.05); ***: p < 0.001 
(1-way ANOVA followed by Bonferroni’s post-test for multiple comparisons). 
 
Interleukin-33 and Stromal Cells in Chronic Viral Infection 
 78 
 
Figure 2.4: Virus-specific CD8+ T cells are depleted during chronic LCMV infection in 
ST2-deficient mice. 
(A-C) We infected C57BL/6 wt (black triangles) or ST2-/- (white squares) mice i.v. with 2x106 
PFU LCMV Clone 13 and took blood on the indicated time points after infection (A). Blood 
was stained for virus-specific CD8+ T cells by specific tetramer-staining for the LCMV 
epitopes GP276 and GP33 and the frequency of LCMV-specific CD8+ T cells was analyzed 
according to the gating strategy outlined in (B). (C) The frequency of virus-specific CD8+ T 
cells was analyzed by calculating the percentage of GP276+ or GP33+ T cells within the 
CD8+ T cell pool and is expressed as maintenance (% of d16), by normalizing the 
respective Tetramer+ percentages to the value obtained on day 16. Symbols and bars 
represent the mean±SEM of 4-5 mice per group. Representative data from one out of two 
independent experiments are shown.  
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Figure 2.5: CTL-intrinsic signaling via ST2 is crucial for the maintenance of virus-
specific CD8+ T cells during chronic viral infection. 
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(A) Adoptive transfer of 500 wild-type (wt) or ST2-deficient (ST2ko) P14 cells into C57BL/6 
mice was followed by i.v. infection with either 2x106 PFU LCMV Clone 13 (chronic) or 200 
PFU LCMV WE (acute) one day later. Blood was taken at indicated time points and 
analyzed by flow cytometry. Transferred P14 cells were identified by CD45.1 expression 
following the gating strategy displayed in (B). Quantification of wild-type P14 cells (black 
circles) or ST2ko P14 cells (white circles) after chronic (C) or acute (D) infection are 
displayed either as percentage of transferred cells of the total CD8+ T cell pool (gated on 
single B220-CD8+ cells, upper panels) or as “maintenance” after normalization to values 
obtained on day 9 after infection (lower panels). Symbols and bars represent the 
mean±SEM of four mice per group. Representative data from one out of three independent 
experiments are shown. (E-F) Blood, spleen and lymph nodes were taken 23 days after 
infection with LCMV and frequencies of transferred cells in the organs after chronic (E) or 
acute (F) infection were analyzed by flow cytometry with gating as outlined in (B). The 
percentage of transferred cells within the CD8+ cell population was analyzed for each organ. 
Bars represent the mean±SEM of five mice per group. Representative data from one out of 
two independent experiments are shown. (G-H) To compensate for the defective expansion 
of ST2ko P14 cells in the early phase of infection, we transferred 500 wt (black circles) or 
5000 ST2ko P14 cells (white circles) and infected the mice one day later with either 2x106 
PFU LCMV Clone 13 (chronic; G) or 200 PFU LCMV WE (acute; H). Blood samples were 
taken at indicated time points after infection and analyzed by flow cytometry with gating 
analogous to (B). Expansion and maintenance of transferred cells is displayed as 
percentage of transferred cells within the total CD8+ T cell pool (gated on B220-CD8+ cells; 
upper panels) or as maintenance as of day 9 by normalizing the percentage of transferred 
cells within the CD8+ cells to the value obtained on day 9 after infection (lower panels). 
Symbols and bars represent the mean±SEM of five mice per group.  
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Figure 2.6: Expression of ST2 on the surface of virus-specific CD8+ T cells is 
continuously detectable until at least day 27 after infection on a subset of cells.  
We transferred 500 wt or ST2-deficient (ST2ko) P14 cells into C57BL/6 recipients and 
infected them one day later i.v. with 2x106 PFU LCMV Clone 13 (chronic) or 200 PFU LCMV 
WE (acute). Blood was taken at indicated time points after infection (A) and the expression 
of ST2 on the surface of transferred cells was analyzed by flow cytometry according to the 
gating strategy outlined in (B). Expression of ST2 on the surface of wild-type P14 cells was 
analyzed both as mean fluorescence intensity (“MFI”; C) and as percentage of transferred 
cells positive for ST2 (D) after chronic (black circles) or acute infection (grey circles). (C) The 
MFI of ST2 was normalized to the background intensity of ST2ko P14 cells, which was 
arbitrarily set to 1 on the respective time points after infection. Symbols and bars represent 
the mean±SEM of five mice per group. Two representative histograms of ST2 expression on 
the surface of wt P14 (black line) or ST2ko P14 (grey shade) on day 23 after chronic or 
acute infection are shown in (E). 
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Figure 2.7: Signaling via IFNAR does not account for for the up-regulation of ST2 on 
the surface of virus-specific CD8+ T cells after LCMV infection. 
(A) We transferred 1.5x103 wt or IFNAR-/- P14 cells into C57BL/6 recipients and infected 
them one day later with 200 PFU LCMV-WE. Blood was taken at indicated time points after 
infection and the spleen was isolated 9 days after infection. The frequency of transferred 
cells in the blood and the expression of ST2 on the surface of transferred cells in the spleen 
was analyzed by flow cytometry according to the gating strategy outlined in (B). (C) The 
expansion of wt (black circles) or IFNAR-/- P14 cells (empty circles) in the blood was 
analyzed as percentage of transferred cells of the total CD8+ T cell pool. (D) ST2 expression 
on the surface of virus-specific CD8+ T cells in the spleen was quantified as mean 
fluorescence intensity of the ST2 signal on transferred cells (left panel) or the percentage of 
ST2+ cells within the transferred cells (right panel). 
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Figure 2.8: IL-33 reporter mice show a slight increase of IL-33 expressing FRCs early 
after chronic LCMV infection and a reduction thereafter. 
(A) We infected hemizygous IL-33 reporter mice i.v. with 2x106 PFU LCMV Clone 13 and 
isolated splenic stromal cells on different times after infection. Spleen stroma was isolated 
by collagenase-digestion and was further analyzed by flow cytometry. The three stromal cell 
populations FRCs (gp38+CD31-), BECs (gp38-CD31+) and DN (gp38-CD31-) were 
identified by gating out doublets and CD45.2+Ter119+7AAD+ cells as outlined in (B). FRCs 
were the only cell population showing detectable GFP signals and MFI of GFP+ FRCs as 
well as the total number of GFP+ FRCs per spleen on different time points after chronic 
infection are shown in (C). Symbols and bars represent the mean±SEM of three mice per 
group. *: p < 0.05 (unpaired student’s t test). 
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Figure 2.9: Virus-specific CD4+ T cells deficient of ST2 are fully functional during viral 
infection. 
We adoptively transferred 500 wt or ST2-deficient (ST2ko) SM1 cells into C57BL/6 
recipients and infected them i.v. with 2x106 PFU LCMV Clone 13 (chronic) or 200 PFU 
LCMV WE (acute) on the day after. Spleens were taken 14 days after infection and the 
functionality of the transferred LCMV-specific CD4+ T cells was analyzed by flow cytometry. 
The gating strategy is outlined in (A). (B) and (C) show the cytokine profile (IFN-γ, TNF-α 
and IL-2) of the transferred wt (black bars) or ST2ko (white bars) SM1 cells after chronic (B) 
or acute (C) infection. Symbols and bars represent the mean±SEM of five mice per group. 
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Figure 2.10: ST2-deficiency in virus-specific CD4+ T cells alters the tissue 
distribution and impairs recirculation of cells in the bloodstream. 
(A) 500 wt or ST2ko SM1 cells were adoptively transferred into C57BL/6 mice followed by i.v. 
infection with 2x106 PFU LCMV Clone 13 (chronic) or 200 PFU LCMV WE (acute) one day 
later. Blood was taken at the indicated time points after infection and the frequency of 
transferred cells was analyzed by flow cytometry following the gating strategy outlined in (B). 
Frequency of wt (black circles) and ST2ko (white circles) SM1 cells after chronic (C) and 
acute (D) infection is expressed as percentage of CD4+ T cells (upper panels) or 
maintenance normalized to values obtained 6 days after infection (in percent; lower panels). 
Symbols and bars represent the mean±SEM of 3-5 mice per group. Representative data 
from one out of at least three independent experiments are shown. (E-F) Blood, spleen and 
lymph nodes of the mice were taken 16 days after chronic (E) or acute (F) infection and 
frequencies of transferred wt (black bars) or ST2ko SM1 cells (white bars) were analyzed by 
flow cytometry (gating analogous to (B); n.d. not determined). Symbols and bars represent 
the mean±SEM of 3-5 mice per group. Representative data from one out of at least three 
independent experiments are shown.  
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Figure 2.11: ST2-deficient virus-specific CD4+ T cells show higher expression of a 
typical marker for T follicular helper cells. 
(A) We adoptively transferred 500 wt or ST2ko SM1 cells i.v. into C57BL/6 recipients and 
infected them one day later with 2x106 PFU LCMV Clone 13. 15 days after infection the Tfh 
phenotype of transferred cells in the spleen was analyzed by flow cytometry with staining for 
CXCR5 (gating strategy shown in (B)). The percentage of CXCR5+ cells within the 
transferred cell population was quantified (C). Bars represent the mean±SEM of five mice 
per group. Representative data from one out of two independent experiments are shown. **: 
p < 0.01 (unpaired student’s t test). 
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3.1 Summary  
Several members of the family arenaviridae can cause viral hemorrhagic fever when 
transmitted to humans. Except for Junin virus, preventive vaccines are not available and 
strategies to stably attenuate arenaviruses remain to be refined. Using lymphocytic 
choriomeningitis virus (LCMV), the prototypic arenavirus, several key concepts of 
arenavirus molecular biology have been unraveled. The virus’ utility for studies on 
antiviral immunity, notably in persistent infection, but also its potential as vaccine 
delivery system has created considerable interest in strategies how to stably accommodate 
transgenes in the bi-segmented viral RNA genome. The large (L) segment expresses the 
viral RNA-dependent RNA polymerase (RdRp) L and the matrix protein Z in an 
ambisense coding strategy. Analogously, the short (S) segment encodes for the 
nucleoprotein NP and the glycoprotein GP. It had previously been shown that foreign 
genes of interest can be introduced in the genome of replication-competent LCMV by 
generating tri-segmented viruses with one L and two S segments. According to this 
strategy, each of the two S segments carries only either NP or GP in their respective 
natural positions and one gene of interest in each of the resulting free spaces (r3LCMVnat). 
Here we demonstrate that such tri-segmented viruses show impaired growth both in vitro 
and in vivo owing to preferential packaging of only one instead of two S segments, thus 
producing replication-deficient bi-segmented viral particles in excess. The selection 
pressure created by this attenuation favors the selection of emerging variants that have 
recombined their two S segments, resulting in phenotypic reversion to wild-type virus 
and transgene loss. Sequence analysis of such recombined RNA species revealed a 
pattern consistent with a copy-choice mechanism of the RdRp, putatively after pausing at 
an RNA hairpin structure, which facilitates template-switch. Accordingly, we 
demonstrate that transposition of the GP ORF, artificially positioning it under 
transcriptional control of the NP promoter (r3LCMVart), prevented the emergence of 
recombined genomes. r3LCMVart exhibited stable transgene expression and reduced 
viremia for >100 days of systemic persistent infection in immune-deficient mice.  
This work provides experimental evidence for inter-segmental recombination as a 
previously postulated mechanism of arenavirus evolution. The resulting r3LCMVart re-
engineering strategy offers reliable transgene expression and stable attenuation, thus 
critically augmenting its utility for basic research as well as for clinical use in vaccination 
and immunotherapy of infectious disease and cancer. 
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3.2 Introduction 
When accidentally transmitted to humans, several members of the Arenaviridae family 
can cause viral hemorrhagic fever associated with significant mortality (Geisbert and 
Jahrling 2004), representing a serious concern for public health in the concerned areas. 
Numerous arenaviruses can be found in rodent populations around the world. In addition 
to the Old World arenavirus Lassa virus (LASV), which can be found in Africa, several 
New World arenaviruses like Junin or Machupo are prevalent in rodents in South 
America (Johnson, Kuns et al. 1966, Tesh, Wilson et al. 1993, Mills, Ellis et al. 1994). 
Except for Junin virus, preventive vaccines remain unavailable for clinical use and anti-
viral therapy is limited to the nucleoside analog ribavirin. Thus there is considerable 
interest in developing new vaccines and treatments for arenaviral infections. This in turn 
requires a better understanding of the molecular biology of the virus and of the viral 
determinants that are shaping viral pathogenesis.  
In order to shed light on these questions, transgenic arenaviruses are extensively used and 
hold great promise for basic research and the vaccine field. Recombinant arenaviruses 
encoding additional genes of interest serve as reporter viruses or as a tool to study the 
function of select viral proteins in the viral life cycle. In the vaccine field transgenic 
arenaviruses could be used as live-attenuated viruses analogously to a Mopeia/LASV 
reassortant in the fight against LASV (Lukashevich, Patterson et al. 2005). Similarly, by 
exchanging the glycoprotein (GP) for an unrelated GP, as reported for vesicular stomatitis 
virus (VSV) (Bergthaler, Gerber et al. 2006), arenaviruses can be attenuated in a directed 
fashion. Recombinant arenaviruses also allow for the generation of replication-deficient 
vaccine vectors by replacing GP with a vaccine antigen. The resulting vector elicits T cell 
responses and protective neutralizing antibodies to the vaccine antigen but not against the 
vector itself, enabling efficient homologous boosts (Flatz, Hegazy et al. 2010).  
Since its recovery entirely from plasmid (Flatz, Bergthaler et al. 2006, Sanchez and de la 
Torre 2006), LCMV, the prototypic model virus in arenavirus research, became a very 
interesting candidate for vaccine development. Many of its characteristics make it a 
promising vector for vaccine design. Firstly, LCMV elicits a broad and long-lived T cell 
response (Homann, Teyton et al. 2001), which is a prerequisite for the induction of potent 
cellular immunity. Secondly, LCMV has a strong tropism for DCs and activates them 
upon infection, thus enabling presentation of the antigen by professional antigen-
presenting cells. Infection and activation of DCs has been shown to be crucial for potent 
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CD8+ T cell responses (Probst, Lagnel et al. 2003, Steinman 2007). Thirdly, LCMV 
induces low neutralizing antibodies against LCMV GP but high protective neutralizing 
antibody responses to foreign transgenes, which is suitable with homologous boost 
strategies and supports its potential as a vaccine vector in humans (Pinschewer, Perez et 
al. 2004).  
LCMV is an enveloped non-cytolytic virus with a cytoplasmic life cycle. Upon entry into 
the host cell subgenomic mRNAs are transcribed from the genome and replicative 
intermediates by the viral polymerase. The LCMV genome consists of two segments of 
single-stranded RNA of negative strand (L: 7.2 kb, S: 3.4 kb). Each segment encodes for 
two viral genes in opposite orientations. The short segment (S segment) encodes the GP 
precursor (GP-C; 75 kDa) and the nucleoprotein (NP; 63 kDa) (Salvato, Shimomaye et al. 
1988). The long segment (L segment) expresses the RNA-dependent RNA polymerase 
(RdRp; L; approx. 200 kDa) and the matrix protein Z (11 kDa) (Fig. 3.1A) (Salvato, 
Shimomaye et al. 1989, Salvato and Shimomaye 1989). GP-C is post-translationally 
cleaved into GP-1 and GP-2 (Buchmeier and Oldstone 1979). Trimers of GP-1 and GP-2 
are assembled as spikes on the surface of virions and mediate entry into host cells. NP 
binds to the viral RNA, forming the nucleocapsid (NC), which serves as a template for 
the viral RdRp. The nucleocapsid associated with the viral polymerase L forms the so-
called ribonucleoprotein (RNP) complex, which is active both in replication and 
transcription and represents the minimum unit of viral infectivity. It has been shown that 
NP and L are the minimal trans-acting factors necessary for viral RNA transcription and 
replication (Lee, Novella et al. 2000). The two genes on each segment are separated by a 
non-coding intergenic region (IGR) and are flanked by 5’ and 3’ untranslated regions 
(UTR). The IGR forms a stable hairpin structure and is involved in structure-dependent 
termination of viral mRNA transcription (Pinschewer, Perez et al. 2005). The terminal 
nucleotides of the UTR show a high degree of complementarity and form secondary 
structures. These panhandles serve as the viral promoter for transcription and replication 
and their analysis by site-directed mutagenesis has revealed sequence- and structure-
dependence, tolerating not even minor sequence changes (Perez and de la Torre 2003).  
The generation of recombinant negative-stranded RNA viruses expressing foreign genes 
has been pursued for a long time. Several strategies have been published for other viruses 
(Garcia-Sastre, Muster et al. 1994, Percy, Barclay et al. 1994, Flick and Hobom 1999, 
Machado, Naffakh et al. 2003), but only one approach, namely the generation of a tri-
segmented genome, has proven successful for LCMV (Emonet, Garidou et al. 2009). Two 
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foreign genes were inserted into the bi-segmented genome of LCMV, resulting in tri-
segmented LCMV particles (r3LCMV) with two S and one L segment. Each of the S 
segments was reengineered and one of the foreign genes inserted at the GP position of 
one S segment and the second foreign gene inserted at the NP position of the other S 
segment (Fig. 3.1B). Recombinant tri-segmented LCMVs have been rescued and are 
viable both in vitro and in vivo (Emonet, Garidou et al. 2009, Popkin, Teijaro et al. 2011).  
The polymerase of RNA viruses lacks proofreading activity and thus introduces 
mutations during replication (Holland, Spindler et al. 1982, Duffy, Shackelton et al. 
2008). However, RNA viruses increase their evolutionary potential not only through 
mutations but also through exchange of genetic material amongst each other, called 
recombination (Worobey and Holmes 1999). Recombination is a fairly common event in 
positive-sense (PS) RNA viruses (Cooper, Purchase et al. 1974, Hahn, Lustig et al. 1988, 
Lai 1992, Holmes, Worobey et al. 1999, Mikkelsen and Pedersen 2000). Negative-sense 
(NS) RNA viruses are generally thought not to recombine at all or only sporadically 
(Chare, Gould et al. 2003), but several events have been documented in recent years, 
notably for hantavirus (Sibold, Meisel et al. 1999, Sironen, Vaheri et al. 2001, Klempa, 
Schmidt et al. 2003) and for the arenavirus Whitewater Arroyo Virus (Charrel, de 
Lamballerie et al. 2001, Archer and Rico-Hesse 2002). More evidence for recombination 
in NS RNA viruses was found by artificial generation of recombined variants in vitro 
(Plyusnin, Kukkonen et al. 2002, Spann, Collins et al. 2003). Recombination between 
two lineages of NS RNA viruses was furthermore confirmed by phylogenetic analysis of 
the filovirus Zaire ebolavirus (Wittmann, Biek et al. 2007). Taken together, this shows 
that intersegmental exchange of genetic information between RNA strands is a rare but 
occurring event in PS as well as segmented and non-segmented NS RNA viruses, 
increasing the evolutionary flexibility of these viruses. Especially in the light of potential 
application in vaccination recombination of recombinant LCMV has to be excluded at 
best before use of recombinant viruses for research and notably clinical application. 
We developed a novel molecular design of tri-segmented transgenic r3LCMV 
(r3LCMVart) in which reshuffling of the GP-encoding S segment with expression of the 
GP from the 3’UTR prevented the emergence of recombined bi-segmented genomes 
during persistent infection. The newly developed r3LCMVart exhibited stable transgene 
expression and attenuated viremia for more than 100 days of persistent infection. Both 
features are critical for human clinical use and recommend r3LCMVart for safe vaccine 
delivery in infectious disease and cancer. 
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3.3 Material and Methods 
3.3.1 Cells 
BHK-21 cells were cultured in high-glucose Dulbecco’s Eagle medium (DMEM; Sigma) 
supplemented with 10 % heat-inactivated fetal calf serum (FCS; Biochrom), 10 mM 
HEPES (Gibco), 1 mM sodium pyruvate (Gibco) and 1x tryptose phosphate broth 
(Sigma). MC57 cells were maintained in Minimum Essential Medium (MEM; Sigma) 
complemented with 5 % heat-inactivated FCS, 2 mM L-glutamine (Gibco) and penicillin-
streptomycin (100’000 U/ml penicillin and 50 mg/l streptomycin; Gibco). Both cell lines 
were cultured at 37 °C in a humidified 5 % CO2 incubator. 
NP-expressing BHK-21 cells were generated by transfecting BHK-21 cells with a 
plasmid expressing NP under the control of the eukaryotic EF1-alpha promoter and 
encoding the puromycin resistance gene according to the manufacturer’s protocol. 48 
hours after transfection, 4 µg/ml puromycin was added to the medium. Another 48 hours 
later, cells were passaged into T150 flasks. Once separate clones became visible, cells 
were harvested and serially diluted into a 96-well plate to obtain single clones. Wells 
were checked optically for the growth of cell populations from single clones and 
respective cells were passaged into 6-well plates once they formed a confluent monolayer. 
NP-expressing BHK-21 cells were cultured in BHK-21 medium in the presence of 
4 µg/ml puromycin. 
GP-expressing BHK-21 cells have previously been described (Flatz, Hegazy et al. 2010). 
Briefly, BHK-21 cells were stably transfected with a plasmid that expresses a codon-
optimized LCMV-GP cDNA and the puromycin resistance cassette (Matter, Pavelic et al. 
2007). GP-expressing clones were selected by the addition of 4 µg/ml puromycin to the 
medium and single clones were obtained by serial dilutions as described for the NP-
expressing BHK-21 cells.  
3.3.2 Plasmids 
The pol-I L, pC-NP and pC-L plasmids have previously been described (Flatz, Bergthaler 
et al. 2006). For the generation of pol-I S plasmids encoding for GFP or RFP as reporter 
genes and either NP or GP, we used a pol-I Bbs/Bsm cloning plasmid as a basis (pol-I 5’-
BsmBI_IGR_BbsI_3’). This plasmid encodes for the 5’ untranslated region (5’ UTR) of 
the viral S segment followed by two BsmBI restriction sites, the intergenic region (IGR), 
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an NP rest and CAT open reading frame (ORF) flanked by BbsI restriction sites and the 
3’ UTR of the S segment. The pol-I S plasmids encoding for GP in its natural 5’ and GFP 
in antisense orientation at the 3’ position (pol-I 5’-GFP_IGR_GP-3’) were cloned by 
inserting GP by BsmBI site-specific restriction and ligation into the pol-I Bbs/Bsm 
plasmid. In a second step GFP was inserted by BbsI digestion and ligation. In order to 
obtain pol-I S plasmids encoding for GP in the artificial 3’ orientation (pol-I 5’-
GFP_IGR_GP-3’), GP was inserted by BbsI digest at the 3’ position into the pol-I 
Bbs/Bsm plasmid and GFP with BsmBI restriction/ligation at the 5’ position. pol-I S 
encoding for GFP or RFP and NP (pol-I 5’-GFP_IGR_NP-3’ or pol-I 5’RFP_IGR_NP-
3’) were cloned by inserting NP instead of GP by BbsI digestion and ligation into the pol-
I Bbs/Bsm cloning plasmid and GFP or RFP by BsmI cloning. The pol-I plasmid with GP 
of LCMV strain WE and NP of LCMV strain Clone 13 (Cl13) were cloned by inserting 
the respective genes by Bbs and Bsm site-specific restriction/ligation at the respective 
sites in the pol-I Bbs/Bsm cloning plasmid. 
The S segment encoding for the WE/WET fusion GP was obtained by replacing the last 
255 base pairs of the WE ORF with a codon-optimized sequence named “WET”. This 
was achieved by PCR amplifying in a first step a fragment of WE GP with one WE 
specific primer (5’-AATCGTCTCTAAGGATGGGTCAGATTGTGACAATG-3’) and a 
WE specific fusion-primer carrying an overhang complementary to the WET sequence 
(5’-AATCGTCTCTAAGGATGGGTCAGATTGTGACAATG-3’). In parallel the WET 
sequence was amplified by PCR using a WET-specific primer (5’-
CTCGGTGATCATGTTATCTGCTTCTTGTTCGATTTGA-3’) and a WET-specific 
fusion-primer complementary to the WE sequence (5’-
AATCGTCTCTTTCTTTATCTCCTCTTCCAGATGG-3’). In a third PCR reaction the 
two PCR products were fused by PCR fusion using the two mentioned fusion-primers. 
The resulting WE/WET fusion fragment was digested with BsmBI and ligated into a pol-I 
BsmBI_IGR_GFP-3’ plasmid that had been digested with the same restriction enzyme.  
The pol-I plasmid encoding for the recombined S segment of the in vivo recombined 
virus r3LCMV-GFPnat #3 was cloned by inserting the synthesized DNA fragment (done 
by Genscript) by site-specific restriction/ligation with SacI and XmaI into a plasmid 
encoding a wild-type S-segment under the control of a pol-I promoter (pol-I 
GP_IGR_NP) resulting in pol-I GP_IGR_GFP_IGR_NP. 
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3.3.3 DNA transfection of cells and rescue of recombinant 
viruses 
BHK-21 cells were seeded into 6-well plates at a density of 4x105 cells/well and 
transfected 24 hours later with different amounts of DNA using either lipofectamine 
(3 µl/µg DNA; Invitrogen) or jetPRIME (2 µl/µg DNA; Polyplus) according to the 
manufacturer’s instructions. For rescue of recombinant bi-segmented viruses entirely 
from plasmid DNA, the two minimal viral trans-acting factors NP and L were delivered 
from pol-II driven plasmids (0.8 µg pC-NP, 1 µg pC-L) and were co-transfected with 
1.4 µg of pol-I L and 0.8 µg of pol-I S. In case of rescue of tri-segmented r3LCMV 
consisting of one L and two S segments, 0.8 µg of both pol-I driven S segments were 
included in the transfection mix. 72 hours after transfection the supernatant was harvested 
and passaged on BHK-21 cells for further amplification of the virus. Viral titers in the 
supernatant were determined by focus forming assay. 
3.3.4 Viruses and growth kinetics of viruses  
Wild-type Cl13 LCMV, originally derived from wild-type LCMV Armstrong, has 
previously been described (Ahmed, Salmi et al. 1984). Stocks of wild-type and 
recombinant viruses were produced by infecting BHK-21 cells at a multiplicity of 
infection (moi) of 0.01 and supernatant was harvested 48 hours after infection. Growth 
curves of viruses were done in vitro in a 6-well format. BHK-21 cells were seeded at a 
density of 6×105 cells/well and infected 24 hours later by incubating the cells together 
with 500 µl of the virus inoculum at a moi of 0.01 for 90 minutes on a rocker plate at 
37°C and 5% CO2. Fresh medium was added and cells incubated at 37 °C/ 5 % CO2 for 
72 to 96 hours. Supernatant was taken at given time points (normally 18, 24, 48, 72 
hours) and viral titers analyzed by focus forming assay. 
3.3.5 Focus forming assay  
Titers of LCMV are determined by focus forming assay. LCMV is a non-cytolytic virus 
that does not lyse its host cells and as such does not create plaques. Nevertheless units in 
this work will be expressed in the more commonly used term plaque forming units (PFU) 
instead of the correct term focus forming units (FFU). MC57 cells were used for focus 
forming assay if not stated otherwise. Cells were seeded at a density of 1.6x105 cells per 
well in a 24-well plate and mixed with 200 µl of 10-fold serial dilutions of virus prepared 
in MEM/ 2 % FCS. After 2-4 hours of incubation at 37 °C, 200 µl of a viscous medium 
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(2 % Methylcellulose in 2x supplemented DMEM) were added per well to ensure 
spreading of viral particles only to neighboring cells. After 48 hours at 37 °C the 
supernatant was flicked off and cells were fixed by adding 200 µl of 4 % 
paraformaldehyde (PFA) in PBS for 30 minutes at room temperature (all following steps 
are performed at room temperature). Cells were permeabilised with 200 µl per well of 
BSS/ 1 % Triton X-100 (Merck Millipore) for 20 minutes and subsequently blocked for 
60 minutes with PBS/ 5 % FCS. For anti-NP staining a rat anti-LCMV-NP monoclonal 
antibody was used as a primary staining antibody at a dilution of 1:30 in PBS/ 2.5 % FCS 
for 60 minutes. For anti-GFP staining purified rat-anti-GFP antibody (Biolegend 338002) 
was used at a dilution of 1:2000 in PBS/ 2.5 % FCS. Plates were washed three times with 
tap water and the secondary HRP-goat-anti-rat-IgG was added at a dilution of 1:100 in 
PBS/ 2.5 % FCS and incubated for 1 hour. The plate was again washed three times with 
tap water. The color reaction (0.5 g/l DAB (Sigma D-5637), 0.5 g/l Ammonium Nickel 
sulfate in PBS/ 0.015 % H2O2) was added and the reaction was stopped after 10 minutes 
with tap water. Stained foci were counted manually and the final titer calculated 
according to the dilution. 
For anti-GP staining of cells, plates were fixed with 50 % MeOH/ 50 % Acetone for 
5 minutes and washed with PBS. Blocking was done as described. As primary antibody 
anti-GP GP83.4 (produced from hybridomas) was diluted 1:10 in PBS/ 2.5 % FCS and 
incubated for 60 minutes. After three washes with tap water, the secondary HRP-rabbit-
anti-mouse IgG antibody was added at a dilution of 1:50 in PBS/ 2.5 % FCS and 
incubated for 60 minutes. After another three washes with tap water the color reaction 
was added as described above. 
In order to determine the viremia of mice in blood, one drop of blood (corresponding to 
50 µl volume) was collected in 950 µl of BSS-heparin (Na-heparin, Braun, 1 IE/ml final), 
mixed by inverting and stored at -80 °C until further use.  
3.3.6 Mice  
AGRAG mice (IFNα/βR-/-, IFNγR-/-, RAG-/-) have previously been described (Pinschewer, 
Flatz et al. 2010) and were bred and housed under specific pathogen-free (SPF) 
conditions. They were bred at the Institut für Labortierkunde of the University of Zurich, 
Switzerland. All animal experiments were performed at the Universities of Geneva and 
Basel in accordance with the Swiss law for animal protection and the permission of the 
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respective responsible cantonal authorities of Geneva and Basel. Infection of the mice 
was done intravenously at a dose of 1×104 PFU per mouse.  
3.3.7 Preparation of viral RNA and Sequencing 
Viral RNA was extracted from cell culture supernatant or the serum of infected mice 
using the QIAamp Viral RNA Mini Kit (QIAGEN) according to the manufacturer’s 
instructions. The reverse-transcription reaction was done with ThermoScript RT-PCR 
System (Invitrogen) and a primer specific for LCMV NP (5’-
GGCTCCCAGATCTGAAAACTGTT-3’) following the manufacturer’s protocol. 
Amplification by PCR was done by using 2 µl of the cDNA from the RT step and NP- 
and GP-specific primers (NP-specific: same as in RT reaction, GP- specific: 5’-
GCTGGCTTGTCACTAATGGCTC-3’). The PCR reaction was done using Phusion 
High-Fidelity DNA Polymerase (NEB). Amplified products were analyzed on and 
excised from a 2 % agarose gel, purified using QIAquick Gel Extraction Kit (QIAGEN) 
and sent for DNA Sanger Sequencing (Microsynth) using the NP- and GP-specific 
primers. 
3.3.8 Flow cytometry 
Blood was stained with antibodies against CD11c (N418), CD11b (M1/70), CD19 (6D5), 
NK1.1 (PK136), CD90.2 (30-H12) and GR-1 (RB6-8C5). The expression of surface 
molecules stained with specific antibodies as well as GFP and RFP expression was 
analyzed on a BD LSR Fortessa flow cytometer using FlowJo software (Tree Star, 
Ashland, OR). 
3.3.9 Statistical analysis  
Statistical significance was determined by two-tailed unpaired t test or 1-way ANOVA 
followed by Dunnett’s or Bonferroni’s post-test for multiple comparisons using Graphpad 
Prism software (version 6.0d). p values of p > 0.5 were considered not statistically 
significant (ns), whereas p values of p < 0.5 were considered significant (*) with 
gradations of p < 0.1 (**) and p < 0.01 (***) being highly significant. 
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3.4 Results  
Recombinant tri-segmented viruses grow to lower titers than wild-type LCMV. 
The genome of wild-type LCMV consists of two single-stranded RNA segments of 
negative polarity (1L, 1S) (Fig. 3.1A). In recent years it has been shown that it is possible 
to introduce additional foreign genes into the genome of bi-segmented LCMV particles 
(Emonet, Garidou et al. 2009). Genes of interest are inserted into the S segment of LCMV 
resulting in viral particles with three RNA segments (2S + 1L). The only currently 
published strategy keeps both NP and GP in their natural position in the S segment, thus 
placing GFP or other transgenes in the respective free sites (r3LCMV-GFPnat) (Fig. 3.1B). 
This was the intuitive approach aimed at minimizing the likely risk that genetic 
reshuffling of the S segment abrogates the resulting genome’s viability. However, we 
hypothesized that it should also be possible to juxtapose GP to the 3’UTR, expressing it 
from the promoter element that normally drives NP (r3LCMV-GFPart; Fig. 3.1C). We 
generated the respective expression plasmids by recombinant cDNA cloning and rescued 
all three viral constructs entirely from plasmid DNA (for details see Materials and 
Methods, (Flatz, Bergthaler et al. 2006) and (Emonet, Garidou et al. 2009). We 
performed comparative growth curves with the three viruses (Fig. 3.1D). All three viruses 
showed highest titers 48 hours after infection, with peak titers of tri-segmented viruses 
10-100 fold lower than wild-type virus. Wild-type LCMV reached 3.4×106 PFU/ml, 
r3LCMV-GFPnat peaked at 2.7×104 PFU/ml and r3LCMV-GFPart at 2.2×105 PFU/ml. 
Irrespective of its similarly reduced peak titers, r3LCMV-GFPnat exhibited somewhat 
higher cell-free infectivity during early time points than r3LCMV-GFPart. 
Packaging of tri-segmented viral particles is less efficient than of bi-segmented virus. 
These observations suggested that the addition of a second S segment impaired and 
delayed viral growth. We hypothesized that this reduction in viral fitness might be due to 
inefficient packaging of all three RNA segments into viral particles, and that an excess of 
bi-segmented particles were formed, which failed to productively replicate when 
infecting fresh cells. For these experiments we used r3LCMVs with two different reporter 
genes i.e. GFP together with GP on one S segment and NP next to red fluorescent protein 
(RFP) on the second S segment. This resulted in two viruses named r3LCMV-GFP/RFPnat 
and r3LCMV-GFP/RFPart, which differed only in the arrangement of GFP and GP on the 
respective S segment. We infected BHK-21 cells with r3LCMV-GFP/RFPnat, r3LCMV-
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GFP/RFPart or bi-segmented r2LCMV and performed focus forming assays on normal 
BHK-21 cells or, in parallel, with stably transfected BHK-21 cells expressing either GP 
(BHK-GP) or NP (BHK-NP) (Flatz, Hegazy et al. 2010) as cell substrate. Wild-type and 
GP-complementing cells were stained for nucleoprotein-expressing viral foci, whereas 
NP-complementing cells were stained for GP-positive foci. Thereby, immunofocus 
formation on wild-type BHK-21 cells detected only tri-segmented virions. BHK-GP cells 
replicated tri-segmented virions as well as bi-segmented ones containing the L segment in 
combination with the NP-expressing S segment (but devoid of the GP-expressing S). 
Conversely, BHK-NP cells replicated tri-segmented LCMV and additionally NP-deficient 
virions consisting of the L and the GP-expressing S segment (but devoid of the NP-
expressing S segment). We found that infectious titers of both r3LCMV-GFP/RFPnat and 
r3LCMV-GFP/RFPart were consistently higher when assessed on BHK-GP or BHK-NP 
cells than when infectivity was tested on wild-type BHK-21 cells. Conversely, titers of 
r2LCMV were similar, irrespective of the cell substrate used to assess its infectivity. In 
order to correct for potential intrinsic differences in permissiveness of each cell line to 
LCMV, each virus’ titer on BHK-21 cells was normalized to one for display, and BHK-
GP as well as BHK-NP titers were expressed as a multiple thereof thus reflecting cell 
substrate-related titer differences (Fig. 3.2A). On either one of the complementing cells, 
an approximately five to ten-fold titer difference was observed for r3LCMV-GFP/RFPnat 
and r3LCMV-GFP/RFPart, which was significantly higher than for r2LCMV. This 
suggested that a majority of the viral particles, which were formed by the two tri-
segmented viruses contained only one of the two S segments encoding either only the 
NP- (NP-only particles) or the GP-expressing S segment (GP-only particles), respectively. 
The 5-fold or greater difference in titer suggested that both, NP-only and also GP-only 
particles outnumbered tri-segmented particles approximately five-fold each, and that tri-
segmented particles made up for less than 10 percent of virions only, which was 
compatible with the reduction in viral peak titers when grown on non-complementing 
cells (Fig. 3.1D). We also validated these findings by flow cytometry. Non-
complementing BHK-21 cells or BHK-NP cells were infected with r3LCMV-GFP/RFPart 
or r2LCMV as gating control and fluorescence intensities of GFP and RFP were assessed 
with a flow cytometer (Fig. 3.2B). Since the minimal transacting factors are not provided 
by wild-type BHK-21 cells, only virions containing at least an L segment together with 
the NP-expressing S segment can initiate an infectious cycle after cell entry, resulting in 
fluorescence signal (RFP). Accordingly, a population of RFP+GFP- cells was observed 
upon infection of BHK-21 cells, reflecting NP-only particles. RFP+GFP+ double-positive 
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cells were evidence of bona fide tri-segmented particles. According to our gating RFP-
GFP+ cells were also observed, yet had a higher RFP MFI than RFP-GFP- cells, 
suggesting that they represented early stages of infection by tri-segmented particles, an 
interpretation that is also supported by the continuity of this population and the 
RFP+GFP+ double positive one. However, when growing tri-segmented r3LCMV-
GFP/RFPart on BHK-NP cells, thus substituting for this minimal transacting factor, we 
observed a 5-fold higher number of RFP-GFP+ cells as compared to infection of non-
complementing BHK-21 cells. Conversely, RFP+GFP- (NP-only particles) and 
GFP+RFP+ double-positive cells (tri-segmented particles) were detected in comparable 
abundance (Fig. 3.2C). These results confirmed at the single-cell level the findings 
obtained by focus forming assay corroborating that tri-segmented virus preparations 
contain a majority of bi-segmented replication-deficient particles. These findings offered 
a likely explanation for attenuated growth of r3LCMV-GFP/RFPnat and r3LCMV-
GFP/RFPart, providing insight into an apparently quite inefficient random packaging of 
tri-segmented viruses. 
Cloning and rescue of recombinant viruses to track recombination in vivo. 
Since tri-segmented viruses show impaired growth kinetics as seen in figure 3.1, we 
hypothesized that there should be high selection pressure on such viruses to recombine 
their genetic information for NP and GP on only one S segment. Inter-segmental 
recombination of arenaviruses is postulated to have led to the phylogenetic evolution of 
the North American clade (Charrel, Feldmann et al. 2002) and thus seemed a likely 
mechanism whereby tri-segmented viruses could re-establish a functional bi-segmented 
genome. Looking at the genomic organization of the two tri-segmented viruses we 
postulated that the selection pressure on r3LCMV-GFPnat might favor recombination 
events in the area of the IGR, to bring GP and NP together on the same segment, while 
getting rid of GFP. In the population of r3LCMV-GFPart selection pressure should be 
equally high, however, the reshuffling of GP and its positioning next to the 3’UTR should 
render it very difficult if not impossible for this virus to combine its two S segments into 
one functional segment (see Fig. 3.7 below). In account of the caveats for the 
identification of RNA recombination and to firmly discriminate it from potential cDNA 
contamination (Boni, de Jong et al. 2010), we cloned an S segment carrying GFP together 
with a recombinant GP ORF in which the terminal 255 nucleotides were codon-optimized. 
The resulting GP had a different nucleotide sequence but identical translation product as 
the wild-type WE strain GP (WE/WET-GP, Fig. 3.3A). This recombinant WE/WET GP 
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ORF did not, however, exist as an infectious bi-segmented virus nor did our laboratory 
possess a cDNA construct where it was associated with NP. Any potential bi-segmented 
virus containing WE/WET on the same segment as NP was therefore deemed clear 
evidence of intersegmental recombination, differentiating such viruses from potentially 
contaminating cDNA or RNA in the respective assays. To test whether the chimeric 
glycoprotein had an effect on viral fitness, we performed cell culture growth curves of the 
recombinant tri-segmented virus carrying the WE/WET fusion GP (r3LCMV-
WEWET/GFPnat) in comparison with a tri-segmented virus carrying the wild-type WE-
GP (r3LCMV-WE/GFPnat) (Fig. 3.3B). Growth kinetics and peak titers of the two viruses 
were comparable (r3LCMV-WE/GFPnat: 1.7x106 PFU/ml, r3LCMV-WEWET/GFPnat: 
2.3x106 PFU/ml). Thus the chimeric WEWET glycoprotein did not detectably impact 
viral growth. 
We expected that potential recombination events should happen between the NP and GP 
genes of the S segment, and thus would likely involve the IGR in some way. Hence we 
introduced a single nucleotide deletion in the intergenic region of the NP-encoding 
S segment, to serve as a genetic tag. The choice of this nucleotide deletion was made 
because it is situated in a stretch that unlike most of the S segment IGR is not conserved 
between strains, neither in sequence nor in length. We reasoned that in case of a 
recombination event this “tagged” (marked as * throughout) intergenic region should 
allow us to identify the genetic origin of S segment IGR sequences. The position of the 
deleted cytosine (marked with an arrow) and a schematic of the resulting NP carrying 
S segment is depicted in Figure 3.3C. In order to test whether the introduced deletion in 
the IGR had an impact on viral growth, we rescued recombinant r3LCMV-GFPnat with or 
without the single nucleotide deletion. Growth curve experiments were performed on 
BHK-21 cells (moi = 0.01). A tri-segmented virus with a wild-type IGR (r3LCMV-
GFPnat) and its comparator with the mutated IGR (r3LCMV-GFPnat IGR*) grew at a 
similar rate and reached indistinguishable peak titers (Figure 3.3D). Consequently the tag 
of the IGR on the NP-carrying S segment did not have a detectable impact on viral fitness, 
thus validating its use for subsequent experimentation in vivo.  
r3LCMV-GFPnat but not r3LCMV-GFPart persistent infection in mice reaches viremia 
levels equivalent to bi-segmented wild-type virus and results in loss of GFP expression. 
Upon rescue of the recombinant r3LCMV-GFPnat we aimed at investigating whether tri-
segmented viruses recombined in vivo. For this purpose we infected AGRAG mice with 
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r3LCMV-GFPnat, r3LCMV-GFPart or a bi-segmented r2LCMV as control. AGRAG mice 
carry deficient genes for the Interferon-α/β receptor, the Interferon-γ receptor and a 
mutation of the RAG1 gene leading to an immuno-deficient phenotype and establishment 
of chronic viremia after infection with tri-segmented LCMV. Blood samples were taken 
over time and viral titers were assessed by focus forming assay (Fig. 3.4A). Carriers of 
bi-segmented LCMV showed high titer viremia in the range of 5×105 PFU/ml blood 
within 5 days after infection, with subsequently stable viremia in the 104 - 105 PFU/ml 
range until at least day 50 post infection. Mice infected with tri-segmented LCMV 
showed viral loads of about 5×103 PFU/ml blood until day 20, in line with attenuated 
growth in cell culture (compare Fig. 3.1D). From day 30 onwards, carriers of r3LCMV-
GFPnat displayed a rise in viral titers, which was not observed in animals infected with 
r3LCMV-GFPart, resulting in a more than 10-fold difference in viremia on day 50. To 
determine whether the dominating virus population still carried the GFP reporter gene, 
thus resulting in GFP expression in infected cells, we performed viral focus formation 
assays with blood samples of r3LCMV-GFPnat and r3LCMV-GFPart carriers taken on day 
127 after infection. We stained for the nucleoprotein or the reporter gene GFP (Fig. 3.4B). 
Whereas staining of blood isolated from r3LCMV-GFPart carriers resulted in equal 
amounts of foci with anti-NP and anti-GFP antibody detection (both assessments 
independently indicating viral titers in the 103 PFU/ml range), we observed at least 100-
fold higher numbers of total (NP+) r3LCMV-GFPnat foci than foci staining for GFP. Viral 
titers of at least 104 PFU/ml were measured based on anti-NP detection, whereas two out 
of three mice failed to show any detectable GFP-positive infectivity and one mouse had a 
residual fraction of GFP-positive foci in the 100 PFU/ml range, corresponding to the 
lower limit of detection of our assays. GFP expression of infected cells was also assessed 
by fluorescence microscopy. GFP-fluorescent foci were virtually undetectable when 
assaying blood from r3LCMV-GFPnat carriers whereas manual counts of GFP-positive 
foci from r3LCMV-GFPart carrier blood matched the titer results obtained with anti-NP 
focus forming assay (data not shown). We further verified reporter gene expression by 
flow cytometric analysis of PBMCs of infected mice on day 120 after infection. We 
found that more than 10 % of CD11b+GR1- monocytes/macrophages were positive for 
GFP in r3LCMV-GFPart infected animals whereas blood from r3LCMV-GFPnat evidenced 
only background levels of GFP, which was comparable to animals infected with non-
fluorescent r2LCMV (Fig. 3.4C-E). This finding further supported the hypothesis that tri-
segmented viruses with GP in their natural position lose reporter gene expression over 
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time whereas transposition of the GP in the artificial 3’UTR juxtaposition prevented 
transgene loss. 
Tri-segmented viruses with GP in the natural position can recombine their two 
S segments resulting in a single S segment with two IGRs and transgene sequence 
rudiments. 
Figure 3.4 had shown elevated viremia and loss of reporter gene expression in mice 
infected with r3LCMV-GFPnat. We hypothesized that a recombination event could 
account for this experimental outcome. Intersegmental recombination should combine GP 
and NP on the same S segment, obviating the need for a second S segment in the viral 
replication cycle. Such an event could then have explained viremia at the level of wild-
type virus in combination with loss of reporter gene expression. To test this possibility we 
isolated viral RNA from the serum of infected mice and used a pair of primers binding to 
NP and GP sequences, respectively, to selectively amplify by RT-PCR only putatively 
recombined RNA molecules, carrying both NP and GP ORFs in ambisense orientation on 
one RNA segment. The resulting PCR fragments were analyzed by gel electrophoresis 
(Fig. 3.5A). The sera of all r3LCMV-GFPnat carriers gave rise to RT-dependent PCR 
products, whereas r3LCMV-GFPart carriers and naïve controls did not show any specific 
bands. Control PCR reactions were performed on mock-RT-treated RNA samples to rule 
out cDNA contaminations as a source of PCR product. Sequencing results of three 
individual r3LCMV-GFPnat carriers are schematically represented in Figure 3.5C. We 
observed that the three mice contained viral RNA segments of distinct sequence yet with 
a similar pattern: C-terminal portions of GP and NP were found in ambisense orientation 
on one RNA segment. Between them both intergenic regions, i.e. the one of the NP-
expressing and the one of the original GP-expressing segment were at least partially 
retained, separated by a fragment of either one or both GFP reporter genes. The direction 
and length of the GFP fragment varied between the three RNA species recovered from 
individual mice, which was indicative of independent recombination events. In further 
support of this notion, the exact same recombined RNA sequence was recovered from 
two consecutive samples taken from the same mouse with more than three weeks interval 
between sampling.  
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Recombinant r2LCMV with two IGRs on the S segment is viable and grows to similar 
titers as bi-segmented LCMV with only one IGR in the S segment. 
The above sequencing data revealed a consistent pattern of viral genetic elements in 
recombined S segments amongst which the dual IGR was particularly noteworthy and 
characteristic. We were unaware of arenaviruses with repeats of intergenic regions on one 
S segment. A dual stem loop is, however, naturally found in the Old World arenavirus 
Mopeia (Wilson and Clegg 1991). Hence we cloned the rearranged S segment of 
r3LCMV-GFPnat carrier #3 with the two IGRs and the remnant of GFP into a pol-I driven 
S segment expression plasmid and rescued the respective virus. Growth kinetics of this 
virus (r2LCMV_2IGRs) on BHK-21 cells were compared to tri-segmented r3LCMV-
GFPnat and bi-segmented r2LCMV (Fig. 3.6). Infectious cell-free titers of 
r2LCMV_2IGRs exceeded those of r3LCMV-GFPnat already at early time points and 
reached identical peak titers as r2LCMV (1.7×107 PFU/ml vs. 1.6×107 PFU/ml, 
respectively). Importantly, r2LCMV_2IGRs grew to considerably higher peak titers than 
its parental tri-segmented r3LCMV-GFPnat attesting to the selective advantage of 
intersegmental recombination despite duplication of the IGR during this process. 
Proposed model of recombination events 
Based on our sequencing results we postulate that tri-segmented LCMV particles can 
recombine their two S segments thus reuniting GP and NP on the same segment. The 
model in Figure 3.7 and its legend summarize the likely molecular steps in RNA 
synthesis. The observation that the GFP remnant between the two IGRs had either one of 
two possible orientations or a combination of both suggested that recombination is based 
on a copy-choice mechanism, which can take place both during genome or antigenome 
synthesis. Copy-choice, a well-known mechanism of RNA recombination, is the result of 
a switch of the RdRp from one template to another one during RNA synthesis, where 
polymerization of the nascent strand continues (Lazzarini, Keene et al. 1981, Kirkegaard 
and Baltimore 1986, King 1988, Cascone, Haydar et al. 1993). This was first suggested 
by Cooper et al. (Cooper, Steiner-Pryor et al. 1974) and later on confirmed as the 
dominant mechanism of recombination in RNA viruses (Kirkegaard and Baltimore 1986, 
Lai 1992, Nagy, Dzianott et al. 1995). Even though copy-choice as a mechanism for RNA 
recombination has only formally been proven for positive-sense RNA viruses, negative-
sense RNA viruses have been shown to exchange genetic information between different 
RNA segments and they fulfill all requirements for copy-choice. The three steps involved 
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in RNA recombination and the physical requirements for a template-switch have been 
dissected and involve the generation of a primer on the donor RNA, strand transfer and 
binding of the RdRp to the acceptor RNA and primer elongation on the acceptor RNA 
(Jarvis and Kirkegaard 1991, Lai 1992, Nagy and Simon 1997).  
During antigenome synthesis the RdRp reads in 5’à3’ direction through the NP ORF 
and the IGR (Fig. 3.7A). At the end of the IGR it supposedly pauses, as suggested by the 
observation that the 3’ end of viral mRNAs projects into this sequence stretch (Meyer and 
Southern 1993) and that the IGR is necessary for transcription termination (Pinschewer, 
Perez et al. 2005). This pausing due to a strong secondary structure is called structure-
dependent polymerase pausing (Auperin, Galinski et al. 1984). Stalling of the polymerase 
enables copy-choice resulting in strand-switch (Kirkegaard and Baltimore 1986) and it 
has been shown that the presence of a secondary structure in the acceptor strand is 
necessary for recombination between virus-associated RNAs (Cascone, Haydar et al. 
1993). Stalling of RNA synthesis has been shown to provide an opportunity for the RdRp 
and/or the nascent strand to interact with the acceptor RNA, thus enabling and initiating a 
recombination event (reviewed in (Nagy and Simon 1997)). 
Since the RdRp can only read in 5’à3’ direction, it can only produce a functional and 
complete S segment when it continues the read somewhere upstream of GP, thus either 
inside the GFP ORF or even in the IGR itself, from where it can subsequently read 
through the complete GP ORF with the 5’UTR attached. Recombination can probably 
also take place during genome synthesis where the polymerase starts reading from the 
5’UTR of the GP-encoding S segment. After replicating the GP ORF and the IGR, the 
secondary structure of the IGR again makes the polymerase to pause, thus enabling copy-
choice and strand-switch to the NP-encoding S segment where it continues the read in 
5’à3’ direction from somewhere randomly within the GFP ORF or inside the IGR, to 
subsequently read through the entire NP ORF with the 3’UTR (Fig. 3.7B). In the RNA 
species analyzed, copy-choice has seemingly favored continuation inside the GFP ORF 
and a direct template switch into an IGR was apparently disfavored. Hence, both of the 
above copy-choice events resulted in viral RNA segments with GP, a first at least 
partially intact IGR, a fragment of GFP in either sense- or anti-sense orientation, a second 
full-length IGR and the NP ORF. The whole RNA segments were flanked by the 5’ and 
3’UTR, which could form a panhandle structure, a known requirement for a functional 
viral promoter (Perez and de la Torre 2003). One should assume that analogous stalling 
and subsequent copy-choice events of the RdRp could also take place during genome or 
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antigenome synthesis of the r3LCMV-GFPart virus. However, as summarized in Figure 
3.7C-D, due to the re-positioning of the GP, the resulting viral segment would carry two 
3’UTRs which would fail to form a functional viral promoter for the RdRp and the 
resulting molecule would not be amplified by the viral polymerase complex. According 
to this model, reshuffling of the GP with the resulting juxtaposition to and expression 
under control of the 3’UTR prevents the tri-segmented virus from recombining its two S 
segments, its reversion to wild-type growth and loss of its transgenes. 
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3.5 Discussion  
Here we have shown that r3LCMV-GPnat can recombine its two S segments resulting in 
wild-type growth and loss of transgene expression. This can be avoided by repositioning 
GP under control of the 3’UTR. The resulting r3LCMV-GPart shows consistently 
attenuated growth in immune-deficient mice with stable transgene expression over at 
least 150 days.  
These results contrast with two studies published by Emonet et al. and Popkin et al. 
(Emonet, Garidou et al. 2009, Popkin, Teijaro et al. 2011). Both groups of investigators 
report that r3LCMV particles have wild-type growth kinetics in cell culture, whereas viral 
loads in mice were dramatically reduced. In our hands, however, tri-segmented LCMV 
consistently showed drastically impaired growth both in vitro and in vivo (Fig. 3.1D). 
The reason for this apparent discrepancy of in vitro kinetics is unclear. One explanation 
could be the use of different cell types for titrating the cell culture supernatants and assess 
viral titers. Whereas Emonet et al. used non-complementing Vero cells for titration of 
viral supernatants, we use MC57G cells. Popkin. et al. did not specify, which cells were 
used for immunofocus assays. Complementing cells would allow the propagation of 
replication-competent tri- but also replication-deficient bi-segmented particles (carrying 
e.g. only the NP-encoding S segment in case of GP-complementing cell lines). In this 
case, titers of tri-segmented viruses would be overestimated. Another important 
discrepancy between our results and the two above reports is the difference in stability of 
transgene expression. We analyzed transgene expression by flow cytometry of circulating 
blood cells. Additionally, we performed focus forming assay from blood and serum 
looking both at GFP-staining and actual fluorescence by immunofluorescence at regular 
intervals up until 150 days after infection. In contrast, Emonet et al. investigated stability 
of the transgene in vitro in ten serial passages of the virus in cell culture, looking at the 
activity of the CAT transgene in infected cells by CAT assay. Popkin et al. assessed GFP 
expression by flow cytometry on day 56 after r3LCMV-GPnat infection in spleen cells of 
IFNAR1-/- mice and found GFP+ cells. However, recombination and subsequent 
selection of recombined viral genomes comprise random events. Hence, the replacement 
of r3LCMV by a newly emerging r2LCMV requires a certain size of the viral pool and 
enough time for the recombined r2LCMV virus to outgrow r3LCMV. We trust that 
infection of immune-deficient mice and transgene expression analysis over 5 months 
represents a demanding setting, whereas passage in vitro drastically limits the pool as 
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well as burst size of the virus, and less than two months of replication in a partially 
immune-competent organism might not have allowed the recombinants enough time to 
outgrow the r3LCMV population. Moreover, the percentage of transgene-positive virions 
was not systematically assessed. Hence the stability of transgene expression as postulated 
by Emonet et al. and Popkin et al. may have been based on both, less stringent test 
settings and assessment.  
The slightly higher cell culture titers of r3LCMV-GPart compared to r3LCMV-GPnat 
might be explained by the stronger viral promoter in the 3’UTR, which leads to 
significantly (~5x) higher mRNA levels as compared to mRNA controlled by the 
promoter in the 5’UTR (Fuller-Pace and Southern 1988). r3LCMV-GPart replication leads 
to higher GP levels, which might lead to enhanced viral growth. We also observed, that 
cells infected with r3LCMV-GFPnat showed higher GFP signals compared to r3LCMV-
GFPart infected cells, both in vitro and in vivo (data not shown). Also this finding is 
consistent with the higher levels of NP mRNA reported by Fuller-Pace et al. (Fuller-Pace 
and Southern 1988). 
We observed that tri-segmented viruses kept their natural tropism since a substantial 
population of monocytes/macrophages in the blood of r3LCMV-GFPart carriers was 
found infected (Fig. 3.4D) and this cell type is a known target of LCMV (Walker and 
Murphy 1987). This finding is in agreement with observations published by Emonet et al. 
who analyzed tropism of r3LCMV after intracranial infection and found it to be 
comparable to wild-type LCMV (Emonet, Garidou et al. 2009).  
Upon isolation of viral RNA from r3LCMV-GFPnat and r3LCMV-GFPart carriers, we 
found the exact same nucleotide sequence in the serum of the same animal on time points 
lying 80 days apart from each other. This is in further support of the hypothesis that 
recombined viral genomes with a single S segment encoding for both NP and GP gain in 
fitness and thus outcompete and displace all other tri-segmented variants (Popkin, Teijaro 
et al. 2011). In addition this observation argues against an artifact of our RT-PCR-based 
analysis. The additional IGR surprisingly does not impair viral growth of recombined 
viruses, which was rather unexpected since the IGR forms a strong secondary hairpin 
structure, which can lead to stalling of the polymerase (Auperin, Galinski et al. 1984).  
In summary, we demonstrate that tri-segmented LCMV can be re-engineered to improve 
genetic stability and ensure constant transgene expression. In addition we provide 
experimental data to confirm intersegmental recombination as a mechanism of 
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arenaviruses to enhance their evolutionary potential, which has already previously been 
postulated to be accountable for a new evolutionary lineage of New World Arenaviruses 
by recombination between two Tacaribe complex viruses by phylogenetic analyses 
(Charrel, de Lamballerie et al. 2001, Charrel, Feldmann et al. 2002). Recombinant LCMV 
expressing additional foreign genes are a promising tool for multiple applications. It can 
be used to assess gene functions in the context of productive viral infection in vivo and in 
research on the mechanisms of viral persistence. Furthermore r3LCMV is gaining interest 
as a tool for vaccination and in vivo antibody production. Administration of r3LCMV not 
only induces a potent cellular immune response but also stimulates antibodies against 
transgenes, using the viral infection as a natural adjuvant (Popkin, Teijaro et al. 2011). 
The natural tropism of LCMV for macrophages and dendritic cells (Sevilla, Kunz et al. 
2000, Sevilla, Kunz et al. 2003, Sevilla, McGavern et al. 2004) enables efficient transport 
of the immunogen to and presentation of the antigen by antigen-presenting cells, ensuring 
induction of efficient immune responses (Popkin, Teijaro et al. 2011).  
This work presents new evidence on how to ensure long-term attenuation of r3LCMV 
and warranting constant expression of transgenes. Both are critical features for use of 
r3LCMV in basic research as well as for potential clinical applications as vaccination 
platform and a tool for immunotherapy of infectious diseases and cancer.  
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3.6 Figures  
 
Figure 3.1: Recombinant tri-segmented viruses show impaired growth compared to 
wild-type LCMV indepenently of the position of the glycoprotein ORF in the genome. 
(A-C) Schematic representation of the genomic organization of bi- and tri-segmented LCMV. 
The bi-segmented genome of wild-type LCMV consists of one S segment encoding for the 
glycoprotein GP and nucleoprotein NP and one L segment encoding for the matrix protein Z 
and the viral polymerase L (A). Both segments are flanked by the respective 5’ and 3’ 
untranslated regions (UTRs). The genome of recombinant tri-segmented LCMV (r3LCMV) 
consists of one L and two S segments with one position where to insert a gene of interest 
(here: green fluorescent protein GFP) into each one of the S segments. (B) r3LCMV-GFPnat 
has all viral genes in their natural position whereas the GP ORF in r3LCMV-GFPart is 
artificially iuxtaposed and expressed under control of the 3’ UTR (C). (D) Growth kinetics of 
the indicated viruses in BHK-21 cells, infected at a multiplicity of infection (moi) of 0.01 (wild-
type LCMV: grey triangles; r3LCMV-GFPnat: black circles; r3LCMV-GFPart: white squares). 
Supernatant was taken at the indicated time points after infection and viral titers were 
determined by focus forming assay. Symbols and bars represent the mean±SEM of three 
replicates per group and are hidden in the symbol size. Data represent one representative of 
three independent experiments. 
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Figure 3.2: Tri-segmented virus preparations contain a majority of bi-segmented 
replication-deficient particles. 
(A) r2LCMV (white bars), r3LCMV-GFP/RFPart (black bars, GFP-GP, RFP-NP) and r3LCMV-
GFP/RFPnat (grey bars, GP-GFP, RFP-NP) were grown on wild-type BHK-21 cells and the 
infectivity of supernatant was determined on wild-type non-complementing BHK-21 cells 
(BHK21), GP-expressing (BHK-GP) or NP-expressing (BHK-NP) BHK-21 cells. Titers on 
BHK-21 and BHK-GP cells were determined by staining NP-positive viral foci. Titers on NP-
complementing BHK-21 cells were determined by counting GP-positive foci. Titers were 
normalized to the average titer obtained when assessed on BHK-21 cells and thus are 
expressed as a multiple thereof. Bars represent the mean±SEM of six replicates per group. 
One representative of at least three independent experiments is shown. ns, not statistically 
significant (p ≥ 0.05); **: p < 0.01 by 1-way ANOVA followed by Dunnett’s post-test using 
r2LCMV as a reference. (B) r2LCMV (left plot) or r3LCMV-GFP/RFPart (middle and right plot) 
were grown on wild-type BHK-21 cells (BHK21) or NP-expressing BHK-21 cells (BHK-NP) 
and fluorescence was assessed 12 hours after infection by flow cytometry. r2LCMV infected 
cells were used as gating control. One representative plot per condition is shown. (C) 
Quantification of GFP+, RFP+ or GFP+RFP+ double positive cells 12 hours after infection 
with r3LCMV-GFP/RFPart on BHK-21 or BHK-NP cells. Bars represent the mean±SEM of 
three replicates per group. One representative of at least three independent experiments is 
shown. ns, not statistically significant (p ≥ 0.05); ***: p < 0.001 by unpaired two-tailed 
student’s t test.  
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Figure 3.3: Design and growth kinetics of recombinant tri-segmented viruses 
carrying a partially codon-optimized GP ORF or a genetic tag in the IGR of the  
S segment. 
(A) Schematic of genetically engineered S segment wherein the 255 C-terminal base pairs 
of GP are codon-optimized and NP is replaced for GFP (GP ORF referred to as “WE/WET”). 
Growth kinetics of the tri-segmented r3LCMV-WEWET/GFPnat consisting of two S and one L 
segment as detailed in Fig. 3.1B, with modification of the GP-containing S segment as 
shown in (A) were performed on BHK-21 cells. Supernatant was taken at the indicated time 
points after infection at moi = 0.01 and viral titers were determined by focus forming assay 
(B). Symbols and bars represent the mean±SEM of three replicates per group are hidden in 
the symbol size. (C) Schematic of the NP-encoding S segment wherein one base pair of the 
IGR has been deleted in order to genetically “tag” this non-coding RNA element. The deleted 
residue (indicated by an arrow) lies outside the critical stem-loop structure of the IGR. 
Comparative growth kinetics of tri-segmented viruses with or without genetic tag in the IGR 
of the NP-encoding S segment (r3LCMV-GFPnat: black circles; r3LCMV-GFPnat IGR*: white 
circles) were performed on BHK-21 cells at a moi of 0.01. Supernatant was collected at the 
indicated time points after infection and viral titers were determined by focus forming assay. 
Symbols and bars represent the mean±SEM of three replicates per group. Representative 
data from one of two independent experiments are shown. 
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Figure 3.4: r3LCMV-GFPnat but not r3LCMV-GFPart persistent infection in mice reaches 
viremia levels equivalent to bi-segmented wild-type virus and results in loss of GFP 
expression. 
(A) We infected AGRAG mice i.v. with 1x104 PFU of r3LCMV-GFPnat (black circles), 
r3LCMV-GFPart (white squares) or control bi-segmented r2LCMV (grey triangles) and 
monitored viremia over time. Symbols and bars represent the mean±SEM of 3-7 mice per 
group. Representative data from one out of two independent experiments are shown. (B) We 
determined LCMV viremia on day 127 after intravenous infection of AGRAG mice with 1x104 
PFU of r3LCMV-GFPnat or r3LCMV-GFPart. Immunofocus assays were performed to detect 
either nucleoprotein NP (grey circles) or GFP (white circles). Symbols represent individual 
mice. ns: not statistically significant (p ≥ 0.05); ***: p < 0.001 (unpaired two-tailed student’s t 
test). (C-E) Blood from AGRAG mice infected with r3LCMV-GFPnat, r3LCMV-GFPart or 
r2LCMV was analyzed on day 120 after infection by flow cytometry for the presence of 
GFP+ cells. Monocytes/macrophages were identified using the gating strategy outlined in 
(C). One representative FACS plot for each group and one representative histogram overlay 
of the GFP expression is shown in (D). (E) Quantification of the GFP+ population within the 
CD11B+ GR1- monocytes/macrophage population. Symbols represent individual mice, bars 
represent the mean±SEM of 3-7 mice per group. 
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Figure 3.5: r3LCMV-GFPnat persistent infection in mice results in S-segment 
recombination and loss of functional full-length transgenes. 
Viral RNA was isolated from the serum of AGRAG mice on day 127 after i.v. infection with 
1x104 PFU r3LCMV-GFPnat or r3LCMV-GFPart. Viral RNA was reverse transcribed and 
cDNA carrying both NP as well as GP sequences was PCR-amplified with appropriate gene-
specific primers. (A) DNA electrophoresis of PCR products obtained subsequent to (+RT, 
lanes 1-8) or without prior reverse transcription of RNA template (-RT, negative control, 
lanes 9-16). Serum of a naive animal was used as negative control (n, lanes 8+16) and a 
plasmid encoding a wild-type LCMV S segment as positive control (p, lane 17). Amplicons of 
lanes 1-3 were subject to Sanger sequencing. (B) Representative cDNA sequence obtained 
from animal #3 (r3LCMV-GFPnat #3) revealing a recombined S segment combining NP and 
GP sequences, two intergenic regions (IGRs, bold) and a C-terminal GFP portion (grey 
highlight). (C) Schematic of three recombined viral S segment sequences isolated on day 
127 after infection, each of them dominating the viral population in one representative 
AGRAG mouse. The tagged IGR originating from the NP-carrying S segment is marked with 
a star (*). The stretch that has been sequenced is indicated by a double-arrow ( ). 
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Figure 3.6: Growth kinetics of recombined virus with two IGRs on the S segment are 
similar to bi-segmented virus. 
BHK-21 cells were infected at moi of 0.01 with either bi-segmented LCMV (grey triangles) 
carrying a wild type S segment, with tri-segmented r3LCMV-GFPnat (black circles) or with 
r2LCMV_2IGRs (white diamonds) carrying one S segment corresponding to the 
recombination product recovered from infected AGRAG mice (compare Fig. 3.5). 
Supernatant was taken at the indicated time points and viral titers were determined by focus 
forming assay. Symbols and bars represent the mean±SEM of three replicates per group 
and are hidden in the symbol size. ns, not statistically significant (p ≥ 0.05); ***: p < 0.001 (1-
way ANOVA followed by Bonferroni’s post-test for multiple comparisons). Representative 
data from one out of two independent experiments are shown. 
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Figure 3.7: Model for the recombination events accountable for r3LCMV-GFPnat 
transgene loss and postulated mechanism of r3LCMV-GFPart genetic stability. 
This model bases itself upon sequence data of LCMV transcription termination (Meyer and 
Southern 1993) combined with reverse genetic evidence for the IGR as transcription 
termination signal (Pinschewer, Perez et al. 2005). Together, these findings suggested 
structure-dependent polymerase pausing when completing the hairpin structure of the IGR. 
The GFP remnant between the two IGRs in recombined S segments was found to originate 
from either one or both S segments, fostering the model that polymerase template switch 
(also referred to as copy-choice) occurred when the polymerase paused, either during 
genome or antigenome synthesis (below scenarios A and B, respectively). (A) During 
antigenome synthesis the RNA dependent RNA polymerase (RdRp) initiates at the 3’UTR of 
a genomic S segment template and then reads through the NP ORF and IGR. At the end of 
the IGR the polymerase pauses due to the secondary structure (”structure-dependent 
polymerase pausing”). Stalling of the polymerase facilitates copy choice and continuation of 
RNA replication on an alternative template (here: GP-encoding S segment genome). 
Template switch must occur upstream of the GP STOP codon and apparently is most likely 
to target sequences close to or at the base of the IGR hairpin. Continuing its read through 
the C-terminus of the second template’s GFP, the polymerase then synthesizes a second 
IGR, the GP ORF and the 5’UTR. (B) During genome synthesis the RdRp initiates RNA 
synthesis at the 3’ end of an antigenomic S segment template containing GP, synthesizes 
the 5’UTR, GP and most or all of the IGR, followed by structure-dependent polymerase 
pausing. Copy choice occurs, switching into the C-terminal portion of the GFP ORF near the 
IGR of an NP-containing S segment. Replication thus adds a fragment of GFP, followed by 
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an IGR in full length, the NP and 3’UTR. (C – D) Template switch analogously to scenarios 
(A) and (B) can also occur during genome and antigenome synthesis of r3LCMV-GFPart. 
This process also can combine NP and GP ORFs onto one RNA segment. The latter is, 
however, made up of two 3’ UTRs instead of a 3’UTR and a 5’UTR, which only together form 
a functional viral promoter. Such molecules can therefore not be amplified by the RdRp and 
thus do not form recombined replication-competent virus. 
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III Global Discussion and Perspective 
This work provides novel mechanistic insights into how to harness the immune system in 
the fight against chronic infection and cancer. We demonstrate that the IL-33/ST2 
pathway plays an important role in driving potent effector CTL responses. We have 
provided a proof-of-principle that exogenous recombinant IL-33, serving as a mimic of 
damage-signals, can augment CTL responses to vaccination (Bonilla, Frohlich et al. 
2012). These observations suggest IL-33 as an adjuvant in cancer immunotherapy. 
Further, we have shown that it essentially contributes to survival of T cells in the chronic 
infection context. Besides IL-21 (Elsaesser, Sauer et al. 2009, Frohlich, Kisielow et al. 
2009, Yi, Du et al. 2009), IL-33 is currently the only cytokine known to specifically 
enhance survival of T cells in chronic viral infection. Therapeutic interventions that 
restore or augment T cell immunity are a promising approach in the fight against chronic 
viral infections and cancer. Immune responses against tumor cells and chronic viral 
infections share many similarities since both are underlying constant and high level 
exposure to their respective antigens, which heavily impacts potent T cell responses. 
Many studies are ongoing to counter suppressive cytokines like TGF-β (Gorelik and 
Flavell 2001), IL-10 (Brooks, Walsh et al. 2010) or LAG3 (Grosso, Kelleher et al. 2007) 
or inhibitory receptors like PD-1 in order to enhance T cell immunity and finally achieve 
better clinical prognosis. Expression of the inhibitory receptor PD-1 on the surface of 
functionally “exhausted” CTLs is associated with persistence of various viruses like 
LCMV or HIV, HBV and HCV in humans (Barber, Wherry et al. 2006, Day, Kaufmann 
et al. 2006, Trautmann, Janbazian et al. 2006, Radziewicz, Ibegbu et al. 2007, Ye, Weng 
et al. 2008) and blockade of the PD-1/PD-L1 pathway with specific antibodies correlates 
with enhanced CD8+ T cell functionality and improved virus control (Barber, Wherry et 
al. 2006, Velu, Titanji et al. 2009). This pathway has therapeutic potential both in chronic 
viral infections and in cancer and blockade of PD-1/PD-L1 has been shown to boost 
tumor-specific immunity in various malignant diseases (Chen, Wu et al. 2008, Fourcade, 
Sun et al. 2010, Matsuzaki, Gnjatic et al. 2010, Zhang, Huang et al. 2010, Sakthivel, 
Gereke et al. 2012). Targeting of the PD-1/PD-L1 pathway was demonstrated to be 
effective to enhance antitumor T cell immunity and the first PD-1 blocker has been 
licensed by the U.S. Food and Drug Administration (FDA) in early September 2014 for 
the treatment of melanoma (FDA 2014). In contrast to these immunomodulatory 
approaches, which target inhibitory pathways or suppressive cytokines to augment the 
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functionality and magnitude of T cell response IL-33 therapy offers a conceptually novel 
approach: It provides a survival and effector differentiation signal to specific CTLs rather 
than blocking inhibition, and thus represents an innovative strategy with great potential 
for synergy. The insights our studies provide into the role of IL-33 in T cell immunity 
should therefore help in refining treatments and improving disease outcome in cancer as 
well as in chronic microbial infections like, HIV, Malaria and tuberculosis.  
An alternative approach to tackle these types of diseases consists in the induction of 
adaptive immunity. Virally vectored vaccines generally hold great promise in this regard 
because of their exquisite ability to not only induce protective antibodies but also strong 
CTL immunity. LCMV has been used for almost a century to elicit potent and long-lived 
CTL immunity in mice (Zinkernagel 2002) and it is known to do the same in humans 
(Kotturi, Swann et al. 2011). Our novel strategy for vectorization of replication-
competent LCMV should thus become a useful vaccine platform that will be helpful in 
combatting the above-mentioned diseases. As we have learned from the work reported 
herein, replicating LCMV but not replication-deficient vectors benefit from the IL-33 
pathway for effector CTL induction (Bonilla, Frohlich et al. 2012) and thus may be 
particularly valuable in the context of cancer vaccination. Viruses as vaccine candidates 
obviously have to be subject to the appropriate safety tests in order to evaluate their 
suitability for clinical use. The demonstration of stable attenuation and vaccine antigen 
expression is a key criterion in this context. This is a drawback of replicating viruses as 
vaccine vectors but it can rightfully be said that replication-competent recombinant 
viruses have recently gained acceptance. This change in the community’s thinking is due, 
in large parts, to the protective capacity of recombinant CMV-based vectors in the 
HIV/SIV context (Hansen, Ford et al. 2011). The promising results of the chimeric 
replication-competent YF17D/Dengue Virus vaccine against Dengue virus infection 
(Sanofi-Pasteur 2014a, Sanofi-Pasteur 2014b) has also helped to renew the self-
confidence of the biomedical community in that infectious diseases long thought of as 
“difficult targets” can be matched with vaccines. We are therefore confident that our viral 
vector has considerable translational potential and may open up new avenues in 
vaccination against persistent infections and tumors. 
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